var title_f3_0_3072="TEP access direct vision";
var content_f3_0_3072=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F56408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F56408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    TEP access direct vision",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jones, DB, Maithel, SK, Schneider, BE. Atlas of minimally invasive surgery. Cin&eacute;-Med, Woodbury, CT 2006. Copyright &copy; 2006 Cin&eacute;-Med, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_0_3072=[""].join("\n");
var outline_f3_0_3072=null;
var title_f3_0_3073="CT scan ectopic parathyroid adenoma";
var content_f3_0_3073=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F82115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F82115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan ectopic parathyroid adenoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 435px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan of ectopic parathyroid adenoma. Small soft-tissue mass (arrow) in the anterior mediastinum.",
"    <div class=\"footnotes\">",
"     A: aorta; a: major branches of the aorta; v: brachiocephalic veins.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eisenberg, RL. Clinical Imaging: An Atlas of Differential Diagnosis, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_0_3073=[""].join("\n");
var outline_f3_0_3073=null;
var title_f3_0_3074="Mitral stenosis apical long axis echocardiogram 2";
var content_f3_0_3074=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/78565/aplaxms2_conv.mp4?title=Mitral+stenosis+apical+long+axis+echocardiogram+2\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 255px; height: 439px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Apical long axis view from a 2-D echocardiogram shows mitral stenosis. The mitral leaflets are thickened and have limited mobility and doming, with failure to open normally during diastole. There is also marked thickening and shortening of the chordae tendineae.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_0_3074=[""].join("\n");
var outline_f3_0_3074=null;
var title_f3_0_3075="Technetium Tc-99m mebrofenin: Patient drug information";
var content_f3_0_3075=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Technetium Tc-99m mebrofenin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/8/28802?source=see_link\">",
"     see \"Technetium Tc-99m mebrofenin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13207110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Choletec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13373994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3560752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used with a special imaging test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13373993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3560525",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to technetium Tc 99m mebrofenin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13373997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13373998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13373999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13373996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3560862",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat for at least 4 hours before your test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13374001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17084 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-BD9846CABD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_0_3075=[""].join("\n");
var outline_f3_0_3075=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13207110\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13373994\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13373993\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13373997\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13373998\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13373999\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13373996\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374001\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/8/28802?source=related_link\">",
"      Technetium Tc-99m mebrofenin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_0_3076="MM lytic lesions";
var content_f3_0_3076=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F78569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F78569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple myeloma lytic lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 451px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this radiograph of the skull in multiple myeloma, the \"punched out\" radiolucent lesions are the result of destruction by nodules of plasma cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rubin E. Pathology. 4th ed. Philadelphia. Lippincott Williams and Wilkins, 2005. Copyright &copy;2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_0_3076=[""].join("\n");
var outline_f3_0_3076=null;
var title_f3_0_3077="Miglitol: Drug information";
var content_f3_0_3077=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Miglitol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/14/22756?source=see_link\">",
"    see \"Miglitol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F196614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Glyset&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F196639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Alpha-Glucosidase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F196617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Type 2 diabetes (noninsulin dependent, NIDDM):",
"     </b>",
"     Oral: Initial: 25 mg 3 times daily at the start of each meal; the dose may be increased to 50 mg 3 times daily after 4-8 weeks and continued for ~3 months; if glycosylated hemoglobin is not satisfactory, may further increase to maximum recommended dose: 100 mg 3 times daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F196618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F196619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;25 mL/minute: No dosage adjustment necessary. Although miglitol is primarily excreted unchanged, the increased plasma levels in renal impairment are not expected to affect efficacy (clinical response is localized to the GI tract); however, the effects on adverse effects are unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute or S",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;2 mg/dL: Use not recommended (not adequately studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F196620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F196594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glyset&reg;: 25 mg, 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F196580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F196598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer orally at the start of each main meal.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F196597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Type 2 diabetes mellitus (noninsulin-dependent, NIDDM):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Monotherapy as an adjunct to diet to improve glycemic control in patients with type 2 diabetes mellitus (noninsulin-dependent, NIDDM) whose hyperglycemia cannot be managed with diet alone",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Combination therapy with a sulfonylurea when diet plus either miglitol or a sulfonylurea alone do not result in adequate glycemic control. The effect of miglitol to enhance glycemic control is additive to that of sulfonylureas when used in combination.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8091996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Glyset&reg; may be confused with Cycloset&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F196637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Flatulence (42%), diarrhea (29%), abdominal pain (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Dermatologic: Rash (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal distention, gastrointestinal pain, ileus, nausea, paralytic ileus, pneumatosis cystoides intestinalis, subileus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F196601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to miglitol or any of component of the formulation; diabetic ketoacidosis; inflammatory bowel disease; colonic ulceration; partial intestinal obstruction or predisposition to intestinal obstruction; chronic intestinal diseases associated with marked disorders of digestion or absorption or with conditions that may deteriorate as a result of increased gas formation in the intestine",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F196584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; GI symptoms: Most common reactions are gastrointestinal related; incidence of abdominal pain and diarrhea tend to diminish considerably with continued treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: Hypoglycemia is unlikely to occur with miglitol monotherapy but may occur with combination therapy (eg, sulfonylurea, insulin).  In patients taking miglitol, oral glucose (dextrose) should be used instead of sucrose (cane sugar) in the treatment of mild-to-moderate hypoglycemia since the hydrolysis of sucrose to glucose and fructose is inhibited by miglitol. Correction of severe hypoglycemia may require the use of either glucagon or I.V. glucose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Not recommended in severe impairment (serum creatinine &gt;2 mg/dL or Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute); has not been adequately studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stress-related states: It may be necessary to discontinue miglitol and administer insulin if the patient is exposed to stress (ie, fever, trauma, infection, surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonylureas and insulin: In combination with a sulfonylurea or insulin will cause a further lowering of blood glucose and may increase the hypoglycemic potential of the sulfonylurea or insulin; dosage reduction of the sulfonylurea or insulin may be required.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F196589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F196590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F196603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been reported in animal reproduction studies; therefore, miglitol is classified as pregnancy category B. Information specific to the use of miglitol during pregnancy has not been located. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is above the normal range. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the mother and the fetus. Until additional safety and efficacy data are obtained, the use of oral agents is generally not recommended as routine management of GDM or type 2 diabetes mellitus during pregnancy. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F196624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk (small amounts)/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6209281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Miglitol is found in breast milk. The exposure to a nursing infant is ~0.4% of a 100 mg maternal dose. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F196602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Glyset Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $146.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $161.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $190.57",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F196592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor therapeutic response by periodic blood glucose tests; measurement of glycosylated hemoglobin is recommended for the monitoring of long-term glycemic control",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F196595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F196604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Diaban (TW);",
"     </li>",
"     <li>",
"      Diamig (IT);",
"     </li>",
"     <li>",
"      Diastabol (AT, CH, CZ, DE, FI, FR, GR, HN, IE, MX, NL, PL, PT, SE);",
"     </li>",
"     <li>",
"      Laiping (CL);",
"     </li>",
"     <li>",
"      Migbose (TW);",
"     </li>",
"     <li>",
"      Plumarol (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F196583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In contrast to sulfonylureas, miglitol does not enhance insulin secretion; the antihyperglycemic action of miglitol results from a reversible inhibition of membrane-bound intestinal alpha-glucosidases which hydrolyze oligosaccharides and disaccharides to glucose and other monosaccharides in the brush border of the small intestine. In patients with diabetes, this enzyme inhibition results in delayed glucose absorption and lowering of postprandial hyperglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F196600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Saturable at high doses: 25 mg dose: Completely absorbed; 100 mg dose: 50% to 70% absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.18 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &lt;4%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/0/3077/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Handelsman Y, Mechanick JI, Blonde L, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2011, 17(Suppl 2):1-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/0/3077/abstract-text/21474420/pubmed\" id=\"21474420\" target=\"_blank\">",
"        21474420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkman M, Briscoe VJ, Clark N, et al, \"Diabetes in Older Adults: A Consensus Report,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012; doi: 10.1111/jgs.12035.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/0/3077/abstract-text/23106132/pubmed\" id=\"23106132\" target=\"_blank\">",
"        23106132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/0/3077/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodbard HW, Jellinger PS, Davidson JA, et al, &ldquo;Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(6):540-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/0/3077/abstract-text/19858063/pubmed\" id=\"19858063\" target=\"_blank\">",
"        19858063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9538 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-FCC50AAECF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_0_3077=[""].join("\n");
var outline_f3_0_3077=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196614\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196639\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196617\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196618\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196619\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196620\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196594\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196580\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196598\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196597\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8091996\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196637\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196601\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196584\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299711\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196589\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196590\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196603\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196624\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6209281\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196602\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196592\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196595\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196604\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196583\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196600\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9538\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9538|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/14/22756?source=related_link\">",
"      Miglitol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_0_3078="Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus";
var content_f3_0_3078=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/0/3078/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/0/3078/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/0/3078/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/0/3078/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/0/3078/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/0/3078/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/0/3078/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two oral classes of drugs lower blood glucose by modifying the intestinal absorption of carbohydrates and fat: alpha-glucosidase inhibitors and lipase inhibitors. The pharmacology and use of these drugs will be discussed here. Other oral hypoglycemic drugs are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=see_link\">",
"     \"Metformin in the treatment of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=see_link\">",
"     \"Sulfonylureas and meglitinides in the treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ALPHA-GLUCOSIDASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alpha-glucosidase inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/0/3077?source=see_link\">",
"     miglitol",
"    </a>",
"    , voglibose) have been studied extensively in Europe and Japan; two of them, acarbose and miglitol, are available in the United States. Taken orally, they inhibit the upper gastrointestinal enzymes (alpha-glucosidases) that convert complex polysaccharide carbohydrates into monosaccharides in a dose-dependent fashion. These drugs slow absorption of glucose; the slower rise in postprandial blood glucose concentrations is potentially beneficial in both type 1 and type 2 diabetes. In older patients with type 2 diabetes, acarbose may also increase insulin sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with type 1 diabetes,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    therapy decreases the amplitude of postprandial glycemic excursions and lowers hemoglobin A1C (A1C) values [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11993?source=see_link\">",
"     \"Estimation of blood glucose control in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     Acarbose",
"    </a>",
"    and voglibose have also been evaluated for the prevention of type 2 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link&amp;anchor=H25#H25\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Alpha-glucosidase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials have demonstrated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    in patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. In one trial 96 patients who were inadequately controlled by diet alone were randomly assigned to receive either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    or acarbose [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/4\">",
"     4",
"    </a>",
"    ]. The A1C values and fasting blood glucose concentrations fell by a similar amount in both groups; postprandial blood glucose concentrations, however, remained high in the glyburide group but fell in the acarbose group. A second trial evaluated 354 patients treated with diet alone or diet plus a sulfonylurea,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , or insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/5\">",
"     5",
"    </a>",
"    ]. As compared with placebo, the addition of acarbose in each of these groups reduced the mean postprandial blood glucose concentration by 63",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and lowered A1C values by 0.4 to 0.9 percentage points; furthermore, more than 50 percent of patients responded to acarbose. In general acarbose has resulted in greater improvement in A1C values than in fasting blood glucose concentrations, consistent with its predominant effect on postprandial hyperglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/0/3077?source=see_link\">",
"     Miglitol",
"    </a>",
"    has similar efficacy, based upon studies in which it was given alone or combined with insulin or a sulfonylurea, as compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. There are no studies that compare miglitol with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    , but they appear to have comparable effects. Miglitol is also effective when combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis of 41 trials of alpha-glucosidase inhibitor therapy (primarily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    trials), beneficial effects were seen (compared to placebo) on A1C (-0.77 percentage points), fasting, and postload glucose and postload insulin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Effects on serum lipids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the effects of alpha-glucosidase inhibitors on serum lipids are conflicting. As an example, in a study of 96 patients with type 2 diabetes, those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    , 100 mg TID, for 24 weeks had a 27 percent decrease in the ratio of serum low-density-lipoprotein (LDL) cholesterol to high-density-lipoprotein (HDL) cholesterol, due to both a decrease in serum LDL cholesterol concentrations (158 to 123",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [4.1 to 3.2",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    and an increase in serum HDL cholesterol concentrations (55 to 64",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.4 to 1.6",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/14\">",
"     14",
"    </a>",
"    ]. By comparison, patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    had no change, while those receiving placebo had a 14 percent increase in the serum",
"    <span class=\"nowrap\">",
"     LDL/HDL",
"    </span>",
"    ratio.",
"   </p>",
"   <p>",
"    In the meta-analysis noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/13\">",
"     13",
"    </a>",
"    ], however, no beneficial effects on lipids were seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Effects on cardiovascular events",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) trial,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    appeared to reduce the risk of a composite cardiovascular disease outcome in patients with impaired glucose tolerance. In this trial, 1429 patients with impaired glucose tolerance were randomly assigned to acarbose (100 mg three times daily or placebo for a mean of 3.3 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/15\">",
"     15",
"    </a>",
"    ]. An a priori secondary objective of the study, designed to evaluate the incidence of diabetes, was to evaluate the development of major cardiovascular events or hypertension. Acarbose therapy significantly reduced the risk of cardiovascular events by 49 percent when compared with placebo (HR 0.51; 95% CI 0.28-0.95; absolute risk reduction of 2.5 percent). This was an unanticipated finding. The major reduction was in myocardial infarction risk (HR 0.09). In addition, the risk of developing hypertension was decreased by 34 percent (HR 0.66; absolute risk reduction of 5.3 percent). Decreasing postprandial hyperglycemia in patients with impaired glucose tolerance may lower the risk of cardiovascular disease and hypertension. These findings are hypothesis-generating and need to be confirmed by further trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main side effects of these drugs are flatulence (which affected 73 percent of patients versus 39 percent in the placebo group in one of the above studies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/5\">",
"     5",
"    </a>",
"    ]) and diarrhea. These symptoms are usually mild, but they may reduce compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/6\">",
"     6",
"    </a>",
"    ]. In one prospective study of 893 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    , only 16 to 20 percent were still taking the drug after one year and half of them stopped the drug during year two [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/16\">",
"     16",
"    </a>",
"    ]. Slow increases in dose minimize these adverse effects.",
"   </p>",
"   <p>",
"    High serum aminotransferase concentrations have been reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. It is unclear if this is a toxic or hypersensitivity-related reaction.",
"   </p>",
"   <p>",
"    In the meta-analysis described above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    doses greater than 50 mg three times daily provided no additional glycemic benefit, but were associated with more side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     Acarbose",
"    </a>",
"    is available as 50 and 100 mg tablets which should be taken with the first bite of each meal. We begin with 50 mg three times daily. Flatulence, diarrhea, and abdominal discomfort are dose related and almost always resolve if the dose is decreased. Few people tolerate more than 300 mg daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LIPASE INHIBITORS (ORLISTAT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"     Orlistat",
"    </a>",
"    (Xenical) is a minimally absorbed drug that inhibits pancreatic and gastric lipases, blocking absorption of approximately 30 percent of ingested fat. In two randomized, double-blind, placebo-controlled trials in obese subjects lasting two years, there was significantly more weight loss with orlistat than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Weight loss was maximal after treatment for six months, after which weight was steadily regained (",
"    <a class=\"graphic graphic_figure graphicRef77227 \" href=\"UTD.htm?6/4/6222\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=see_link&amp;anchor=H16#H16\">",
"     \"Drug therapy of obesity\", section on 'Orlistat'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In obese patients with impaired glucose tolerance, the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    to a weight-loss program can improve glucose tolerance and slow the rate of progression to type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In diabetic patients, the weight loss induced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    is associated with improvement in glycemic control. As an example, in a one-year trial of 391 obese patients with type 2 diabetes, the orlistat group lost 6 percent of initial body weight, as compared with 4 percent in the placebo group (p&lt;0.001) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/23\">",
"     23",
"    </a>",
"    ]. A1C values decreased in both groups, related to the extent of weight loss. The orlistat group, however, had significantly greater decreases in serum total cholesterol and LDL cholesterol concentrations than the placebo group, independent of the degree of weight loss (",
"    <a class=\"graphic graphic_figure graphicRef81454 \" href=\"UTD.htm?33/56/34702\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another clinical trial 503 diabetic patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    or placebo (combined with a reduced-calorie diet in both groups). After one year, weight loss was greater in the orlistat group (-4.6 &plusmn; 0.3 versus -1.7 &plusmn; 0.3 percent, respectively; p = 0.014 after adjusting for changes in metformin and sulfonylurea therapy during the trial) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/24\">",
"     24",
"    </a>",
"    ]. Similar findings were reported in a second study of patients receiving insulin rather than metformin [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3078/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, orlistat may be a useful adjunct (but not primary) therapy for patients with type 2 diabetes.",
"   </p>",
"   <p>",
"    The pharmacology, efficacy, and side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=see_link&amp;anchor=H16#H16\">",
"     \"Drug therapy of obesity\", section on 'Orlistat'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alpha-glucosidase inhibitors (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"       acarbose",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/0/3077?source=see_link\">",
"       miglitol",
"      </a>",
"      , voglibose) inhibit the upper gastrointestinal enzymes (alpha-glucosidases) that convert complex polysaccharide carbohydrates into monosaccharides and thereby slow absorption of glucose and reduce postprandial blood glucose concentration. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Alpha-glucosidase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alpha-glucosidase inhibitors are less potent than the sulfonylureas or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      , lowering A1C by only 0.4 to 0.9 percentage points. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main side effects of alpha-glucosidase inhibitors, which may limit their acceptance, are flatulence and diarrhea. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although alpha-glucosidase inhibitors have been studied as monotherapy for initial treatment of diabetes, we do not consider them to be usual first-line therapy because of reduced efficacy, expense, and poor tolerance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"       \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"       Orlistat",
"      </a>",
"      (a lipase inhibitor) is a minimally absorbed drug that inhibits pancreatic and gastric lipases, blocking absorption of approximately 30 percent of ingested fat. In diabetic patients, the weight loss induced by orlistat is associated with improvement in glycemic control. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Lipase inhibitors (Orlistat)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"       Orlistat",
"      </a>",
"      may be a useful adjunct (but not primary) therapy for patients with type 2 diabetes. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Lipase inhibitors (Orlistat)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/1\">",
"      Meneilly GS, Ryan EA, Radziuk J, et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 2000; 23:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/2\">",
"      Hollander P, Pi-Sunyer X, Coniff RF. Acarbose in the treatment of type I diabetes. Diabetes Care 1997; 20:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/3\">",
"      McCulloch DK, Kurtz AB, Tattersall RB. A new approach to the treatment of nocturnal hypoglycemia using alpha-glucosidase inhibition. Diabetes Care 1983; 6:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/4\">",
"      Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diabetes Care 1994; 17:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/5\">",
"      Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994; 121:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/6\">",
"      Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 1999; 22:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/7\">",
"      Mitrakou A, Tountas N, Raptis AE, et al. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus. Diabet Med 1998; 15:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/8\">",
"      Johnston PS, Coniff RF, Hoogwerf BJ, et al. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care 1994; 17:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/9\">",
"      Johnston PS, Lebovitz HE, Coniff RF, et al. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998; 83:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/10\">",
"      Johnston PS, Feig PU, Coniff RF, et al. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients. Diabetes Care 1998; 21:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/11\">",
"      Johnston PS, Feig PU, Coniff RF, et al. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition. Diabetes Care 1998; 21:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/12\">",
"      Chiasson JL, Naditch L, Miglitol Canadian University Investigator Group. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care 2001; 24:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/13\">",
"      van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/14\">",
"      Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med 1997; 103:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/15\">",
"      Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/16\">",
"      Catalan VS, Couture JA, LeLorier J. Predictors of persistence of use of the novel antidiabetic agent acarbose. Arch Intern Med 2001; 161:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/17\">",
"      Andrade RJ, Lucena MI, Rodr&iacute;guez-Mendiz&aacute;bal M. Hepatic injury caused by acarbose. Ann Intern Med 1996; 124:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/18\">",
"      Carrascosa M, Pascual F, Aresti S. Acarbose-induced acute severe hepatotoxicity. Lancet 1997; 349:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/19\">",
"      Fujimoto Y, Ohhira M, Miyokawa N, et al. Acarbose-induced hepatic injury. Lancet 1998; 351:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/20\">",
"      Sj&ouml;str&ouml;m L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/21\">",
"      Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/22\">",
"      Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/23\">",
"      Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/24\">",
"      Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3078/abstract/25\">",
"      Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care 2002; 25:1033.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1787 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-210.101.131.232-B327878308-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_0_3078=[""].join("\n");
var outline_f3_0_3078=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ALPHA-GLUCOSIDASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Effects on serum lipids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Effects on cardiovascular events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LIPASE INHIBITORS (ORLISTAT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1787\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1787|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/4/6222\" title=\"figure 1\">",
"      Mean weight change orlistat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/56/34702\" title=\"figure 2\">",
"      HgbA1c and cholesterol orlistat",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=related_link\">",
"      Drug therapy of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11993?source=related_link\">",
"      Estimation of blood glucose control in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=related_link\">",
"      Metformin in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=related_link\">",
"      Sulfonylureas and meglitinides in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_0_3079="Long-term follow-up of the patient with classical Hodgkin lymphoma";
var content_f3_0_3079=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Long-term follow-up of the patient with classical Hodgkin lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/0/3079/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/0/3079/contributors\">",
"     Peter M Mauch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/0/3079/contributors\">",
"     Jonathan W Friedberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/0/3079/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/0/3079/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/0/3079/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/0/3079/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/0/3079/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1167671467\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Hodgkin lymphoma (formerly called Hodgkin's disease) are evaluated at the time of initial presentation to determine the stage of the disease, which is then used to determine whether the patient will be treated with radiotherapy, chemotherapy, or both. Patients are then reevaluated at regular intervals during and after treatment to assess the response and detect possible recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13512?source=see_link\">",
"     \"Overview of the treatment of classical Hodgkin lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the long-term follow-up of patients treated with Hodgkin lymphoma. The recommended approach to monitoring during and after therapy for Hodgkin lymphoma and the treatment of relapsed disease will be reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30007?source=see_link\">",
"     \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7784?source=see_link\">",
"     \"Relapse of classical Hodgkin lymphoma after initial radiotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=see_link\">",
"     \"Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1167672602\">",
"    <span class=\"h1\">",
"     FOLLOW-UP FOR RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapse after initial treatment will occur in approximately 10 to 15 percent of patients with early-stage disease and up to 40 percent of patients with advanced-stage disease at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Following the completion of therapy and restaging after the documentation of complete response, patients are seen at periodic intervals to assess a possible relapse. When planning the post-treatment surveillance strategy, care should be taken to limit the number of computed tomography (CT) scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. There is no role for routine positron emissions tomography (PET) or",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging in the longitudinal follow-up of asymptomatic patients after response assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1167672609\">",
"    <span class=\"h2\">",
"     Overall approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of therapy, the frequency and extent of visits depends upon the comfort of both the patient and physician. The value and cost-effectiveness of different screening components is described in the following section. Our general approach is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should be seen at three to six month intervals during the first three years, at six month intervals in the fourth and fifth years, and annually thereafter.",
"     </li>",
"     <li>",
"      The frequency and type of radiologic studies should reflect the initial sites of disease. Appropriate investigation should accompany any concern about symptoms or signs of possible recurrent disease.",
"     </li>",
"     <li>",
"      A complete blood count, erythrocyte sedimentation rate, and biochemical profile should be performed at each visit.",
"     </li>",
"     <li>",
"      The appropriate use and frequency of other imaging studies, such as CT and PET scan scanning, is not clear and is the subject of ongoing studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This approach is consistent with that proposed by the Cotswolds committee and the International Working Group [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Although, the 2012 update of the Hodgkin lymphoma NCCN guidelines recommends CT every 6 to 12 months out to 3 years following completion of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/10\">",
"     10",
"    </a>",
"    ], we disagree with this approach. As described in the next section, we feel that the use of CT as part of follow-up of asymptomatic patients treated for Hodgkin lymphoma is unsupported by available data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1167672616\">",
"    <span class=\"h2\">",
"     History and physical",
"    </span>",
"    &nbsp;&mdash;&nbsp;The screening value and cost-effectiveness of procedures other than the history, physical examination, and possibly chest x-ray are not clear. There have been no prospective randomized studies of routine follow-up in patients with HL. Retrospective reviews have shown that the majority of relapses are detected from the evaluation of symptoms rather than routine examination, blood tests, or imaging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Three studies that best illustrate this point are highlighted below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective review of 210 patients followed after having achieved a complete or partial remission showed 37 relapses detected in a total of 2512 clinic visits [",
"      <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/11\">",
"       11",
"      </a>",
"      ]. Thirty relapses (81 percent) were diagnosed in symptomatic patients; one-half of these symptomatic relapses resulted in an earlier appointment being scheduled. In only four cases was relapse detected as a result of routine physical examination in an asymptomatic patient.",
"     </li>",
"     <li>",
"      A retrospective cost and benefit analysis of routine follow-up examined 709 patients treated with radiotherapy for early-stage Hodgkin lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/12\">",
"       12",
"      </a>",
"      ]. Relapse occurred in 157 patients at a median of 1.9 years post-treatment. Relapse was suspected primarily by history in 55 percent of patients, physical examination in 14 percent, chest x-ray in 23 percent, and abdominal x-ray in 7 percent. Only one relapse was detected by a routine laboratory study.",
"     </li>",
"     <li>",
"      We developed a decision-analytic model to evaluate three surveillance strategies in patients treated for HL: follow-up with non-CT modalities (ie, history, physical exam, routine blood work, and chest x-ray) or with these modalities (except chest x-ray) plus routine annual CT for 5 or 10 years [",
"      <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/14\">",
"       14",
"      </a>",
"      ]. Among those with early-stage disease, there was a decrease in quality-adjusted life expectancy for patients followed with CT compared with non-CT modalities.",
"     </li>",
"     <li>",
"      A population-based study of 2071 HL survivors reported that of 5352 CT scans performed in follow-up years two through five, only 125 were followed within six months by the administration of chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1167672623\">",
"    <span class=\"h2\">",
"     Sites of relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The site of relapse is partially determined by the type of initial therapy given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1167672630\">",
"    <span class=\"h3\">",
"     After chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients treated with chemotherapy, relapse usually occurs in previous areas of involvement; new nodal sites tend to be adjacent to prior sites of disease (ie, extension) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/16\">",
"     16",
"    </a>",
"    ]. If, however, the patients also received complementary radiation therapy, relapse is more likely to occur in previously uninvolved nodal regions or extranodal sites such as the liver or lungs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=see_link&amp;anchor=H9396359#H9396359\">",
"     \"Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy\", section on 'Sites of relapse'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1167672637\">",
"    <span class=\"h3\">",
"     After radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of proper radiation technique and dose should achieve an in-field disease control rate of 96 to 99 percent. This was illustrated in a report from the Patterns of Care Study of the American College of Radiology where nodal areas treated to a dose of 30 to 45 Gy had a 4 percent in-field recurrence rate [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. There are randomized trials in stage I-II disease currently evaluating the radiation dose needed for in-field control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7784?source=see_link&amp;anchor=H4#H4\">",
"     \"Relapse of classical Hodgkin lymphoma after initial radiotherapy\", section on 'Sites of relapse'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1167672644\">",
"    <span class=\"h1\">",
"     FOLLOW-UP FOR LONG-TERM COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HL survivors are at risk of developing therapy-related complications that may present years after treatment (eg, second malignancies, cardiac disease, radiation-induced hypothyroidism) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. These complications have surfaced as significant causes of increased mortality among HL survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Screening for some of these entities is advised in the hope that early detection may lead to better management. As such, HL survivors should be assessed periodically to monitor for these potential complications.",
"   </p>",
"   <p>",
"    The malignancies that can occur include acute nonlymphocytic leukemia, non-Hodgkin lymphoma, and solid tumors such as lung cancer, breast cancer, and salivary gland carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The exact rates of secondary malignancy with the involved-field radiation technique used more commonly today is unknown, but predicted to be lower than that observed with more extensive radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The risk of acute leukemia peaks at five to nine years, while the solid tumor risk is less increased initially but progressively increases after 10 years. Acute leukemia is primarily a complication of chemotherapy, non-Hodgkin lymphoma appears to be unrelated to the type of therapy, and both lung cancer and breast cancer are primarily related to radiation therapy, particularly mantle irradiation for breast cancer. Lung cancer rates are similar after radiation therapy alone or MOPP chemotherapy alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=see_link\">",
"     \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1167672651\">",
"    <span class=\"h2\">",
"     Routine testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend the following approach to long term follow-up in patients treated for HL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A complete blood count should be obtained at each visit in part to screen for bone marrow dysfunction.",
"     </li>",
"     <li>",
"      For patients with a significant smoking history, clinicians should consider performing an annual spiral CT scan for lung cancer screening, starting five years after the diagnosis of Hodgkin lymphoma. Although there are no prospective data on this approach, it is supported by decision analysis showing a survival gain comparable to that of other generally well accepted cancer screening methods [",
"      <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Annual mammography should be performed in women treated with mantle irradiation starting 8 to 10 years after treatment or at age 40, whichever is first [",
"      <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/26\">",
"       26",
"      </a>",
"      ]. Twenty to 30 percent of patients who received chest irradiation before the age of 35 will develop breast cancer (",
"      <a class=\"graphic graphic_table graphicRef78361 \" href=\"UTD.htm?22/5/22620\">",
"       table 1",
"      </a>",
"      ). Based on the high risk of breast cancer in woman who received radiation to the chest between the age of 10 and 35 years, annual breast MRI screening has been recommended as an adjunct to mammography by an expert panel convened by the American Cancer Society [",
"      <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. The combination of mammography plus ultrasound may be an acceptable, less costly, alternative in this age group [",
"      <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/29\">",
"       29",
"      </a>",
"      ]. Either of these more intensive screening methods would be expected to increase the rate of false positives. The role of chemoprevention with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      is yet undefined in this patient group.",
"     </li>",
"     <li>",
"      Women should be advised to undergo annual cervical smears.",
"     </li>",
"     <li>",
"      Routine testing of thyroid function, with a serum thyroid stimulating hormone and T4 level, at least on an annual basis, is also recommended, particularly for those patients who received mantle irradiation or any other field involving the neck.",
"     </li>",
"     <li>",
"      Annual influenza vaccine should be considered, especially in high risk patients (eg, those that have received chest radiation or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ). If a patient has anatomic or functional asplenia (due to splenectomy or splenic irradiation), we recommend immunization with the polyvalent S. pneumoniae, conjugate quadrivalent meningococcal polysaccharide, and conjugate H. influenzae type b vaccines every six years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1167672658\">",
"    <span class=\"h2\">",
"     Cardiac and vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular disease is another potential complication of the treatment of HL [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/30\">",
"     30",
"    </a>",
"    ]. Cardiac irradiation has been associated with arrhythmias, myocardial infarction and coronary artery disease, pericarditis, myocarditis, pericardial effusion and tamponade, and sudden cardiac death, and the use of anthracyclines can significantly add to this risk [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Irradiation of the neck",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mediastinum, especially when administered at a young age, has been associated with an increased risk of stroke and transient ischemic attack (TIA) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link&amp;anchor=H12#H12\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\", section on 'Hodgkin lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although radiation risks have been reduced by regimens that limit the radiation dose delivered to the heart [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/35,36\">",
"     35,36",
"    </a>",
"    ] and by minimizing other cardiac risk factors (eg, use of cardiotoxic chemotherapy), long-term survivors of HL treated with &ge;35 Gy to the mediastinum should be considered for coronary artery disease screening studies (eg, stress testing) beginning 5 to 10 years following completion of such therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/37\">",
"     37",
"    </a>",
"    ]. All other cardiac risk factors should be minimized (eg, smoking, obesity, hyperlipidemia, hypertension, hyperglycemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/38\">",
"     38",
"    </a>",
"    ]. We recommend a baseline resting echocardiogram and stress echocardiogram at 10 years after radiation therapy. Prospective studies to evaluate the efficacy of these modalities are in progress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1167672665\">",
"    <span class=\"h2\">",
"     Screening for colorectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absolute risk of colorectal cancer in a 40-year-old patient treated for HL at age 15 or 25 is 6.1 and 3.9 per 10,000 per year, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3079/abstract/39\">",
"     39",
"    </a>",
"    ]. This is the same or greater than the risk of colorectal cancer in 50- to 54-year-old adults (4.5 per 10,000 per year), the age at which routine colorectal screening is recommended. Accordingly, clinicians should consider starting colorectal screening in such long-term HL survivors at least 10 years earlier than would be recommended for the general population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=see_link&amp;anchor=H12#H12\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\", section on 'Guidelines for average risk screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/37/13908?source=see_link\">",
"       \"Patient information: Hodgkin lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1167672679\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relapse after initial treatment will occur in approximately 10 to 15 percent of patients with early-stage disease and up to 40 percent of patients with advanced-stage disease at diagnosis. There is no role for routine PET or",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      imaging in the longitudinal follow-up of asymptomatic patients after response assessment. We model our follow-up strategy after the Cotswolds recommendations. (See",
"      <a class=\"local\" href=\"#H1167672602\">",
"       'Follow-up for relapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to evaluating the patient for recurrent disease, periodic assessment for long-term complications of therapy (eg, second malignancies, cardiac disease, radiation-induced hypothyroidism) is also indicated. (See",
"      <a class=\"local\" href=\"#H1167672644\">",
"       'Follow-up for long-term complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/1\">",
"      Oza AM, Ganesan TS, Leahy M, et al. Patterns of survival in patients with Hodgkin's disease: long follow up in a single centre. Ann Oncol 1993; 4:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/2\">",
"      Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/3\">",
"      Berrington de Gonz&aacute;lez A, Mahesh M, Kim KP, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med 2009; 169:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/4\">",
"      Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 2007; 357:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/5\">",
"      Sodickson A, Baeyens PF, Andriole KP, et al. Recurrent CT, cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults. Radiology 2009; 251:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/6\">",
"      Voss SD, Chen L, Constine LS, et al. Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: a report from the Children's Oncology Group. J Clin Oncol 2012; 30:2635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/7\">",
"      Petrausch U, Samaras P, Veit-Haibach P, et al. Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up? Ann Oncol 2010; 21:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/8\">",
"      Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/9\">",
"      Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf (Accessed on May 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/11\">",
"      Radford JA, Eardley A, Woodman C, Crowther D. Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. BMJ 1997; 314:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/12\">",
"      Torrey MJ, Poen JC, Hoppe RT. Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies. J Clin Oncol 1997; 15:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/13\">",
"      Dryver ET, Jernstr&ouml;m H, Tompkins K, et al. Follow-up of patients with Hodgkin's disease following curative treatment: the routine CT scan is of little value. Br J Cancer 2003; 89:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/14\">",
"      Guadagnolo BA, Punglia RS, Kuntz KM, et al. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol 2006; 24:4116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/15\">",
"      Hodgson DC, Grunfeld E, Gunraj N, Del Giudice L. A population-based study of follow-up care for Hodgkin lymphoma survivors: opportunities to improve surveillance for relapse and late effects. Cancer 2010; 116:3417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/16\">",
"      Young RC, Canellos GP, Chabner BA, et al. Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer 1978; 42:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/17\">",
"      Hanks GE, Kinzie JJ, White RL, et al. Patterns of care outcome studies. Results of the national practice in Hodgkin's disease. Cancer 1983; 51:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/18\">",
"      Kinzie JJ, Hanks GE, MacLean CJ, Kramer S. Patterns of care study: Hodgkin's disease relapse rates and adequacy of portals. Cancer 1983; 52:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/19\">",
"      Mauch P, Ng A, Aleman B, et al. Report from the rockefellar foundation sponsored international workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy. Eur J Haematol 2005; 75: s66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/20\">",
"      Provencio M, Mill&aacute;n I, Espa&ntilde;a P, et al. Analysis of competing risks of causes of death and their variation over different time periods in Hodgkin's disease. Clin Cancer Res 2008; 14:5300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/21\">",
"      Kiserud CE, Loge JH, Foss&aring; A, et al. Mortality is persistently increased in Hodgkin's lymphoma survivors. Eur J Cancer 2010; 46:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/22\">",
"      Swerdlow AJ, Douglas AJ, Hudson GV, et al. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. BMJ 1992; 304:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/23\">",
"      Boukheris H, Ron E, Dores GM, et al. Risk of radiation-related salivary gland carcinomas among survivors of Hodgkin lymphoma: a population-based analysis. Cancer 2008; 113:3153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/24\">",
"      Hodgson DC, Koh ES, Tran TH, et al. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 2007; 110:2576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/25\">",
"      De Bruin ML, Sparidans J, van't Veer MB, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009; 27:4239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/26\">",
"      Bloom JR, Stewart SL, Hancock SL. Breast cancer screening in women surviving Hodgkin disease. Am J Clin Oncol 2006; 29:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/27\">",
"      Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/28\">",
"      Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/29\">",
"      Alm El-Din MA, El-Badawy SA, Taghian AG. Breast cancer after treatment of Hodgkin's lymphoma: general review. Int J Radiat Oncol Biol Phys 2008; 72:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/30\">",
"      Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol 2011; 154:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/31\">",
"      Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007; 109:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/32\">",
"      Myrehaug S, Pintilie M, Tsang R, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 2008; 49:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/33\">",
"      De Bruin ML, Dorresteijn LD, van't Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 2009; 101:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/34\">",
"      Bowers DC, McNeil DE, Liu Y, et al. Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2005; 23:6508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/35\">",
"      Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993; 270:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/36\">",
"      Boivin JF, Hutchison GB, Lubin JH, Mauch P. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 1992; 69:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/37\">",
"      Heidenreich PA, Schnittger I, Strauss HW, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol 2007; 25:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/38\">",
"      Chen AB, Punglia RS, Kuntz KM, et al. Cost effectiveness and screening interval of lipid screening in Hodgkin's lymphoma survivors. J Clin Oncol 2009; 27:5383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3079/abstract/39\">",
"      Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 2007; 25:1489.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15410 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-4FABCF92AE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_0_3079=[""].join("\n");
var outline_f3_0_3079=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1167672679\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1167671467\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1167672602\">",
"      FOLLOW-UP FOR RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1167672609\">",
"      Overall approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1167672616\">",
"      History and physical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1167672623\">",
"      Sites of relapse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1167672630\">",
"      - After chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1167672637\">",
"      - After radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1167672644\">",
"      FOLLOW-UP FOR LONG-TERM COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1167672651\">",
"      Routine testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1167672658\">",
"      Cardiac and vascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1167672665\">",
"      Screening for colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1167672679\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/15410\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/15410|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/5/22620\" title=\"table 1\">",
"      Breast cancer risk Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30007?source=related_link\">",
"      Monitoring of the patient with classical Hodgkin lymphoma during and after treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13512?source=related_link\">",
"      Overview of the treatment of classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/37/13908?source=related_link\">",
"      Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7784?source=related_link\">",
"      Relapse of classical Hodgkin lymphoma after initial radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=related_link\">",
"      Second malignancies after treatment of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=related_link\">",
"      Staging and prognosis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=related_link\">",
"      Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_0_3080="Intermediate case 20 answer";
var content_f3_0_3080=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Acute anterior ST elevation MI (STEMI) with right bundle branch block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 226px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADiAd4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD12xtLZ7G4JuHzuvhhdWn/AOe7Y4zyT6fx9TzRrdpbJouostw5YWt4QDq07ZOeOCcHPoeG6miy1XTksbhW1GwDFr4gHUzk5nJHHfI5A/iHJo1vVdOk0XUUj1GwZ2tbxVVdTLEkngAdyew/i6mn7vKfXJVvbLSXxPq+78y3fWVqVuMXEhzI3TWJ3z+5x3bn0z3Py9KjvLW1XVLHFw2GvjknWZzx9mfkNnI5GN3X+HpUl9rGmFbjGp6ecyN01Mvn9zjv154z3Py9KjvNW01tUsWXUtPKrfFmI1U4A+zOMlvTJA3ep203y2MoKtbaXwvq+3qSW1laiWzJuJBiOPOdYnXHySdTn5foOnA/iNVba0tvt8iGd8C1sj/yFpwc+ZJnPPbHTonUdTVq21jTBLZ51PTxiOPOdTK4+STqf4foOnA/iNVLbVtOF/Ix1GwCm1slBOpkciSTI9iMjI/hzkUPluUlW97SWy6vv6ltLK13S/6RJ/rE/wCYxOP+WzH1545z2HzdTVSxtLZ7G4JuHzuvhhdWn/57tjjPJPp/H1PNW01jTN0v/Ez0/wD1if8AMTI/5bMfx9c9h83U1UstV05LG4VtRsAxa+IB1M5OZyRx3yOQP4hyaPduCVaz0luur7PzDW7S2TRdRZbhywtbwgHVp2yc8cE4OfQ8N1NW76ytStxi4kOZG6axO+f3OO7c+me5+XpVTW9V06TRdRSPUbBna1vFVV1MsSSeAB3J7D+Lqat32saYVuManp5zI3TUy+f3OO/XnjPc/L0oXLcEq3KtJby6vy8yO8tbVdUscXDYa+OSdZnPH2Z+Q2cjkY3df4elSW1laiWzJuJBiOPOdYnXHySdTn5foOnA/iNR3mraa2qWLLqWnlVvizEaqcAfZnGS3pkgbvU7akttY0wS2edT08YjjznUyuPkk6n+H6DpwP4jQuXUmSrci0l8Pd935lW2tLb7fIhnfAtbI/8AIWnBz5kmc89sdOidR1NWksrXdL/pEn+sT/mMTj/lsx9eeOc9h83U1UttW04X8jHUbAKbWyUE6mRyJJMj2IyMj+HORVtNY0zdL/xM9P8A9Yn/ADEyP+WzH8fXPYfN1NC5SqqrXdlLp1fZeZUsbS2exuCbh87r4YXVp/8Anu2OM8k+n8fU80a3aWyaLqLLcOWFreEA6tO2TnjgnBz6HhupostV05LG4VtRsAxa+IB1M5OZyRx3yOQP4hyaNb1XTpNF1FI9RsGdrW8VVXUyxJJ4AHcnsP4uppe7ylpVvbLSXxPq+78y3fWVqVuMXEhzI3TWJ3z+5x3bn0z3Py9KjvLW1XVLHFw2GvjknWZzx9mfkNnI5GN3X+HpUl9rGmFbjGp6ecyN01Mvn9zjv154z3Py9KjvNW01tUsWXUtPKrfFmI1U4A+zOMlvTJA3ep203y2MoKtbaXwvq+3qSW1laiWzJuJBiOPOdYnXHySdTn5foOnA/iNVba0tvt8iGd8C1sj/AMhacHPmSZzz2x06J1HU1attY0wS2edT08YjjznUyuPkk6n+H6DpwP4jVS21bThfyMdRsAptbJQTqZHIkkyPYjIyP4c5FD5blJVve0lsur7+pbSytd0v+kSf6xP+YxOP+WzH1545z2HzdTVSxtLZ7G4JuHzuvhhdWn/57tjjPJPp/H1PNW01jTN0v/Ez0/8A1if8xMj/AJbMfx9c9h83U1UstV05LG4VtRsAxa+IB1M5OZyRx3yOQP4hyaPduCVaz0luur7PzDW7S2TRdRZbhywtbwgHVp2yc8cE4OfQ8N1NW76ytStxi4kOZG6axO+f3OO7c+me5+XpVTW9V06TRdRSPUbBna1vFVV1MsSSeAB3J7D+Lqat32saYVuManp5zI3TUy+f3OO/XnjPc/L0oXLcEq3KtJby6vy8yO8tbVdUscXDYa+OSdZnPH2Z+Q2cjkY3df4elSW1laiWzJuJBiOPOdYnXHySdTn5foOnA/iNR3mraa2qWLLqWnlVvizEaqcAfZnGS3pkgbvU7akttY0wS2edT08YjjznUyuPkk6n+H6DpwP4jQuXUmSrci0l8Pd935lW2tLb7fIhnfAtbI/8hacHPmSZzz2x06J1HU1aSytd0v8ApEn+sT/mMTj/AJbMfXnjnPYfN1NVLbVtOF/Ix1GwCm1slBOpkciSTI9iMjI/hzkVbTWNM3S/8TPT/wDWJ/zEyP8Alsx/H1z2HzdTQuUqqq13ZS6dX2XmVLG0tnsbgm4fO6+GF1af/nu2OM8k+n8fU80a3aWyaLqLLcOWFreEA6tO2TnjgnBz6HhupostV05LG4VtRsAxa+IB1M5OZyRx3yOQP4hyaNb1XTpNF1FI9RsGdrW8VVXUyxJJ4AHcnsP4uppe7ylpVvbLSXxPq+78y3fWVqVuMXEhzI3TWJ3z+5x3bn0z3Py9KjvLW1XVLHFw2GvjknWZzx9mfkNnI5GN3X+HpUl9rGmFbjGp6ecyN01Mvn9zjv154z3Py9KjvNW01tUsWXUtPKrfFmI1U4A+zOMlvTJA3ep203y2MoKtbaXwvq+3qSW1laiWzJuJBiOPOdYnXHySdTn5foOnA/iNVba0tvt8iGd8C1sj/wAhacHPmSZzz2x06J1HU1attY0wS2edT08YjjznUyuPkk6n+H6DpwP4jVS21bThfyMdRsAptbJQTqZHIkkyPYjIyP4c5FD5blJVve0lsur7+pbSytd0v+kSf6xP+YxOP+WzH1545z2HzdTVSxtLZ7G4JuHzuvhhdWn/AOe7Y4zyT6fx9TzVtNY0zdL/AMTPT/8AWJ/zEyP+WzH8fXPYfN1NVLLVdOSxuFbUbAMWviAdTOTmckcd8jkD+Icmj3bglWs9Jbrq+z8w1u0tk0XUWW4csLW8IB1adsnPHBODn0PDdTVu+srUrcYuJDmRumsTvn9zju3Ppnufl6VU1vVdOk0XUUj1GwZ2tbxVVdTLEkngAdyew/i6mrd9rGmFbjGp6ecyN01Mvn9zjv154z3Py9KFy3BKtyrSW8ur8vMjvLW1XVLHFw2GvjknWZzx9mfkNnI5GN3X+HpUltZWolsybiQYjjznWJ1x8knU5+X6DpwP4jUd5q2mtqliy6lp5Vb4sxGqnAH2Zxkt6ZIG71O2pLbWNMEtnnU9PGI4851Mrj5JOp/h+g6cD+I0Ll1Jkq3ItJfD3fd+ZVtrS2+3yIZ3wLWyP/IWnBz5kmc89sdOidR1NWksrXdL/pEn+sT/AJjE4/5bMfXnjnPYfN1NVLbVtOF/Ix1GwCm1slBOpkciSTI9iMjI/hzkVbTWNM3S/wDEz0//AFif8xMj/lsx/H1z2HzdTQuUqqq13ZS6dX2XmVLG0tnsbgm4fO6+GF1af/nu2OM8k+n8fU80a3aWyaLqLLcOWFreEA6tO2TnjgnBz6HhupostV05LG4VtRsAxa+IB1M5OZyRx3yOQP4hyaNb1XTpNF1FI9RsGdrW8VVXUyxJJ4AHcnsP4uppe7ylpVvbLSXxPq+78y3fWVqVuMXEhzI3TWJ3z+5x3bn0z3Py9KjvLW1XVLHFw2GvjknWZzx9mfkNnI5GN3X+HpUl9rGmFbjGp6ecyN01Mvn9zjv154z3Py9KjvNW01tUsWXUtPKrfFmI1U4A+zOMlvTJA3ep203y2MoKtbaXwvq+3qSW1laiWzJuJBiOPOdYnXHySdTn5foOnA/iNVba0tvt8iGd8C1sj/yFpwc+ZJnPPbHTonUdTVq21jTBLZ51PTxiOPOdTK4+STqf4foOnA/iNVLbVtOF/Ix1GwCm1slBOpkciSTI9iMjI/hzkUPluUlW97SWy6vv6ltLK13S/wCkSf6xP+YxOP8Alsx9eeOc9h83U1UsbS2exuCbh87r4YXVp/8Anu2OM8k+n8fU81bTWNM3S/8AEz0//WJ/zEyP+WzH8fXPYfN1NVLLVdOSxuFbUbAMWviAdTOTmckcd8jkD+Icmj3bglWs9Jbrq+z8w1u0tk0XUWW4csLW8IB1adsnPHBODn0PDdTVu+srUrcYuJDmRumsTvn9zju3Ppnufl6VU1vVdOk0XUUj1GwZ2tbxVVdTLEkngAdyew/i6mrd9rGmFbjGp6ecyN01Mvn9zjv154z3Py9KFy3BKtyrSW8ur8vMjvLW1XVLHFw2GvjknWZzx9mfkNnI5GN3X+HpUltZWolsybiQYjjznWJ1x8knU5+X6DpwP4jUd5q2mtqliy6lp5Vb4sxGqnAH2Zxkt6ZIG71O2pLbWNMEtnnU9PGI4851Mrj5JOp/h+g6cD+I0Ll1Jkq3ItJfD3fd+ZVtrS2+3yIZ3wLWyP8AyFpwc+ZJnPPbHTonUdTVpLK13S/6RJ/rE/5jE4/5bMfXnjnPYfN1NVLbVtOF/Ix1GwCm1slBOpkciSTI9iMjI/hzkVbTWNM3S/8AEz0//WJ/zEyP+WzH8fXPYfN1NC5SqqrXdlLp1fZeZUsbS2exuCbh87r4YXVp/wDnu2OM8k+n8fU80a3aWyaLqLLcOWFreEA6tO2TnjgnBz6HhupostV05LG4VtRsAxa+IB1M5OZyRx3yOQP4hyaNb1XTpNF1FI9RsGdrW8VVXUyxJJ4AHcnsP4uppe7ylpVvbLSXxPq+78y3fWVqVuMXEhzI3TWJ3z+5x3bn0z3Py9K5n4nW8EWhloZmdjfJwdRluOPKPIVzg/73Xt0rpr7WNMK3GNT085kbpqZfP7nHfrzxnufl6VzPxP1CyutDKWt5aTv9uRtsN8ZzjyiM47jP8X4Up8vLoa5aqv1mlzKVvV+XmdNp92psLgfaJjl78YLw87p2Pb1745P8PFGvXanQtTH2iY5tLwY3w87jnt69+5/h4qOyur1bC4H2HVWGdQJO62x/rzuB+fPXhsd/u8Ua5dXraJqStYaqqm0vQWZrbAGeScPnHrjn+7VXXKcqgvbL4fifVd2aF9eB1uP9ImbdIx5eE5/c7e35ccY/2qivr5f7V09vtU//AB/ls+Zb5/49ZBn0z29Me9Go3d9sud2nat/rWzva16/Zz1w/XHpxj3pl5dX51awJsNXDDUCQC1ruJ+yvwPnxux+GB60SasYwgrfZ+F9V2LFtdqs1mftEw2xxjIeHjCSDjP1788nPOKp2t2BqUo+0TDFpYjAeHjbLKe/p27j+Lip7S7vvPsNunatnyotu1rXONkuMZfp1xnnGc84qpa3V79udhY6rzaWA2hrbgebJtPL9M9O+Qd3GKbauUoL3vh2XVfzGgl2A0v8ApEwzIh+/DziZj/XPHGTz8uKp6fdqbC4H2iY5e/GC8PO6dj29e+OT/DxU8d3fb5/+Jdq3+tjzhrXr9ofr8/XOfbOc8YqpZXV6thcD7DqrDOoEndbY/wBedwPz568Njv8Ad4ourgqas/h3XVdmSa9dqdC1MfaJjm0vBjfDzuOe3r37n+Hirl9eB1uP9ImbdIx5eE5/c7e35ccY/wBqs/XLq9bRNSVrDVVU2l6CzNbYAzyTh849cc/3at6jd32y53adq3+tbO9rXr9nPXD9cenGPehNXBU1yr4d5dV5BfXy/wBq6e32qf8A4/y2fMt8/wDHrIM+me3pj3qW2u1WazP2iYbY4xkPDxhJBxn69+eTnnFV7y6vzq1gTYauGGoEgFrXcT9lfgfPjdj8MD1p9pd33n2G3TtWz5UW3a1rnGyXGMv064zzjOecUlJakyguRfD8Pdd2QWt2BqUo+0TDFpYjAeHjbLKe/p27j+LiriXYDS/6RMMyIfvw84mY/wBc8cZPPy4rPtbq9+3OwsdV5tLAbQ1twPNk2nl+menfIO7jFW47u+3z/wDEu1b/AFsecNa9ftD9fn65z7ZznjFNNFVYK7+H7PVdkQafdqbC4H2iY5e/GC8PO6dj29e+OT/DxRr12p0LUx9omObS8GN8PO457evfuf4eKjsrq9WwuB9h1VhnUCTutsf687gfnz14bHf7vFGuXV62iakrWGqqptL0Fma2wBnknD5x645/u0rrlNFBe2Xw/E+q7s0L68Drcf6RM26Rjy8Jz+529vy44x/tVFfXy/2rp7fap/8Aj/LZ8y3z/wAesgz6Z7emPel1G8vfKuQ2m6r/AK1ySzWvP+j98P6enY+tR3l1fnVrAmw1cMNQJALWu4n7K/A+fG7H4YHrQ2rGNOCt9n4X1XYsW12qzWZ+0TDbHGMh4eMJIOM/Xvzyc84rOivJF1UCKd9n2ayWXMkIwqvMfl9wdvXpzu7VctLu+8+w26dq2fKi27Wtc42S4xl+nXGecZzziqlrdXv252FjqvNpYDaGtuB5sm08v0z075B3cYptq6K9mve+HZdV/MjQS7AaX/SJhmRD9+HnEzH+ueOMnn5cVT0+7U2FwPtExy9+MF4ed07Ht698cn+Hip47u+3z/wDEu1b/AFsecNa9ftD9fn65z7ZznjFVLK6vVsLgfYdVYZ1Ak7rbH+vO4H589eGx3+7xRdXBU1Z/Duuq7Mk167U6FqY+0THNpeDG+Hncc9vXv3P8PFXL68Drcf6RM26Rjy8Jz+529vy44x/tVn65dXraJqStYaqqm0vQWZrbAGeScPnHrjn+7VvUbu+2XO7TtW/1rZ3ta9fs564frj04x70Jq4KmuVfDvLqvIL6+X+1dPb7VP/x/ls+Zb5/49ZBn0z29Me9S212qzWZ+0TDbHGMh4eMJIOM/Xvzyc84qveXV+dWsCbDVww1AkAta7ifsr8D58bsfhgetPtLu+8+w26dq2fKi27Wtc42S4xl+nXGecZzzikpLUmUFyL4fh7ruyC1uwNSlH2iYYtLEYDw8bZZT39O3cfxcVcS7AaX/AEiYZkQ/fh5xMx/rnjjJ5+XFZ9rdXv252FjqvNpYDaGtuB5sm08v0z075B3cYq3Hd32+f/iXat/rY84a16/aH6/P1zn2znPGKaaKqwV38P2eq7Ir6deK2n3H+kTHL34wXh/inY49ee/f+7xS69dqdC1MfaJjm0vBjfDzuOe3r37n+Hio7K6vVsLgfYdVYZ1Ak7rbH+vO4H589eGx3+7xRrl1etompK1hqqqbS9BZmtsAZ5Jw+ceuOf7tK65TRQXtl8PxPqu7NC+vA63H+kTNukY8vCc/udvb8uOMf7VRX18v9q6e32qf/j/LZ8y3z/x6yDPpnt6Y96NRu77Zc7tO1b/Wtne1r1+znrh+uPTjHvTLy6vzq1gTYauGGoEgFrXcT9lfgfPjdj8MD1ok1YxhBW+z8L6rsWLa7VZrM/aJhtjjGQ8PGEkHGfr355OecVw3xH8ZL4Q0K61UXU4khj0pRGrQEyqty7SRrkHnyw+OMjqe1dpaXd959ht07Vs+VFt2ta5xslxjL9OuM84znnFeL/tHWtzq/ha1tnjurbatvcgz+UQVhtb+TA2MTyFIHpzu/hySZNaPLTqNWvZdVfc9tS7AaX/SJhmRD9+HnEzH+ueOMnn5cVT0+7U2FwPtExy9+MF4ed07Ht698cn+HijTtVnvrUXdnZ6pNbTmGWORHtSHVp2Kn7/fORjjOc8YqOyur1bC4H2HVWGdQJO62x/rzuB+fPXhsd/u8U7q5oqas/h3XVdmSa9dqdC1MfaJjm0vBjfDzuOe3r37n+Hirl9eB1uP9ImbdIx5eE5/c7e35ccY/wBqs/XLq9bRNSVrDVVU2l6CzNbYAzyTh849cc/3at6jd32y53adq3+tbO9rXr9nPXD9cenGPehNXBU1yr4d5dV5BfXy/wBq6e32qf8A4/y2fMt8/wDHrIM+me3pj3qW2u1WazP2iYbY4xkPDxhJBxn69+eTnnFV7y6vzq1gTYauGGoEgFrXcT9lfgfPjdj8MD1ohv7uFrOSSx1RESGNi5e1AVRHLyCXwBjPXtnPOKSktSZQXIvh+Huu7OQ+G3jG48R33iVbwGCTSr5NLUxPGBIkM8hRsNyCFYDqRkEkgHA7dLsBpf8ASJhmRD9+HnEzH+ueOMnn5cV4z+ztd38TeK47iC+ur+6uNO1a4kt1t40Ju41mUbWbjknGOOmQvSvYY7u+3z/8S7Vv9bHnDWvX7Q/X5+uc+2c54xTTViItVY86t06rpZEGn3amwuB9omOXvxgvDzunY9vXvjk/w8Ua9dqdC1MfaJjm0vBjfDzuOe3r37n+Hio7K6vVsLgfYdVYZ1Ak7rbH+vO4H589eGx3+7xRrl1etompK1hqqqbS9BZmtsAZ5Jw+ceuOf7tK65TpUF7ZfD8T6ruzQvrwOtx/pEzbpGPLwnP7nb2/LjjH+1UV9fL/AGrp7fap/wDj/LZ8y3z/AMesgz6Z7emPejUbu+2XO7TtW/1rZ3ta9fs564frj04x70y8ur86tYE2GrhhqBIBa13E/ZX4Hz43Y/DA9aJNWMYQVvs/C+q7Fi2u1WazP2iYbY4xkPDxhJBxn69+eTnnFU7W7A1KUfaJhi0sRgPDxtllPf07dx/FxU9pd33n2G3TtWz5UW3a1rnGyXGMv064zzjOecVUtbq9+3OwsdV5tLAbQ1twPNk2nl+menfIO7jFNtXKUF73w7Lqv5jQS7AaX/SJhmRD9+HnEzH+ueOMnn5cVT0+7U2FwPtExy9+MF4ed07Ht698cn+Hip47u+3z/wDEu1b/AFsecNa9ftD9fn65z7ZznjFVLK6vVsLgfYdVYZ1Ak7rbH+vO4H589eGx3+7xRdXBU1Z/Duuq7Mk167U6FqY+0THNpeDG+Hncc9vXv3P8PFXL68Drcf6RM26Rjy8Jz+529vy44x/tVn65dXraJqStYaqqm0vQWZrbAGeScPnHrjn+7VvUbu+2XO7TtW/1rZ3ta9fs564frj04x70Jq4KmuVfDvLqvIL6+X+1dPb7VP/x/ls+Zb5/49ZBn0z29Me9S212qzWZ+0TDbHGMh4eMJIOM/Xvzyc84qveXV+dWsCbDVww1AkAta7ifsr8D58bsfhgetPtLu+8+w26dq2fKi27Wtc42S4xl+nXGecZzzikpLUmUFyL4fh7ruyC1uwNSlH2iYYtLEYDw8bZZT39O3cfxcVcS7AaX/AEiYZkQ/fh5xMx/rnjjJ5+XFZ9rdXv252FjqvNpYDaGtuB5sm08v0z075B3cYq3Hd32+f/iXat/rY84a16/aH6/P1zn2znPGKaaKqwV38P2eq7Ig0+7U2FwPtExy9+MF4ed07Ht698cn+HijXrtToWpj7RMc2l4Mb4edxz29e/c/w8VHZXV6thcD7DqrDOoEndbY/wBedwPz568Njv8Ad4o1y6vW0TUlaw1VVNpegszW2AM8k4fOPXHP92ldcpooL2y+H4n1XdmhfXgdbj/SJm3SMeXhOf3O3t+XHGP9quU+K1yJtAwJpZM36NhniOf3JGfk5z244/Gum1G7vtlzu07Vv9a2d7WvX7OeuH649OMe9cv8VJ7qXQWFxaahCv8AaCHdcGArnyTx+7Yndj8Me9Ko1ym2WQSxVJ6fevI6HT4JBYXBNnCMPfnPkIMYnbJ+/wBug9O27rSa7BINC1ImzhH+iXhJECcYPJ+/26D07Z61Wsbe6+wzlJLBRuvuulSZyJ25zv474P8AAODmk1uC6Gi6iXksCotbwkLpUing9jv4Pof4ehp3fKZpfvl7y+J9H3Zg/D7VNS1qDxi2pJDL9h8SX9jARaxJ5UUcY2p8rD7oyecnPO5jwewvraX+1dPH2CDP28jb9nTGfsshxjzOnfGcZ5zniqDaU1it/wDYo9ItvOuZJpfJ0V4t8hhyXPz9TgHnnI3dK87/AGl0uYfhdqbPJa4+3QqPI0+S3YZUZG4ucDr8vU5z0ptuxzU04QvzJvll0fY9YtoJDNZgWcLbo4yAYEO7KScn5+c4zzjOB0wAadrBIdSlIs4Tm0sTnyE5zLLg/f79D699vWsvwbPqGreHvDmoXEmnebeafa3Eg/smQjc8LseA/wA3J6jrgH+E1ZtoLo38n7yw3/ZbIknSpCDmST/b69cn+LoMYobd0aQfNFvmWqXR90a6QSbpf9DhOJEH+oTj98wx9/14+gxwBk09PgkFhcE2cIw9+c+Qgxidsn7/AG6D07butUNE1CDW4Li50bVtD1C3SZIzLa2DTIreaTtyspAO1lOOpBAqWxt7r7DOUksFG6+66VJnInbnO/jvg/wDg5ou7jS91+8t10fZlrXoJBoWpn7HCMWl4c+QnGDyfv8AboPTtu61cvoJFW4zZwpiRhxAgx+5zjhzjjnvzz14rI1uC6Gi6iXksCotbwkLpUing9jv4Pof4ehq3fW94FuMS6eMSNjGkypj9znvJx647H5ulCbuCXur3lvLo/Iyr/XrUfE3TfCZ04jVCh1MZtI/KMPlSR4z5vXdzjp3zn5a6G2gkM1mBZwtujjIBgQ7spJyfn5zjPOM4HTAB+fjc35/bEFq08LAQ/Z1DWLmJY/sXm7RBu3Abju69SW74r3W2t7wy2eZdPOY4850mVs/JJ1HmfN9R1wD/CaE3qc1Kr7WDu7cumz8/wCrbhawSHUpSLOE5tLE58hOcyy4P3+/Q+vfb1q4kEm6X/Q4TiRB/qE4/fMMff8AXj6DHAGT5Zc+PbiTVpE8H6VH4rjt4LT+0LrTtP3QwKrOzKrmXEs3zL8in592MqVNdd4M1lvFXh6DWrEW8NtcuNkdxpDh123MiEELKQPu9MnIwvUUKRtOcZSsprp0l5eRs6fBILC4Js4Rh7858hBjE7ZP3+3Qenbd1o16CQaFqZ+xwjFpeHPkJxg8n7/boPTtu61Vsbe6+wzlJLBRuvuulSZyJ25zv474P8A4OaTW4LoaLqJeSwKi1vCQulSKeD2O/g+h/h6Gld8pul++XvL4n0fdmvfQSKtxmzhTEjDiBBj9znHDnHHPfnnrxUV9bS/2rp4+wQZ+3kbfs6Yz9lkOMeZ074zjPOc8VzHjDxXpHhq6Fprev6DY3dxMFihk06RHw0RCsR5mUTcCNzYUHkmty8trkanYhn08/wCnkLjR5cD/AEZzyvmZI6/L1z83Tim5OxhTtspr4X0fYtNm2ihuJLESJHAkpWO0ErOBHIeEVtzkgHgDJIHGQAfBIvGms+KND1zXNOjgP/CKyaVqTizRbcX9ttkeSGbE8gXhmLDc5OwKUVgQOqh8d+LdXjsb/wAEeCrfXtIkTbHdzqlqJmRpUYqhlZip2k7m2klfujbyXF38UtOF3etpPgu/a3s7aV7a1trwyzoHkIWPIwZGwwPZuAMnihu5hVbd3GWltbJ9/P8AC1zzvVdQ8TLN4Q1VoNW1BvEdxqWrrodrqMsH7ghTFAkkbbiqqu9VAU/MVC5PPoeheKZPDPwX8N30n2fxFqWoM9jZyY2fbZ5LgjHmtkhlXd8zqpyuCMk4fB408SeJdUFn4E03S38lS2oy61o11bx2k4nAFqSjN++G/wCZeRtAAJIrlLq78Q+J/EeneGvEFtpOn3mj+IFvVuLC2lKXHyXc5wHIbaGhZO2M/wCycl9SYu11GV1dK+ttvz9V6efsMGp23iPwG+s6ZbwvZXunXU8beTHuUdwcSHDIflI52kEfN1rfvoJFW4zZwpiRhxAgx+5zjhzjjnvzz14rym70HUvAcviSTRdJ+3+G9Ttrq7e3sbEKbG4X5XKRvIpCMgQjazlCpUIMjPVeHvE1p4qtL99Ju7Fbm1mMd3Zy6PLDPaSeQcxyKZPlIZWHcbkYgkKaE3c6YSTjGMpK/vdH5eR099bS/wBq6ePsEGft5G37OmM/ZZDjHmdO+M4zznPFS20EhmswLOFt0cZAMCHdlJOT8/OcZ5xnA6YAPFeJvEx07xtpugW1muq6y7PfC0s9IClIREU3HzZ0BBYthQc5UsccBs3U/EnjqGSy/sL4f/biI1EgvVgt8na2Cu2eTfkFiT8v3B6HAm9dBSlFwS51t2l5+R3dpbudTk/0SHBtLH5jAp6yy4P3+/f17gdaffzRabY399fQW8NpajzppGgXEaLK5Y/f6cEcZ4GOgyfJrv4nMyfZ9C01bjxdcLZ2kOiXukvBOrlpX3SAy/c2AOzqWysiA7OSIfHuqeONP8K6xaeKLDwqbTUrW6tln02O4V4WWC5l6SADkRMvXgAcHBAEyKtZOXuSvt0dtkdf8MPGVn4x0m9S309LbUbWF7q6tzEjiJbj99GyyB8MNrEDgMuCCtdbr0Eg0LUz9jhGLS8OfITjB5P3+3Qenbd1ryjWYLvwBrCeIbHTri80D+zbvTLi30/S3cWvk3Lukzo0q8BS6hyT5ajack895canb6n4Ju9astQ0q50mXT7ydbiLS5FBQZycl/lIwRyPkwQRmlf3TWnO1a05q6k76Pz1OnvoJFW4zZwpiRhxAgx+5zjhzjjnvzz14rxH4eweKF+Jum+GNVW5uI/CdzdJd3dxOsx1E3MTvbeZGZOMRozDLNt5GQSBWjYeN/H2vxJeaR8PrIaNeSlre9uXFufKKkLI0e5mUbP3mBu9QWGCYNN+LumRNaw+OTZeGdetb5vtWnXGjXEnlL5DBXBDHKNuXC8HJzyoBI5OxzuUHy81RJWfSSvp/X5dTb+BMt/eL4pivbifVHtfEdzbRyXYWVgipwoGVAHU7VAXPTGADynxw0291Hx94Ys7G0L3E+gagsccaBTIz28iKepySzAZOOvQV6xpOow3yaHNb6jpDx6jBHJahtLk3TjypGOFMgLHAycDtnjaa5sD7X8UNEltrzTZ3GhzozR2EjKGS8t0cEB/mYNuUnPVWXAOKbexq4rllFSv8PR/zLyNn4WQu3w28LkWsTj+zLH5miVjzx1Ljr06cgY4HJ29PgkFhcE2cIw9+c+Qgxidsn7/AG6D07buteW/CLxPHZeG9C8MeI9QtNM8SpFHEthqmkTRzMouXRFVmKK527BhclgNvVSa9Isbe6+wzlJLBRuvuulSZyJ25zv474P8A4OaObUdGSnTupLddH2Za16CQaFqZ+xwjFpeHPkJxg8n7/boPTtu61cvoJFW4zZwpiRhxAgx+5zjhzjjnvzz14rB8Uy/2d4c1K51K90q2tVtrpWkl054hkuFUb2kwCSQqn+EkDkmm2Ws2Oux3raDrnh7URE53mysi+wGFsZKynaCVbAPcFugoTd9jRW5UuZby6PyNu+tpf7V08fYIM/byNv2dMZ+yyHGPM6d8ZxnnOeK534jwuPhz4hP2WIZ0Sc58leR9mnOfv8AXgnPXgHHABsx6ha6lrqWthqmh3lxaaiY54rfTndoG+zyjbIgkJHKONhwdyk9iKx/ia0tp8ONelu7nT0iOkSIT/ZsiFmeCVVG4uRksVG7GCcH+E0JvUzqfwr8y+Hs/MqeCNC0/wAL+PtU0myBlmu9F0e5jS4ijZ2jhaS23DDDghYt3qXP3R09BSCTdL/ocJxIg/1CcfvmGPv+vH0GOAMnyfxFdReGfi3pWua7fafZ6fc6FDpwupNMm8lZjdBwr/NgFlWQ7ywBEbjjGa73RNQg1uC4udG1bQ9Qt0mSMy2tg0yK3mk7crKQDtZTjqQQKEzKlFRThzJWfZ+Rf0+CQWFwTZwjD35z5CDGJ2yfv9ug9O27rVfxbYz3HhTW4IoY7eSTT75FmSBd0Z5G4YkzlSeMdO2etQwLNBpd3PJPpsMMf293eTS5FChZmyxYyAADnBP3Bwc9ayZPEekaxp+pW+leIfDmozLZXcjQ2VqZHC9j8sp2jHRiMLnBzmlzPlOtqMqtnJayfR92eceC7vx1f2+taxBpTy32g2S+Gxps98kkN1fRD9/cOS4AdFAY9d+Th810fwTn1q8TU4NdS5v7u08VXdubi8hhOWFs+6IKspCBSC2xf3Y3DazYIr0TVhPa2t7PPdaZBDEzu8jaXJEqKICSSTJhQOvPT73SqtvcxatLpl7pd/o1/Zy3zCKe10x5ImxbyA4KyEEAhhtBznntiht2OalSaaftL2i+j7ehtW0EhmswLOFt0cZAMCHdlJOT8/OcZ5xnA6YAPP6zrOm+GludR16SxsbNbOzPmTRoC53TNhRvy7MFb5QCzAHgVwPxA8YhPC/j/TruK3VtIs7e0dotPP777XbMEbJk+Vg8hByDwquN33a6PQfh/o+m6pHJDZWE89va2BgkvbG5vDABK+0RGWVtgGP4SA3RQO7cncvmbclCSei6S/m9CnD8Rp1kTVLvwnLB4Nu54Y7XXHEQGHnKpLLEzqYYT8/zsfuhBxvFd3p8EgsLgmzhGHvznyEGMTtk/f7dB6dt3Ws/XdCl13RNW0m7uLSO3vYzbO8WlSB0V5XUlCXO0gHjIPQL1FcL4L8W2OjaTc+HPE3iDR7LWtHNxaSvqVqyvdfOTHMsjSjeWGeTgqQwYcgku7ii3C8ZT3fZ9npt93oz0rXoJBoWpn7HCMWl4c+QnGDyfv8AboPTtu61cvoJFW4zZwpiRhxAgx+5zjhzjjnvzz14rg08aeH9estTtNJ8SeHru5WG9i+zxWLrLIVBbMYMnzDaCQ4BUAHrg1qaj4m0ePUbjTT4l8LpqP2gwi1+zbJd5j2hAhlyDv424zu59qFLU0i04x99by6PyOjvraX+1dPH2CDP28jb9nTGfsshxjzOnfGcZ5znikZktIobm7htYbaKBJZJZo41RUEchLsTIBjAJJJH3cnGADzPjrXY/Cs+i3mrTaXFZzaylo0z6XJGkG+2kw7Zk+6D1XIxndnAwfNPhn8O9U1++bXddvdnhzVL19XttGltZJEufNZnR7mNWAYYiiZU3ODnno4YTeuhhUq6KEXd27PTd/qtjq9N+JNhdaoNRh0iT/hEnhtLVtemtRHCk3myAFlZgwiY7kMxwu9dpwDur0xIJN0v+hwnEiD/AFCcfvmGPv8Arx9BjgDJ5+60ltUS/sL02MkF1p9rDOP7NmG9HeVWAZZAQSCcsD82QBgjNcP8PtWHhbVLr4f63qNlb3VhcRx6RLqFjI76haNMdm1y67nUsYygA+4FXO04E2VUbhO0p3vbWz7LT/L8T0zT4JBYXBNnCMPfnPkIMYnbJ+/26D07butGvQSDQtTP2OEYtLw58hOMHk/f7dB6dt3Wqtjb3X2GcpJYKN1910qTORO3Od/HfB/gHBzSa3BdDRdRLyWBUWt4SF0qRTwex38H0P8AD0NK75TqS/fL3l8T6PuzXvoJFW4zZwpiRhxAgx+5zjhzjjnvzz14rlPitC8egZa1iiAv0GViVMHySccOeO+OnfPat++t7wLcYl08YkbGNJlTH7nPeTj1x2PzdK5n4nwzx6GTM1oy/bkAEOnvbkfuj/EzHA/2evelUb5TXLF/tNL3vwfkdNp6t9guP3sx+e//AOWU3/PdvVu/fPA/iyaNeVv7C1P97N/x6XnWKb1/3u/fPA/iyaqWNpbPY3BNw+d18MLq0/8Az3bHGeSfT+Pqea5PxV8LvA96mu6rcaPavqF1HeXM0o1W4G+UvvB2hgOvIXGD14xTV+U5p86rL2d37z3sur9Tc17xxoGn+Ll8M3eqsuqTknayShEdogI43Zn+V5Mnap5IXk4ZVbC+P9tHqHhax0W4Ny/9s6/ZaesgWVTCXwTJhiQxwpUKefmBzgYN25+FvgSPRbvS4ND09bJ5hI0ceoTMWZImKNuzuYgu2CTn5ivQmq9r8KvAWjeIdKu9N0Wxgnjv8pINWuG24gdgQSxxhwCG6hgB703e2pxuFWcVFdtdvmvPT0v5CaH4nh8NfD7wE5ttV1O5vNOsoILPTbeSWdyLZ2YqpkXKqFOSDgZ4wM5pDSfFfjeKS28RGPw1pssdiLnToPOu5rq3E0waKSZWVUVxz8gOQQAR8ynif2ddDu73VLOfXLa5sIvDds+nRQXVzLATPO8szyoeDDiNo0IA+YMDn5iK9ttrS2+3yIZ3wLWyP/IWnBz5kmc89sdOidR1NJ3diqEfa025N2stFbul3OE1zwpN4FvLfxD4BguI7S1+z2mo6HZWUr/boBcMqyKAdxnTPDM2SP4gVbdrr4zeFLuGx8O+LdRSOO+uHmh0yaFAPtDZUefJGWboSqgnkAhmBx1yWVrul/0iT/WJ/wAxicf8tmPrzxznsPm6mqljaWz2NwTcPndfDC6tP/z3bHGeSfT+PqeaetzZUlFPlk0rrouz8zitU8eavq2i6na6N4L8Vw3bWtxiXVrNrS3jUuA7s5mJIUEkqoJJGCD94XNT1jxt4eu9RtL/AES58TWjO8lrqVgGtyZJEwsEsMkhKKuSDLlsRhS275q6nW7S2TRdRZbhywtbwgHVp2yc8cE4OfQ8N1NW76ytStxi4kOZG6axO+f3OO7c+me5+XpQua4Kn7qblK/vdF5dLnh/h25v9W+OPhzVNZ0mfRNXm1fU4Li1fzZXjEemWyr84IZwRlhjs2eQRXSeE9Km+Kumw6t4m1a8n8LX0zfZdCjt3jQRxNNGhldG3ucx79quFDE44XaN/wCKHh7U9Ti0xvB+sWum6/DqRMF7dalLMsaNaSLIAWDYyDjdjOQBxgGt7w14d0nQtO0nTdNd4bS2giRR/a0qc7ZCzNswFYkktgAZb/aNJXOSFCzkpXs1fZf5+pPo9hb6fObWwQWttHaWWyGC3lREzLKeArAdSTxwSflwawLbw54j0VvEDeHdfgmju7172C11OwupBFLJMxMYkSZdsZfLfcYgu2MtkndtrS2+3yIZ3wLWyP8AyFpwc+ZJnPPbHTonUdTVpLK13S/6RJ/rE/5jE4/5bMfXnjnPYfN1NNXO2tThJ6t6W7dl5nnEcnxbi0y7kt4vB84T7a3lA6gHdhK29RuIXlsgbiB03kGmXc/xF8WaJqEs6p4IsoIbvdG0cl9dXLI2HU7sRrC2SNw+bKZOQwJ7+xtLZ7G4JuHzuvhhdWn/AOe7Y4zyT6fx9TzRrdpbJouostw5YWt4QDq07ZOeOCcHPoeG6mlrygqEfbJc0vi8u763uYOk+BHtL7UdV8Va1P4l1ma3bTTc3GnG3T7J5ZkMRjXgksxyXydoXooIbMu/hVZWt9ZaXpWu65ZeF7i8MdzoiCd4GX7OzFYyx8yMP+8EgDEush5UAV3l9ZWpW4xcSHMjdNYnfP7nHdufTPc/L0qO8tbVdUscXDYa+OSdZnPH2Z+Q2cjkY3df4elDvYzhQptJa7Pt29f+AWNHsorC20qzs2litre3hiiQRznYixuFA+bJwBjI6844DZjtVb+0pf3sw/0Sx/5ZTf8APWX/AGu3bHB/hwaLaytRLZk3EgxHHnOsTrj5JOpz8v0HTgfxGqttaW32+RDO+Ba2R/5C04OfMkznntjp0TqOppu90bKMUpJN7Lou68zWRTul/ezf6xP+WU3/AD2b/a/HnnPA+bJrxDULO7uf2kNDe38+SG10u+uLghJAEXz76MMQTnG6RRnoN/Ofmz7Glla7pf8ASJP9Yn/MYnH/AC2Y+vPHOew+bqaxrHw9o7X1zrO0f2oYb2y+0Lq0+4wi5ZgmN2DzkgfxZJPNDvcznBSjZN/Eui7PzNnXlb+wtT/ezf8AHpedYpvX/e7988D+LJrlvH/gWfV9fh8Q6Fr97oev2yvaNdJaSTLPbmIt5bpI2PvZxn1JOQF272t2lsmi6iy3Dlha3hAOrTtk544Jwc+h4bqat31lalbjFxIcyN01id8/ucd259M9z8vSjW5bhCUEm3vLovLzOf8ADPhJvD+rJeahq95q2v6jqC/btSltJYTMI7SURgRowChVOMcsclidpCjrLZW86z/ezD93H0imOPkk6Ybn8MDk44Bzn3lrarqlji4bDXxyTrM54+zPyGzkcjG7r/D0qS2srUS2ZNxIMRx5zrE64+STqc/L9B04H8RoV9SeSMaaSb+Hsu78wtVb+0pf3sw/0Sx/5ZTf89Zf9rt2xwf4cGvMP2mrS9f4a3F5YzyqLG8SSc7ZF/dOZ4GGST184Ag/3iOu7PottaW32+RDO+Ba2R/5C04OfMkznntjp0TqOpqj4q8J6X4o8P6lo1/d3MdrdtEHaPVpC2BcFuA4ZT0HJU4HzdTQrtCxUFOMopu+nRdl5mxp6t9guP3sx+e//wCWU3/PdvVu/fPA/iya4HU/hTo1jZaxLYX+rW2mSSS6k+ixxn7A0sPQGNlPyEqrFSdoKKGBCqB2djaWz2NwTcPndfDC6tP/AM92xxnkn0/j6nmjW7S2TRdRZbhywtbwgHVp2yc8cE4OfQ8N1NLXlNZU4TrJSu/efRd35mvfKQtx+9mOJG6xTDP7n3b8Oecc/d4qO9Q/2lp+Zp939oEZ8qf/AJ9ZOcbs5xj3/Cq99ZWpW4xcSHMjdNYnfP7nHdufTPc/L0qG4hsn1GxaK73odQZSw1qdgMW8gPzZ4wwwW65yvTNOV7EQStu/hfRdvUyoPh74OaS1DeF9EIdELf8AEozyVcnp16Dpwe3AOfLvhjYf2L+0D4j0S1uJf7OtbD7RbRCJgIPPltJWRFTGFBbAHTjI5Oa9strK1EtmTcSDEcec6xOuPkk6nPy/QdOB/Ea43QvBVjZfEnW/ED3e+W8sdPSMDU5UaP5tsikjk/6iI8k7ecdBTd7mFWknKLjfRrottfP0Ov1rRbDXtNvdO1iH7XZTsqSRSwTMDmZxn73BHUHqD0IYE1554Y8aweFbK98PePNRksbvTorw22oXZkxq0ImZfNA3kiVmVt0Zyc4OGyQvoyWVrul/0iT/AFif8xicf8tmPrzxznsPm6msa48O6HrenFdXtra+WCa9khW41CSURuJ2CsoPG7HQ9W5J5pa3NnTWsot3uui7PzOQl8Lt40F74u8X20xtksbo6No93FJItqnXzpV3FRM+ckZYIAoYswBXrbv4e+Do1nK+F9EG12A/4lG3jyt3fpz2PPfpxWhrdpbLouoMlw5Itbw4OrTtnngYJwc+h4Ydat31lalbjFxIcyN01id8/ucd259M9z8vShXuEKUFFb7y6Ly8zjde+EfgW/1ixM3h61j3XX2dltra5t1KCB3+5G687uf73A528V598a/AsOnS6RL4QtLDTW8ReRoNykcEkCh5pVkR1VBj/liysQCCrYCnkj2+8tbVdUscXDYa+OSdZnPH2Z+Q2cjkY3df4elYXijwhb+Im8NBdSNr/Z1/Z6ixkv5pA4iEpKct+7JzjcMlDjH3jS1dzGvQg6acU72XRd359jobVW/tKX97MP8ARLH/AJZTf89Zf9rt2xwf4cGuL1HwM3h6a/1v4cgaZqirmTTIraUWmpFWdYo3TeojYMq7XUrgswOSWNdVbWlt9vkQzvgWtkf+QtODnzJM557Y6dE6jqatJZWu6X/SJP8AWJ/zGJx/y2Y+vPHOew+bqaaudFaEJPVvp0XZeZ5Lba3e/Em207QdPurnSo0+23XiixaG586BPP4s2kzgead4P3TtUlu6t1/jH4ceEdT0G5N1oNlutba4eFobSWFk8vIQbkYHaMng/KP4gTit7T7Cy+x3brKVd5L4sU1WYFj5xAJAPJwo6/fxk07W7S2TRdRZbhywtbwgHVp2yc8cE4OfQ8N1NLXlFGjF1f3jbblrovPz2OYu/hL4ZN0ZdQ/tLU7a0cCxsr+W5lt7JVhB2xqz8KdqAq5YYRf4QQWa18HvAd3rdtJJ4fgQz3nlOsEN1Cm0WzMAESQAcqDgAHvnBNdrfWVqVuMXEhzI3TWJ3z+5x3bn0z3Py9KjvLW1XVLHFw2GvjknWZzx9mfkNnI5GN3X+HpQ722M4UKTVrPZ9I9vU4WL4L+FxJBb2Mmp2Gl3JtZrzToPNeC8aPzXXzd+52HJGFZVOcgArmu+tVb+0pf3sw/0Sx/5ZTf89Zf9rt2xwf4cGi2srUS2ZNxIMRx5zrE64+STqc/L9B04H8RqrbWlt9vkQzvgWtkf+QtODnzJM557Y6dE6jqabumaQpwgpKN1oui/m9TWRTul/ezf6xP+WU3/AD2b/a/HnnPA+bJrAHh3SNRP9oahp1pd31tJeNDcT2LvJGUuXK7XYkrgknP8JPOTzWmlla7pf9Ik/wBYn/MYnH/LZj688c57D5upqpY2ls9jcE3D53XwwurT/wDPdscZ5J9P4+p5o1uUlHler3XRdn5md4s8H+HL+01XUL/RNNur9ra5ka5n01nkZk4Ul2ycgAcn7uMHJpdS+H3hJtOvrIeHdLS2lch0j01oskQthsg5VhubB+8Mk5xxWhrdpbJouostw5YWt4QDq07ZOeOCcHPoeG6mrd9ZWpW4xcSHMjdNYnfP7nHdufTPc/L0oV7i5IOKvfeXReXmcbrfwr8O3yWGkXk2tTaUNRj8q0e6vXihSO1O2NEaQgKdmD/GFZtrKMbe+tlbzrP97MP3cfSKY4+STphufwwOTjgHOfeWtquqWOLhsNfHJOsznj7M/IbORyMbuv8AD0qS2srUS2ZNxIMRx5zrE64+STqc/L9B04H8RoV9SPZU4QXLdXj2j5+YWqt/aUv72Yf6JY/8spv+esv+127Y4P8ADg066020v3Q30K3JtrqOeAzW0r+VKJnAkXJ+Vhk4PXkgENkmnbWlt9vkQzvgWtkf+QtODnzJM557Y6dE6jqatJZWu6X/AEiT/WJ/zGJx/wAtmPrzxznsPm6mhXNKqjd6vp0XZeYaerfYLj97Mfnv/wDllN/z3b1bv3zwP4smjXlb+wtT/ezf8el51im9f97v3zwP4smqljaWz2NwTcPndfDC6tP/AM92xxnkn0/j6nmjW7S2TRdRZbhywtbwgHVp2yc8cE4OfQ8N1NLXlNEl7Zav4n0Xd+Zr3ykLcfvZjiRusUwz+592/DnnHP3eK5T4rKRoHMkrf6egw0cq/wDLE8/OxGfY8++OK376ytStxi4kOZG6axO+f3OO7c+me5+XpXM/E63gi0MtDMzsb5ODqMtxx5R5CucH/e69ulKpflNcsS+s0tX9y8vM27LVdOSxuFbUbAMWviAdTOTmckcd8jkD+IcmjW9V06TRdRSPUbBna1vFVV1MsSSeAB3J7D+Lqat6fdqbC4H2iY5e/GC8PO6dj29e+OT/AA8Ua9dqdC1MfaJjm0vBjfDzuOe3r37n+HinZ8pklH2y0fxP7Xm/IL7WNMK3GNT085kbpqZfP7nHfrzxnufl6VHeatprapYsupaeVW+LMRqpwB9mcZLemSBu9TtrQvrwOtx/pEzbpGPLwnP7nb2/LjjH+1UV9fL/AGrp7fap/wDj/LZ8y3z/AMesgz6Z7emPem07GNNRts/hf2vL0ILbWNMEtnnU9PGI4851Mrj5JOp/h+g6cD+I1UttW04X8jHUbAKbWyUE6mRyJJMj2IyMj+HORWvbXarNZn7RMNscYyHh4wkg4z9e/PJzziqdrdgalKPtEwxaWIwHh42yynv6du4/i4oadyko+9o9l9rz9ATWNM3S/wDEz0//AFif8xMj/lsx/H1z2HzdTVSy1XTksbhW1GwDFr4gHUzk5nJHHfI5A/iHJrXS7AaX/SJhmRD9+HnEzH+ueOMnn5cVT0+7U2FwPtExy9+MF4ed07Ht698cn+HiizuCUeV6Pdfa8n5FTW9V06TRdRSPUbBna1vFVV1MsSSeAB3J7D+Lqat32saYVuManp5zI3TUy+f3OO/XnjPc/L0o167U6FqY+0THNpeDG+Hncc9vXv3P8PFXL68Drcf6RM26Rjy8Jz+529vy44x/tUJO4JR5Vo95fa9PIz7zVtNbVLFl1LTyq3xZiNVOAPszjJb0yQN3qdtSW2saYJbPOp6eMRx5zqZXHySdT/D9B04H8Rqe+vl/tXT2+1T/APH+Wz5lvn/j1kGfTPb0x71LbXarNZn7RMNscYyHh4wkg4z9e/PJzzihJ6kyUeRaP4f5vN+RkW2racL+RjqNgFNrZKCdTI5EkmR7EZGR/DnIq2msaZul/wCJnp/+sT/mJkf8tmP4+uew+bqaLW7A1KUfaJhi0sRgPDxtllPf07dx/FxVxLsBpf8ASJhmRD9+HnEzH+ueOMnn5cUJMqqo3ej6fa8l5GRZarpyWNwrajYBi18QDqZyczkjjvkcgfxDk0a3qunSaLqKR6jYM7Wt4qqupliSTwAO5PYfxdTVvT7tTYXA+0THL34wXh53Tse3r3xyf4eKNeu1OhamPtExzaXgxvh53HPb179z/DxSs+U0Sj7ZaP4n9rzfkOvdV09obmRb+yaMSkF11IuoJgOBnoc4OM8nBXpmobzVtNbVLFl1LTyq3xZiNVOAPszjJb0yQN3qdtaF9eB1uP8ASJm3SMeXhOf3O3t+XHGP9qor6+X+1dPb7VP/AMf5bPmW+f8Aj1kGfTPb0x705J2Maaj2fwv7Xl6EFtrGmCWzzqenjEcec6mVx8knU/w/QdOB/EaqW2racL+RjqNgFNrZKCdTI5EkmR7EZGR/DnIrXtrtVmsz9omG2OMZDw8YSQcZ+vfnk55xVO1uwNSlH2iYYtLEYDw8bZZT39O3cfxcUNO5SUfe0ey+15+gJrGmbpf+Jnp/+sT/AJiZH/LZj+PrnsPm6mqllqunJY3CtqNgGLXxAOpnJzOSOO+RyB/EOTWul2A0v+kTDMiH78POJmP9c8cZPPy4qnp92psLgfaJjl78YLw87p2Pb1745P8ADxRZ3BKPK9HuvteT8ipreq6dJouopHqNgzta3iqq6mWJJPAA7k9h/F1NW77WNMK3GNT085kbpqZfP7nHfrzxnufl6Ua9dqdC1MfaJjm0vBjfDzuOe3r37n+Hirl9eB1uP9ImbdIx5eE5/c7e35ccY/2qEncEo8q0e8vtenkZ95q2mtqliy6lp5Vb4sxGqnAH2Zxkt6ZIG71O2pLbWNMEtnnU9PGI4851Mrj5JOp/h+g6cD+I1PfXy/2rp7fap/8Aj/LZ8y3z/wAesgz6Z7emPepba7VZrM/aJhtjjGQ8PGEkHGfr355OecUJPUmSjyLR/D/N5vyMi21bThfyMdRsAptbJQTqZHIkkyPYjIyP4c5FW01jTN0v/Ez0/wD1if8AMTI/5bMfx9c9h83U0Wt2BqUo+0TDFpYjAeHjbLKe/p27j+LiriXYDS/6RMMyIfvw84mY/wBc8cZPPy4oSZVVRu9H0+15LyMiy1XTksbhW1GwDFr4gHUzk5nJHHfI5A/iHJo1vVdOk0XUUj1GwZ2tbxVVdTLEkngAdyew/i6mrmn3udOuUFzPhpL75fMhwSZ2x09eff8Au8UmvXanQtTH2iY5tLwY3w87jnt69+5/h4pWfKaJR9stH8T+15vyC+1jTCtxjU9POZG6amXz+5x3688Z7n5elR3mraa2qWLLqWnlVvizEaqcAfZnGS3pkgbvU7a0L68Drcf6RM26Rjy8Jz+529vy44x/tVFfXy/2rp7fap/+P8tnzLfP/HrIM+me3pj3ptOxjTUbbP4X9ry9CC21jTBLZ51PTxiOPOdTK4+STqf4foOnA/iNVLbVtOF/Ix1GwCm1slBOpkciSTI9iMjI/hzkVr212qzWZ+0TDbHGMh4eMJIOM/Xvzyc84qna3YGpSj7RMMWliMB4eNssp7+nbuP4uKGncpKPvaPZfa8/QE1jTN0v/Ez0/wD1if8AMTI/5bMfx9c9h83U1UstV05LG4VtRsAxa+IB1M5OZyRx3yOQP4hya10uwGl/0iYZkQ/fh5xMx/rnjjJ5+XFU9Pu1NhcD7RMcvfjBeHndOx7evfHJ/h4os7glHlej3X2vJ+RU1vVdOk0XUUj1GwZ2tbxVVdTLEkngAdyew/i6mrd9rGmFbjGp6ecyN01Mvn9zjv154z3Py9KNeu1OhamPtExzaXgxvh53HPb179z/AA8VcvrwOtx/pEzbpGPLwnP7nb2/LjjH+1Qk7glHlWj3l9r08jPvNW01tUsWXUtPKrfFmI1U4A+zOMlvTJA3ep21Jbaxpgls86np4xHHnOplcfJJ1P8AD9B04H8Rqe+vl/tXT2+1T/8AH+Wz5lvn/j1kGfTPb0x71LbXarNZn7RMNscYyHh4wkg4z9e/PJzzihJ6kyUeRaP4f5vN+RkW2racL+RjqNgFNrZKCdTI5EkmR7EZGR/DnIq2msaZul/4men/AOsT/mJkf8tmP4+uew+bqaLW7A1KUfaJhi0sRgPDxtllPf07dx/FxVxLsBpf9ImGZEP34ecTMf6544yeflxQkyqqjd6Pp9ryXkZFlqunJY3CtqNgGLXxAOpnJzOSOO+RyB/EOTRreq6dJouopHqNgzta3iqq6mWJJPAA7k9h/F1NW9Pu1NhcD7RMcvfjBeHndOx7evfHJ/h4o167U6FqY+0THNpeDG+Hncc9vXv3P8PFKz5TRKPtlo/if2vN+QX2saYVuManp5zI3TUy+f3OO/XnjPc/L0qO81bTW1SxZdS08qt8WYjVTgD7M4yW9MkDd6nbWhfXgdbj/SJm3SMeXhOf3O3t+XHGP9qor6+X+1dPb7VP/wAf5bPmW+f+PWQZ9M9vTHvTadjGmo22fwv7Xl6EFtrGmCWzzqenjEcec6mVx8knU/w/QdOB/EaqW2racL+RjqNgFNrZKCdTI5EkmR7EZGR/DnIrXtrtVmsz9omG2OMZDw8YSQcZ+vfnk55xVO1uwNSlH2iYYtLEYDw8bZZT39O3cfxcUNO5SUfe0ey+15+gJrGmbpf+Jnp/+sT/AJiZH/LZj+PrnsPm6mqllqunJY3CtqNgGLXxAOpnJzOSOO+RyB/EOTWul2A0v+kTDMiH78POJmP9c8cZPPy4qnp92psLgfaJjl78YLw87p2Pb1745P8ADxRZ3BKPK9HuvteT8ipreq6dJouopHqNgzta3iqq6mWJJPAA7k9h/F1NW77WNMK3GNT085kbpqZfP7nHfrzxnufl6Ua9dqdC1MfaJjm0vBjfDzuOe3r37n+Hirl9eB1uP9ImbdIx5eE5/c7e35ccY/2qEncEo8q0e8vtenkZ95q2mtqliy6lp5Vb4sxGqnAH2Zxkt6ZIG71O2pLbWNMEtnnU9PGI4851Mrj5JOp/h+g6cD+I1PfXy/2rp7fap/8Aj/LZ8y3z/wAesgz6Z7emPepba7VZrM/aJhtjjGQ8PGEkHGfr355OecUJPUmSjyLR/D/N5vyMi21bThfyMdRsAptbJQTqZHIkkyPYjIyP4c5FWotX0xfMB1SwJ8xOTqeM/vm546+uew+bqaW1uwNSlH2iYYtLEYDw8bZZT39O3cfxcVcS7AaX/SJhmRD9+HnEzH+ueOMnn5cUJMqqo3ej6fa8l5GRZarpyWNwrajYBi18QDqZyczkjjvkcgfxDk0a3qunSaLqKR6jYM7Wt4qqupliSTwAO5PYfxdTVvT7tTYXA+0THL34wXh53Tse3r3xyf4eKNeu1OhamPtExzaXgxvh53HPb179z/DxSs+U0Sj7ZaP4n9rzfkF9rGmFbjGp6ecyN01Mvn9zjv154z3Py9K5n4n6hZXWhlLW8tJ3+3I22G+M5x5RGcdxn+L8K7K+vA63H+kTNukY8vCc/udvb8uOMf7Vcp8VrkTaBgTSyZv0bDPEc/uSM/Jzntxx+NKafKa5Yo/WqVk/v9PI27K6vVsLgfYdVYZ1Ak7rbH+vO4H589eGx3+7xRrl1etompK1hqqqbS9BZmtsAZ5Jw+ceuOf7tSafBILC4Js4Rh7858hBjE7ZP3+3Qenbd1o16CQaFqZ+xwjFpeHPkJxg8n7/AG6D07butO3u7mClD2y0j8T7935k+o3d9sud2nat/rWzva16/Zz1w/XHpxj3pl5dX51awJsNXDDUCQC1ruJ+yvwPnxux+GB61YvoJFW4zZwpiRhxAgx+5zjhzjjnvzz14qK+tpf7V08fYIM/byNv2dMZ+yyHGPM6d8ZxnnOeKGtNzGEoW2j8L79vULS7vvPsNunatnyotu1rXONkuMZfp1xnnGc84qpa3V79udhY6rzaWA2hrbgebJtPL9M9O+Qd3GK0LaCQzWYFnC26OMgGBDuyknJ+fnOM84zgdMAGnawSHUpSLOE5tLE58hOcyy4P3+/Q+vfb1pta7lKUPe0jsu/83qTx3d9vn/4l2rf62POGtev2h+vz9c59s5zxiqlldXq2FwPsOqsM6gSd1tj/AF53A/Pnrw2O/wB3itBIJN0v+hwnEiD/AFCcfvmGPv8Arx9BjgDJp6fBILC4Js4Rh7858hBjE7ZP3+3Qenbd1otruClCz0juu/Z+ZHrl1etompK1hqqqbS9BZmtsAZ5Jw+ceuOf7tW9Ru77Zc7tO1b/Wtne1r1+znrh+uPTjHvUGvQSDQtTP2OEYtLw58hOMHk/f7dB6dt3Wrl9BIq3GbOFMSMOIEGP3OccOccc9+eevFCWu4KUOVaR3l38vMr3l1fnVrAmw1cMNQJALWu4n7K/A+fG7H4YHrT7S7vvPsNunatnyotu1rXONkuMZfp1xnnGc84ovraX+1dPH2CDP28jb9nTGfsshxjzOnfGcZ5znipbaCQzWYFnC26OMgGBDuyknJ+fnOM84zgdMAFJb6kylDkWkfh8+78zPtbq9+3OwsdV5tLAbQ1twPNk2nl+menfIO7jFW47u+3z/APEu1b/Wx5w1r1+0P1+frnPtnOeMVBawSHUpSLOE5tLE58hOcyy4P3+/Q+vfb1q4kEm6X/Q4TiRB/qE4/fMMff8AXj6DHAGS0vMqrKF3pHp37LzM+yur1bC4H2HVWGdQJO62x/rzuB+fPXhsd/u8Ua5dXraJqStYaqqm0vQWZrbAGeScPnHrjn+7UmnwSCwuCbOEYe/OfIQYxO2T9/t0Hp23daNegkGhamfscIxaXhz5CcYPJ+/26D07butK3u7milD2y0j8T7935k+o3d9sud2nat/rWzva16/Zz1w/XHpxj3pl5dX51awJsNXDDUCQC1ruJ+yvwPnxux+GB61YvoJFW4zZwpiRhxAgx+5zjhzjjnvzz14qK+tpf7V08fYIM/byNv2dMZ+yyHGPM6d8ZxnnOeKGtNzGEoW2j8L79vULS7vvPsNunatnyotu1rXONkuMZfp1xnnGc84qpa3V79udhY6rzaWA2hrbgebJtPL9M9O+Qd3GK0LaCQzWYFnC26OMgGBDuyknJ+fnOM84zgdMAGnawSHUpSLOE5tLE58hOcyy4P3+/Q+vfb1pta7lKUPe0jsu/wDN6k8d3fb5/wDiXat/rY84a16/aH6/P1zn2znPGKqWV1erYXA+w6qwzqBJ3W2P9edwPz568Njv93itBIJN0v8AocJxIg/1CcfvmGPv+vH0GOAMmnp8EgsLgmzhGHvznyEGMTtk/f7dB6dt3Wi2u4KULPSO679n5keuXV62iakrWGqqptL0Fma2wBnknD5x645/u1b1G7vtlzu07Vv9a2d7WvX7OeuH649OMe9Qa9BINC1M/Y4Ri0vDnyE4weT9/t0Hp23dauX0EircZs4UxIw4gQY/c5xw5xxz35568UJa7gpQ5VpHeXfy8yveXV+dWsCbDVww1AkAta7ifsr8D58bsfhgetPtLu+8+w26dq2fKi27Wtc42S4xl+nXGecZzzii+tpf7V08fYIM/byNv2dMZ+yyHGPM6d8ZxnnOeKltoJDNZgWcLbo4yAYEO7KScn5+c4zzjOB0wAUlvqTKUORaR+Hz7vzM+1ur37c7Cx1Xm0sBtDW3A82TaeX6Z6d8g7uMVbju77fP/wAS7Vv9bHnDWvX7Q/X5+uc+2c54xUFrBIdSlIs4Tm0sTnyE5zLLg/f79D699vWriQSbpf8AQ4TiRB/qE4/fMMff9ePoMcAZLS8yqsoXekenfsvMz7K6vVsLgfYdVYZ1Ak7rbH+vO4H589eGx3+7xRrl1etompK1hqqqbS9BZmtsAZ5Jw+ceuOf7tSafBILC4Js4Rh7858hBjE7ZP3+3Qenbd1o16CQaFqZ+xwjFpeHPkJxg8n7/AG6D07butK3u7milD2y0j8T7935k+o3d9sud2nat/rWzva16/Zz1w/XHpxj3pl5dX51awJsNXDDUCQC1ruJ+yvwPnxux+GB61YvoJFW4zZwpiRhxAgx+5zjhzjjnvzz14qK+tpf7V08fYIM/byNv2dMZ+yyHGPM6d8ZxnnOeKGtNzGEoW2j8L79vULS7vvPsNunatnyotu1rXONkuMZfp1xnnGc84qpa3V79udhY6rzaWA2hrbgebJtPL9M9O+Qd3GK0LaCQzWYFnC26OMgGBDuyknJ+fnOM84zgdMAGnawSHUpSLOE5tLE58hOcyy4P3+/Q+vfb1pta7lKUPe0jsu/83qTx3d9vn/4l2rf62POGtev2h+vz9c59s5zxiqlldXq2FwPsOqsM6gSd1tj/AF53A/Pnrw2O/wB3itBIJN0v+hwnEiD/AFCcfvmGPv8Arx9BjgDJp6fBILC4Js4Rh7858hBjE7ZP3+3Qenbd1otruClCz0juu/Z+ZHrl1etompK1hqqqbS9BZmtsAZ5Jw+ceuOf7tW9Ru77Zc7tO1b/Wtne1r1+znrh+uPTjHvUGvQSDQtTP2OEYtLw58hOMHk/f7dB6dt3Wrl9BIq3GbOFMSMOIEGP3OccOccc9+eevFCWu4KUOVaR3l38vMr3l1fnVrAmw1cMNQJALWu4n7K/A+fG7H4YHrT7S7vvPsNunatnyotu1rXONkuMZfp1xnnGc84ovraX+1dPH2CDP28jb9nTGfsshxjzOnfGcZ5znipbaCQzWYFnC26OMgGBDuyknJ+fnOM84zgdMAFJb6kylDkWkfh8+78zPtbq9+3OwsdV5tLAbQ1twPNk2nl+menfIO7jFW47u+3z/APEu1b/Wx5w1r1+0P1+frnPtnOeMVBawSHUpSLOE5tLE58hOcyy4P3+/Q+vfb1q4kEm6X/Q4TiRB/qE4/fMMff8AXj6DHAGS0vMqrKF3pHp37LzM+yur1bC4H2HVWGdQJO62x/rzuB+fPXhsd/u8Ua5dXraJqStYaqqm0vQWZrbAGeScPnHrjn+7UmnwSCwuCbOEYe/OfIQYxO2T9/t0Hp23daNegkGhamfscIxaXhz5CcYPJ+/26D07butK3u7milD2y0j8T7935k+o3d9sud2nat/rWzva16/Zz1w/XHpxj3pl5dX51awJsNXDDUCQC1ruJ+yvwPnxux+GB61YvoJFW4zZwpiRhxAgx+5zjhzjjnvzz14qK+tpf7V08fYIM/byNv2dMZ+yyHGPM6d8ZxnnOeKGtNzGEoW2j8L79vULS7vvPsNunatnyotu1rXONkuMZfp1xnnGc84qpa3V79udhY6rzaWA2hrbgebJtPL9M9O+Qd3GK0LaCQzWYFnC26OMgGBDuyknJ+fnOM84zgdMAGnawSHUpSLOE5tLE58hOcyy4P3+/Q+vfb1pta7lKUPe0jsu/wDN6k8d3fb5/wDiXat/rY84a16/aH6/P1zn2znPGKqWV1erYXA+w6qwzqBJ3W2P9edwPz568Njv93itBIJN0v8AocJxIg/1CcfvmGPv+vH0GOAMmnp8EgsLgmzhGHvznyEGMTtk/f7dB6dt3Wi2u4KULPSO679n5keuXV62iakrWGqqptL0Fma2wBnknD5x645/u1b1G7vtlzu07Vv9a2d7WvX7OeuH649OMe9Qa9BINC1M/Y4Ri0vDnyE4weT9/t0Hp23dauX0EircZs4UxIw4gQY/c5xw5xxz35568UJa7gpQ5VpHeXfy8yveXV+dWsCbDVww1AkAta7ifsr8D58bsfhgetPtLu+8+w26dq2fKi27Wtc42S4xl+nXGecZzzii+tpf7V08fYIM/byNv2dMZ+yyHGPM6d8ZxnnOeKltoJDNZgWcLbo4yAYEO7KScn5+c4zzjOB0wAUlvqTKUORaR+Hz7vzM+1ur37c7Cx1Xm0sBtDW3A82TaeX6Z6d8g7uMVbju77fP/wAS7Vv9bHnDWvX7Q/X5+uc+2c54xUFrBIdSlIs4Tm0sTnyE5zLLg/f79D699vWriQSbpf8AQ4TiRB/qE4/fMMff9ePoMcAZLS8yqsoXekenfsvMz7K6vVsLgfYdVYZ1Ak7rbH+vO4H589eGx3+7xRrl1etompK1hqqqbS9BZmtsAZ5Jw+ceuOf7tSafBILC4Js4Rh7858hBjE7ZP3+3Qenbd1o16CQaFqZ+xwjFpeHPkJxg8n7/AG6D07butK3u7milD2y0j8T7935k+o3d9sud2nat/rWzva16/Zz1w/XHpxj3rl/ipPdS6CwuLTUIV/tBDuuDAVz5J4/dsTux+GPeutvoJFW4zZwpiRhxAgx+5zjhzjjnvzz14rlPitC8egZa1iiAv0GViVMHySccOeO+OnfPalNe7ua5ZKDxVKyX4+Xmatjb3X2GcpJYKN1910qTORO3Od/HfB/gHBzSa3BdDRdRLyWBUWt4SF0qRTwex38H0P8AD0NW9PVvsFx+9mPz3/8Ayym/57t6t3754H8WTRryt/YWp/vZv+PS86xTev8Avd++eB/Fk07e6Qqr9slf7T6Lu/IL63vAtxiXTxiRsY0mVMfuc95OPXHY/N0qO8t7n+1LAM+nn/TiFxo8oA/0Zzyvmcjr8vXPzdOK8Wvtd1kWlwx1nUy3/CzW0/macZttuPJyWxsxx5Z7e1e6XyN/aunfv5/+P88+TcZ/49ZOfvZz2x1xznHFDWhy0MS5p+SfRdvQgtre8MtnmXTzmOPOdJlbPySdR5nzfUdcA/wmqltBdG/k/eWG/wCy2RJOlSEHMkn+3165P8XQYxWvbK3nWf72Yfu4+kUxx8knTDc/hgcnHAOadqrf2lL+9mH+iWP/ACym/wCesv8Atdu2OD/Dg02tTdVX72vRdF39AS3vN0v73T/9Yn/MJlP/AC2Yf89OOOMdx8vUVVsbe6+wzlJLBRuvuulSZyJ25zv474P8A4Oa1kU7pf3s3+sT/llN/wA9m/2vx55zwPmyap6erfYLj97Mfnv/APllN/z3b1bv3zwP4smi2olVdnr1XRdn5FTW4LoaLqJeSwKi1vCQulSKeD2O/g+h/h6Grd9b3gW4xLp4xI2MaTKmP3Oe8nHrjsfm6Ua8rf2Fqf72b/j0vOsU3r/vd++eB/Fk1cvlIW4/ezHEjdYphn9z7t+HPOOfu8UJagqr5Vr1l0Xl5GfeW9z/AGpYBn08/wCnELjR5QB/oznlfM5HX5eufm6cVJbW94ZbPMunnMcec6TK2fkk6jzPm+o64B/hNT3yN/aunfv5/wDj/PPk3Gf+PWTn72c9sdcc5xxUtsredZ/vZh+7j6RTHHySdMNz+GByccA5EtyZVXyLX7PZd35GRbQXRv5P3lhv+y2RJOlSEHMkn+3165P8XQYxVtLe83S/vdP/ANYn/MJlP/LZh/z0444x3Hy9RRaq39pS/vZh/olj/wAspv8AnrL/ALXbtjg/w4NXEU7pf3s3+sT/AJZTf89m/wBr8eec8D5smhIqrVd3r26LsvIybG3uvsM5SSwUbr7rpUmciduc7+O+D/AODmk1uC6Gi6iXksCotbwkLpUing9jv4Pof4ehq3p6t9guP3sx+e//AOWU3/PdvVu/fPA/iyaNeVv7C1P97N/x6XnWKb1/3u/fPA/iyaVvdNFVftkr/afRd35BfW94FuMS6eMSNjGkypj9znvJx647H5ulR3lvc/2pYBn08/6cQuNHlAH+jOeV8zkdfl65+bpxV+/QhbgmWY4kYcxTD/lj7t+HPOOfu8VHfI39q6d+/n/4/wA8+TcZ/wCPWTn72c9sdcc5xxTa0MadV23+y+i7ehBbW94ZbPMunnMcec6TK2fkk6jzPm+o64B/hNVLaC6N/J+8sN/2WyJJ0qQg5kk/2+vXJ/i6DGK0w4gWCZ5LnZHAjkR29xI2AkhwqodzHjgL1zwOoPgVt471zxRoGv63ptxKG8LyaVqBjtDJbi/tlEjyQy7Z5FjAyxI3HOwDYrZFElqRPFezbT3aXRd/Q91S3vN0v73T/wDWJ/zCZT/y2Yf89OOOMdx8vUVVsbe6+wzlJLBRuvuulSZyJ25zv474P8A4Oa8V0fxHq2n+JPAWseI/EN3p+l+IrvUtUmt7m9f7PbQMAYIixfDqvDr0w0hGA2a9u0SeK80Vrq0vDcW0322WKWNZmSRDMSGDbsEEEHPT+9k80W1Kp4iUot+a6L+V+RFrcF0NF1EvJYFRa3hIXSpFPB7HfwfQ/wAPQ1bvre8C3GJdPGJGxjSZUx+5z3k49cdj83SjXlb+wtT/AHs3/HpedYpvX/e7988D+LJq5fKQtx+9mOJG6xTDP7n3b8Oecc/d4oS1LVV8q16y6Ly8jPvLe5/tSwDPp5/04hcaPKAP9Gc8r5nI6/L1z83TipLa3vDLZ5l085jjznSZWz8knUeZ831HXAP8Jqe+Rv7V079/P/x/nnybjP8Ax6yc/ezntjrjnOOKltlbzrP97MP3cfSKY4+STphufwwOTjgHIluTKq+Ra/Z7Lu/IyLaC6N/J+8sN/wBlsiSdKkIOZJP9vr1yf4ugxiraW95ul/e6f/rE/wCYTKf+WzD/AJ6cccY7j5eootVb+0pf3sw/0Sx/5ZTf89Zf9rt2xwf4cGriKd0v72b/AFif8spv+ezf7X48854HzZNCRVWq7vXt0XZeRk2NvdfYZyklgo3X3XSpM5E7c538d8H+AcHNJrcF0NF1EvJYFRa3hIXSpFPB7HfwfQ/w9DVvT1b7BcfvZj89/wD8spv+e7erd++eB/Fk0a8rf2Fqf72b/j0vOsU3r/vd++eB/Fk0re6aKq/bJX+0+i7vyC+t7wLcYl08YkbGNJlTH7nPeTj1x2PzdKiu7W4XU7FS2nc352gaPKAD9mcnK7+R1+Xrn5unFaN8pC3H72Y4kbrFMM/ufdvw55xz93ivB/C134nXx3H4d1/WtWtLPwm98b7XJ7p3a58+CRreaSNmIUrErOu7eFAIbjinJKxze3lG1tbp9F29O138j2y2t7wy2eZdPOY4850mVs/JJ1HmfN9R1wD/AAmsLXNSHh7T9U1jUZrBbey060nlP9mMC4DyYVS0oBZj8uSQHJCjFch8G9Yg1vxXNLpPia7m0mG0jtYLG8vZby7umj3B71kMheFctsCLtDBtxVOBW58TLSy1HRH0nU7l1g1STRbPyysoMoe9O5F+bkhA7DA5AO0DBNJoFiZOnOa7Lou/odD4eu5tb0Wz1W1eyW3vooLmJZNJcsqSSFgDtlIBwQCATn7oPGalsbe6+wzlJLBRuvuulSZyJ25zv474P8A4OazvhapPw28L4klX/iWWPCxykf8AjrAe/wBeBg5Nbenq32C4/ezH57//AJZTf8929W7988D+LJp21NY1ZOLfmui7PyKmtwXQ0XUS8lgVFreEhdKkU8Hsd/B9D/D0NW763vAtxiXTxiRsY0mVMfuc95OPXHY/N0o15W/sLU/3s3/HpedYpvX/AHu/fPA/iyauXykLcfvZjiRusUwz+592/DnnHP3eKEtQVV8q16y6Ly8jPvLe5/tSwDPp5/04hcaPKAP9Gc8r5nI6/L1z83TipLa3vDLZ5l085jjznSZWz8knUeZ831HXAP8ACanvkb+1dO/fz/8AH+efJuM/8esnP3s57Y645zjipbZW86z/AHsw/dx9Ipjj5JOmG5/DA5OOAciW5Mqr5Fr9nsu78jktC1Y6l4p17S4Psy3elQ6bHcO+lOUcybpBtxKT0bBJxu6Adz0KW95ul/e6f/rE/wCYTKf+WzD/AJ6cccY7j5eory/4J6fNZ+L/AB5cT3TMdSu4rmJVWViEW+vIMHBA4MXHXqACDXriKd0v72b/AFif8spv+ezf7X48854HzZNNIzhiJzi5Pv2X+Rk2NvdfYZyklgo3X3XSpM5E7c538d8H+AcHNJrcF0NF1EvJYFRa3hIXSpFPB7HfwfQ/w9DVvT1b7BcfvZj89/8A8spv+e7erd++eB/Fk1B4ttpbnwprkEV3cQSSaffIsqxT5QnIyPn98+38WTzU2XKdDrSVXTX3n0Xd+RPfW94FuMS6eMSNjGkypj9znvJx647H5ulR3lvc/wBqWAZ9PP8ApxC40eUAf6M55XzOR1+Xrn5unFeFaTc+KfE3h/xFfa7ruveGrfQ7KPRLmWGSe9L3kB3XFwwjYEPtRUY8/LKx3bVYV3fw31J7/wAUanbQX8uqafaalCsGsW899cQXRaylZ0QSTy7WQ4DbXyQy5wBihnLSxUm0v7r6Ls/LyO+tre8MtnmXTzmOPOdJlbPySdR5nzfUdcA/wmqlvBc/bpMyWG/7LZZJ0qQg5kk/2+vXJ/j4Axite2VvOs/3sw/dx9Ipjj5JOmG5/DA5OOAc07VW/tKX97MP9Esf+WU3/PWX/a7dscH+HBptanQqsve16Lou/oCW95ul/e6f/rE/5hMp/wCWzD/npxxxjuPl6iqtjb3X2GcpJYKN1910qTORO3Od/HfB/gHBzWsindL+9m/1if8ALKb/AJ7N/tfjzzngfNk1T09W+wXH72Y/Pf8A/LKb/nu3q3fvngfxZNFtQVV2evVdF2fkVNbguhouol5LAqLW8JC6VIp4PY7+D6H+Hoat31veBbjEunjEjYxpMqY/c57yceuOx+bpRryt/YWp/vZv+PS86xTev+93754H8WTVy+Uhbj97McSN1imGf3Pu34c845+7xQlqCqvlWvWXReXkZ95b3P8AalgGfTz/AKcQuNHlAH+jOeV8zkdfl65+bpxUltb3hls8y6ecxx5zpMrZ+STqPM+b6jrgH+E1PfI39q6d+/n/AOP88+TcZ/49ZOfvZz2x1xznHFS2yt51n+9mH7uPpFMcfJJ0w3P4YHJxwDkS3JlVfItfs9l3fkZFtBdG/k/eWG/7LZEk6VIQcySf7fXrk/xdBjFW0t7zdL+90/8A1if8wmU/8tmH/PTjjjHcfL1FFqrf2lL+9mH+iWP/ACym/wCesv8Atdu2OD/Dg1cRTul/ezf6xP8AllN/z2b/AGvx55zwPmyaEiqtV3evbouy8jJsbe6+wzlJLBRuvuulSZyJ25zv474P8A4OaTW4LoaLqJeSwKi1vCQulSKeD2O/g+h/h6Grenq32C4/ezH57/8A5ZTf8929W7988D+LJo15W/sLU/3s3/HpedYpvX/e7988D+LJpW900VV+2Sv9p9F3fkF9b3gW4xLp4xI2MaTKmP3Oe8nHrjsfm6VzPxPhnj0MmZrRl+3IAIdPe3I/dH+JmOB/s9e9dlfKQtx+9mOJG6xTDP7n3b8Oecc/d4rlPispGgcySt/p6DDRyr/yxPPzsRn2PPvjilUXumuWVG8TSX6Ly8jUsbS2exuCbh87r4YXVp/+e7Y4zyT6fx9TzRrdpbJouostw5YWt4QDq07ZOeOCcHPoeG6miy1XTksbhW1GwDFr4gHUzk5nJHHfI5A/iHJqr4o8TaDaaLfJda5pEDy2t4sayauAXOeign5jyOP4s5NHu8pm5VIVVKXMlzd/N+Zq31lalbjFxIcyN01id8/ucd259M9z8vSsnxldWug6fPq2ZblbKSa6MS61PmQR2cjYVskjJXG7rzt6Vz3iv4v+GdOm1CGwN1rn2YGa5l0m4NxFChjVQS7MqvneT8pYgI4YAKaqfE7WNK8ceEtP0/w9rtoyaxqsFu08Gp8wwtAXlMgcqVAiDghhuydm3nFOSjY5Y15cujesXbX5d++nqdH8PNXsPF3hrRNchF1aJcRANFNrE4KMnnIwyG4G5TjpwV4G4gattaW32+RDO+Ba2R/5C04OfMkznntjp0TqOprmPg2NP8P+CtK0yTVLR0tbi7hSaW8Nv5qJdXah8ZO0HHYnGevzGpdf+Ivhjw3czPd6nBc3JtbNI7OyvHnnlkDSt5YRM7WIx97CqWXnkUe7oXCpVVPmnfVLr1v6nWJZWu6X/SJP9Yn/ADGJx/y2Y+vPHOew+bqaqWNpbPY3BNw+d18MLq0//PdscZ5J9P4+p5rySOx1vU7S48e2Wr2dh4zlnSe20u71I7I7IO4Fg3zgHcdsrMdpDYPyElhvWvxLvzI+k2/hK7GqKZpLlrrWYo7OJZZN5KXAZllK71BVQS3zHGVIpe7cI1K1nzRktU+vZ/1Y73W7S2TRdRZbhywtbwgHVp2yc8cE4OfQ8N1NW76ytStxi4kOZG6axO+f3OO7c+me5+XpXmer+PfFd1p99aJ4NsYfNguYhcN4rglRN5++UHzOB12jl/rSaxP4u8NX8V/p3ie08Z2symK/0641GC2bzvs4UXELgKqp8oGznnI+cuWDTjcaqVuVWjPd9/Ir+LNautK/aK8OWMmpXyeGp4USVBqM7wfaZVnSMmXkqxKKAeOAw+7ur1W2srUS2ZNxIMRx5zrE64+STqc/L9B04H8RrxrxEJ7/AFRPFPia9sNMYeI9EeHT01NLkW8EIIZnnUjC7rmUlyDtKYGVYMOm1Lx5q2oeKp9B8GJoUMmmRWzXGp6zqjrbMzxO3losZD5ww5BwpVlI+YEi5TmhOtFS5lLXZa36+fky7431uHw7bmHTWN3r97bWUGmWR1afdPP5kmd2GGEQfM2WVUHRgWFWPh9q663DqtlrD/Z9f0q8W2v4otUuo42PnMyyxBm3GN1wwY89W5rN8MaWD4vHiPxf4g0TUdThsbSKyjt7gwwWG5iJVjLMzFvl5bIIDnjBCg8WeHbK78TR+KfCfiHSdH8SwMEld7zfBqEfmNiOcAhiMrH84OQqhsEhSqXKb1PrTk52lbTS/ktd9/63OxsbS2exuCbh87r4YXVp/wDnu2OM8k+n8fU80a3aWyaLqLLcOWFreEA6tO2TnjgnBz6Hhuprhtvi/UNCVH8e+GNFuxLdyS/YImnLDzWygM0pBV8hh8gJGMk9TX1/wudaOr6h4m8bWupTR2ssuk2dleSWsGn3SZ2XCIJWaSXcSV3Nzls9sHu8pq5YjnvCEnr1du/meh66dK0+zu7m/wBRW2tkclpptbmCLmLaMszAHJIAJ6k7elY2n+JfC2u+KE07RtdhvLq2vA8qx61cMuw2z/MkmcMMgAuhJBIU4DDPGz6P4i8SfZtP+Ivibwne+H7fc1zbabfzLJqEwgxG8hJXAVvm+XALjbtxt29j43tLDW9Q0260zxJb6TrFrczJbajb6mJPJWS2O7ergq8ZZI85AJKhQV60PlMYPFPVRlaz7329To7aytRLZk3EgxHHnOsTrj5JOpz8v0HTgfxGqttaW32+RDO+Ba2R/wCQtODnzJM557Y6dE6jqa4HT9L8Yw31jK/xe0qZEMb+VNZQqhUBjsYq4YDAKnaQRv4IzmtXzvEMktysfjPwpbtJZ20azrbzZQ7pNpUG6K70J3EEEDjjrlvlubJ1/evGWy6+fqdmlla7pf8ASJP9Yn/MYnH/AC2Y+vPHOew+bqa8m+Jeu3mg+KPANvpt7P8AZdS1TULW7gTUp3WVGnWNSwDDoJCw5wxALA1bk8O+JG1i81O3+Lltb3VxKweEYe1RC4CCOF5CFKMrNvJJIYE8li3neqG9XWrnW/FyxXV54ZtbWOa4gkEgvZf7UE7T2v8AC48hm3DKYLHIXkBPluc9adZQalGS1T3ey36n0PrdpbJouostw5YWt4QDq07ZOeOCcHPoeG6msTxb4v8AB2gakdO1bxAkF7POVES6vczFMwqAZCMhAd6/M+3PI+6CRxVl4W0TxToc/ifx6+maj4ivIJry2t31CZP7PTCtFbeUWwzK28lSPmZ3znqe9l0bwNbafqFlaaf4Whs7mQedBDNHsl2RFk3LjD7WJIJ/iOPehctzVPFSgmk1q+r8t9dDavLW1XVLHFw2GvjknWZzx9mfkNnI5GN3X+HpUltZWolsybiQYjjznWJ1x8knU5+X6DpwP4jXm1xp/iHw5qVtbeCvFnhq50RLrFpZazfSsNPUQPhVmjIZ48MUBfldsaAkZz0UF3r/AJtrjxj4OB2JgtbzgL8r8HF3wRyCB0JAHU5Fy6hzV3BLllt3fn5m7bWlt9vkQzvgWtkf+QtODnzJM557Y6dE6jqa5j4vyWWlfC/xbcySTyBrQwKq6nNIS0krRqdrNhwC4Jz2+bknFYmtaBq3iHUmlu/iVDpixafBHANGuXtEMpkba0oaVy+zklAVxuBBXndS1+/8TnXPDfhvUtU8N67od9cwPf6gvmwlRb3AlbzcSNGvmbODtwd3Rc5IuWwq7xDUkoy6db9F5/11O207WdDbwKfEl1fSWmly291db5tVnVlR5coCgPLkEALyXJ7modM8SeGfFnhzWLnw5qzXa29vdLIraldIyk/MuY5MEgjpkYfDZ5UgcR4B01ryK00jxNe2f9i+D57hNNaSdI/7TnSSQR3G0klERGTYij52JYu2MV1Pjfw14d1R9Q1vStYh0nxE1rcq97p+qfPdKudkUyEFZVPy/KQGcKvzDFGnKOE8TOopxjK19tU+vmdvfWVqVuMXEhzI3TWJ3z+5x3bn0z3Py9KZfWltHqlgDO43XxPzazP0+yuQQxOQOnzDn+Hoa4ext/FWnx3YvfiboGr734NzaDKkRtkr5cyZyCF+bPKgDAzmvqVr4qnkitYvijosU/8AaT3C3MVmMW6tC+FUtKVKfeXJBfLDLHND5bBF11b3ZbPr5ep6HbWVqJbMm4kGI4851idcfJJ1Ofl+g6cD+I15l8V4IE1TwOqzMR/b2jA51GViMtc55JymMDp9zt941tQ694ssbqK4nuvBWr2y2gdbW11Sewl80LIQgd2kXpxzt5ZeVGc8tq/ivQvGOufDbyrlooru6tdR3m5ZVha0W5LxyFsbDvdBwMYyVOCCR8r2M6k6k4zi1K7S3v8AzLz8zUs/h54n0zR20jQ/iKbSxguF+yySo0s8UIdlSHd5gRlX72fLBHBG0HbVzwrLPZ+L9Y8Oalqt9qMD2M9/Y3M166MoE7QzRs8e1JGLKsgAQEiU7icCu8TWNM3S/wDEz0//AFif8xMj/lsx/H1z2HzdTXC+NtGs/EWmWl5pev2WmeItJub650+5OpFly0x3RuvdJF445YHPIyrN8tzT2daEPcUtGur2s/M6/W7S2TRdRZbhywtbwgHVp2yc8cE4OfQ8N1NW76ytStxi4kOZG6axO+f3OO7c+me5+XpXl+q/F1YtPn0rU/CviE6q9rJDM9nItxbCWVQcpIspVkBPrz/FyDXTan49nNrdm28M3rzku0aSa5Y7S3kkAEi4Jxn+LB/u4PShctylOq4qyl17+XmdNeWtquqWOLhsNfHJOsznj7M/IbORyMbuv8PSq9/Jp2j6cdSvbi5FrZWguJvL1W4LBUilZsANwcD7o6HA/iNcTD8Sby01ywi8X6KbWJrprlLzS9RfUIUQ27Dy5BEGkV18yNC4Uh2D7cKKw/F/xf8ADl/4P1/Tbq31fS7mXTZrS1+3RSqLtzDKmUxnAy6cNtxuA6FsJcuplUqzjS5nzL3et138yDRPBuvWp8Lap4Mn0Oymj8M2Nrd2upXl1GBJJKZWceUQQ28MWXgLknknI2/E2jeKdA8MeIddHjee+v7FzfxWazGG0aFJS7RFfnlbhXIIlU/MpznJrvYtX0+O7mkF9ZOBZ2QAGp4LFZJCVGSACMjIzhcg1dTWNM3S/wDEz0//AFif8xMj/lsx/H1z2HzdTTSiN4erTTjDm6dX2Wu5heC7q21/wbY6ufNtjf21zc+QdXnJj3ybgp5GTz6fP1PNaWt2lsmi6iy3Dlha3hAOrTtk544Jwc+h4bqa8w8Hah4h8J6bdeE9L0zR7jSbR7+PTdXuvEKRoImdnQyxKC7ndkYVUD5HAA310R1jxTHZ36axeeDNRt3tZgEsNYuLWTJH7xcMkobLH5Om4Llhk4C93lLhVre0TlGe/n5ncX1lalbjFxIcyN01id8/ucd259M9z8vSo7y1tV1SxxcNhr45J1mc8fZn5DZyORjd1/h6VwV9deOtRF/Bc+LPA+kQM5aO406aa8nBCA4xM4QgrlSxBOTgAZ4ZNpet6V4l0y60T4gWN9FJOVvhrWoPcR+YY3b7QgjZNg2s0YVSi/cBzjND5bEwnXtfllaz79vUbqd/qtv8cvCelW+oTp4bl05Ptcf9pSBfPaO7KZkzvQ/uT8qnAxj+Lnc8T+I9B8Jur6pdXTzz21olraWuo3EtxdSB5T5aIpzngDBIVCy8gtz5n8QrO60fw9qXi7UNa0a+1631TS9RtoLGdvJKW4aNEaMtvDZkcthzj5QpAOB6R4F0jT9EYanq2pWV9rlzZ2qXOqTakSXk81nkijOAERcxjYoAVVQ4zR7tzOnLE8042lrZ6t6K/a/9amZHoXjHX9R1O9l8RTeFNPZNlhYQ3/2mdZPOfbLcM29Wx97bG2MMp3AglpvhrrEd7aX/AIc8QX5fxZpC3Md8U1OZEug0mVniAO1lYEZAAJbO4LkZ7tNY0zdL/wATPT/9Yn/MTI/5bMfx9c9h83U1xmu+HvDmv3FlqsmrxaZrenTXrwX9lqarOUMz4jberBkYOxCkfMGbkBmBfu3NeTEJXXM9e7109eh1Gt2lsmi6iy3Dlha3hAOrTtk544Jwc+h4bqat31lalbjFxIcyN01id8/ucd259M9z8vSuF8Q6dqMlpIbL4mXBt1gu/Pt5ZbOV5x/CqFYV25PJ4beOm2qWu+B9MdrrUtN8dXcfir7TuTWrjVxcSeTt3m3MQCRtCTnC4HzEDleCe7cd8RZWjLd9fTzLPxw12Pwfo2karBcXRiXxBai4Fvqs8krQCMtIqZYcsEK7s9GK9K2df8SaN4fvLG1xqmqaq0EUi6dpt/cSz7OULNhgsSgyDlmUDkDOTXDfETRtY8S3E48S+IvCt5olrBdm3isZrktJctZkRzPEXkz5bAhSCzEnaB8w29V8JI7bTdLTVda1SwfXdcdNQvme/MZh3RuI4OfnRY02rtYnacgHDYCXKc8Xim2rStZd9l8+5m+HPDut69rM+peKNX1TRYhHaG30Wz19sRx5ZCJpUG5zuRpAAw8sP3yVFWK6174f3N/a61b+IvGGiyTrJY6hYajJNdRDzGPkyxqylvuufN6Dcp4LBV9FttW04X8jHUbAKbWyUE6mRyJJMj2IyMj+HORVtNY0zdL/AMTPT/8AWJ/zEyP+WzH8fXPYfN1NNctjWeHqRm5RUr6a330RUsbS2exuCbh87r4YXVp/+e7Y4zyT6fx9TzRrdpbJouostw5YWt4QDq07ZOeOCcHPoeG6miy1XTksbhW1GwDFr4gHUzk5nJHHfI5A/iHJo1vVdOk0XUUj1GwZ2tbxVVdTLEkngAdyew/i6ml7vKdSVb2y0l8T6vu/Mt31lalbjFxIcyN01id8/ucd259M9z8vSuZ+J1vBFoZaGZnY3ycHUZbjjyjyFc4P+917dK6a+1jTCtxjU9POZG6amXz+5x3688Z7n5elcz8T9QsrrQylreWk7/bkbbDfGc48ojOO4z/F+FKfLy6GuWqr9Zpcylb1fl5nTafdqbC4H2iY5e/GC8PO6dj29e+OT/DxWd4007R9a0W6bV7O21B7e2vGgN1FbS+UzHOVyCQTgE45OBt4q7ZXV6thcD7DqrDOoEndbY/153A/Pnrw2O/3eKNcur1tE1JWsNVVTaXoLM1tgDPJOHzj1xz/AHaq65Tk9mnWV1H4n1Xdlp3t7aya1s2MNtEdkUMZgVEQQbAAq8AAYXA4xwOaxJdA8O2vjXTtetLCC31b7bMDdwrbJI4kt2LsxGAzFh9456tg5Zs7mo3d9sud2nat/rWzva16/Zz1w/XHpxj3pl5dX51awJsNXDDUCQC1ruJ+yvwPnxux+GB60OSsYwpprVR+F9V2PFmhtZNd13wHpF1PG+sa/Fe6kgkKsti1pHLct5i8JvdjEoY4IkKkZ6el+C9B0Lwk9xZeHbUWMD29m8gjeEtI3nTMSzMSzYycbiSBwcKBV7TdMgt/EsWt2/h+9j1e5tYIZLtFtBK6BJMDJfpgAc8kIAc7UxYtbq9+3OwsdV5tLAbQ1twPNk2nl+menfIO7jFDauKFCzm5crenVae8aCXYDS/6RMMyIfvw84mY/wBc8cZPPy4qnp92psLgfaJjl78YLw87p2Pb1745P8PFTx3d9vn/AOJdq3+tjzhrXr9ofr8/XOfbOc8YqpZXV6thcD7DqrDOoEndbY/153A/Pnrw2O/3eKd1c0VNWfw7rquzJNeu1OhamPtExzaXgxvh53HPb179z/DxVy+vA63H+kTNukY8vCc/udvb8uOMf7VZ+uXV62iakrWGqqptL0Fma2wBnknD5x645/u1b1G7vtlzu07Vv9a2d7WvX7OeuH649OMe9CauCprlXw7y6ryMD4laPZ+MdFk0K/uphBe3TYkLwnY4tnKSYVlztdVOMhSBg8mmfDTRIvCuj2yPcTnU7111DU5vOhPmXciP5rL0VVzgAYGB1GSCd+8ur86tYE2GrhhqBIBa13E/ZX4Hz43Y/DA9afaXd959ht07Vs+VFt2ta5xslxjL9OuM84znnFJNakSpLlT934e67sgtbsDUpR9omGLSxGA8PG2WU9/Tt3H8XFXEuwGl/wBImGZEP34ecTMf6544yeflxWfa3V79udhY6rzaWA2hrbgebJtPL9M9O+Qd3GKtx3d9vn/4l2rf62POGtev2h+vz9c59s5zximmi6sFd/D9nquyINPu1NhcD7RMcvfjBeHndOx7evfHJ/h4o167U6FqY+0THNpeDG+Hncc9vXv3P8PFR2V1erYXA+w6qwzqBJ3W2P8AXncD8+evDY7/AHeKNcur1tE1JWsNVVTaXoLM1tgDPJOHzj1xz/dpXXKaKC9svh+J9V3ZoX14HW4/0iZt0jHl4Tn9zt7flxxj/aqK+vl/tXT2+1T/APH+Wz5lvn/j1kGfTPb0x70ajd32y53adq3+tbO9rXr9nPXD9cenGPemXl1fnVrAmw1cMNQJALWu4n7K/A+fG7H4YHrRJqxjCCt9n4X1XYsW12qzWZ+0TDbHGMh4eMJIOM/Xvzyc84qna3YGpSj7RMMWliMB4eNssp7+nbuP4uKntLu+8+w26dq2fKi27Wtc42S4xl+nXGecZzziqlrdXv252FjqvNpYDaGtuB5sm08v0z075B3cYptq5Sgve+HZdV/MaCXYDS/6RMMyIfvw84mY/wBc8cZPPy4qnp92psLgfaJjl78YLw87p2Pb1745P8PFTx3d9vn/AOJdq3+tjzhrXr9ofr8/XOfbOc8YqpZXV6thcD7DqrDOoEndbY/153A/Pnrw2O/3eKLq4KmrP4d11XZkmvXanQtTH2iY5tLwY3w87jnt69+5/h4q5fXgdbj/AEiZt0jHl4Tn9zt7flxxj/arP1y6vW0TUlaw1VVNpegszW2AM8k4fOPXHP8Adq3qN3fbLndp2rf61s72tev2c9cP1x6cY96E1cFTXKvh3l1XkF9fL/aunt9qn/4/y2fMt8/8esgz6Z7emPepba7VZrM/aJhtjjGQ8PGEkHGfr355OecVXvLq/OrWBNhq4YagSAWtdxP2V+B8+N2PwwPWn2l3fefYbdO1bPlRbdrWucbJcYy/TrjPOM55xSUlqTKC5F8Pw913ZBa3YGpSj7RMMWliMB4eNssp7+nbuP4uKuJdgNL/AKRMMyIfvw84mY/1zxxk8/Lis+1ur37c7Cx1Xm0sBtDW3A82TaeX6Z6d8g7uMVbju77fP/xLtW/1secNa9ftD9fn65z7ZznjFNNFVYK7+H7PVdkQafdqbC4H2iY5e/GC8PO6dj29e+OT/DxRr12p0LUx9omObS8GN8PO457evfuf4eKjsrq9WwuB9h1VhnUCTutsf687gfnz14bHf7vFGuXV62iakrWGqqptL0Fma2wBnknD5x645/u0rrlNFBe2Xw/E+q7s0L68Drcf6RM26Rjy8Jz+529vy44x/tUzUb0f2npbG6lx9uLAiS3zj7NIMntntzxj3puo3d9sud2nat/rWzva16/Zz1w/XHpxj3pl5dX51awJsNXDDUCQC1ruJ+yvwPnxux+GB60SasYQpqy+H4X1XYsW12qzWZ+0TDbHGMh4eMJIOM/Xvzyc84rzrwl4JttA+Jmq69aapMLW4tImSw/dkQyTTI8rKzSHGXhLYCjG8A4C8+gWl3fefYbdO1bPlRbdrWucbJcYy/TrjPOM55xVS1ur37c7Cx1Xm0sBtDW3A82TaeX6Z6d8g7uMU21cboxbbfLpbqu5oJdgNL/pEwzIh+/DziZj/XPHGTz8uKp6fdqbC4H2iY5e/GC8PO6dj29e+OT/AA8VPHd32+f/AIl2rf62POGtev2h+vz9c59s5zxiqlldXq2FwPsOqsM6gSd1tj/XncD8+evDY7/d4ourlKmrP4d11XZkmvXanQtTH2iY5tLwY3w87jnt69+5/h4q5fXgdbj/AEiZt0jHl4Tn9zt7flxxj/arP1y6vW0TUlaw1VVNpegszW2AM8k4fOPXHP8Adq3qN3fbLndp2rf61s72tev2c9cP1x6cY96E1cFTXKvh3l1XkF9fL/aunt9qn/4/y2fMt8/8esgz6Z7emPeuD+JfhIeLNY8C3kX72XSb+3ebz5oRGtr8zyjafvEmKNVB7thuDmu5vLq/OrWBNhq4YagSAWtdxP2V+B8+N2PwwPWn2l3fefYbdO1bPlRbdrWucbJcYy/TrjPOM55xSTWpnUpKVNL3fhXVd2QWt2BqUo+0TDFpYjAeHjbLKe/p27j+LiriXYDS/wCkTDMiH78POJmP9c8cZPPy4rPtbq9+3OwsdV5tLAbQ1twPNk2nl+menfIO7jFW47u+3z/8S7Vv9bHnDWvX7Q/X5+uc+2c54xTTRpVgrv4fs9V2RBp92psLgfaJjl78YLw87p2Pb1745P8ADxRr12p0LUx9omObS8GN8PO457evfuf4eKjsrq9WwuB9h1VhnUCTutsf687gfnz14bHf7vFGuXV62iakrWGqqptL0Fma2wBnknD5x645/u0rrlNFBe2Xw/E+q7s0L68Drcf6RM26Rjy8Jz+529vy44x/tVFfXy/2rp7fap/+P8tnzLfP/HrIM+me3pj3o1G7vtlzu07Vv9a2d7WvX7OeuH649OMe9MvLq/OrWBNhq4YagSAWtdxP2V+B8+N2PwwPWiTVjGEFb7Pwvquwy7hsNVtoLLVokvbJo4RJBcLbyRnaHIyr5HBxjdyO/O2ktbsDUpR9omGLSxGA8PG2WU9/Tt3H8XFT2l3fefYbdO1bPlRbdrWucbJcYy/TrjPOM55xVS1ur37c7Cx1Xm0sBtDW3A82TaeX6Z6d8g7uMU21cpQXvfDsuq/mNBLsBpf9ImGZEP34ecTMf6544yeflxVPT7tTYXA+0THL34wXh53Tse3r3xyf4eKnju77fP8A8S7Vv9bHnDWvX7Q/X5+uc+2c54xVSyur1bC4H2HVWGdQJO62x/rzuB+fPXhsd/u8UXVwVNWfw7rquzJNeu1OhamPtExzaXgxvh53HPb179z/AA8VcvrwOtx/pEzbpGPLwnP7nb2/LjjH+1Wfrl1etompK1hqqqbS9BZmtsAZ5Jw+ceuOf7tW9Ru77Zc7tO1b/Wtne1r1+znrh+uPTjHvQmrgqa5V8O8uq8gvr5f7V09vtU//AB/ls+Zb5/49ZBn0z29Me9S212qzWZ+0TDbHGMh4eMJIOM/Xvzyc84qveXV+dWsCbDVww1AkAta7ifsr8D58bsfhgetPtLu+8+w26dq2fKi27Wtc42S4xl+nXGecZzzikpLUmUFyL4fh7ruyC1uwNSlH2iYYtLEYDw8bZZT39O3cfxcVcS7AaX/SJhmRD9+HnEzH+ueOMnn5cVn2t1e/bnYWOq82lgNoa24HmybTy/TPTvkHdxircd3fb5/+Jdq3+tjzhrXr9ofr8/XOfbOc8YppoqrBXfw/Z6rsiDT7tTYXA+0THL34wXh53Tse3r3xyf4eKNeu1OhamPtExzaXgxvh53HPb179z/DxUdldXq2FwPsOqsM6gSd1tj/XncD8+evDY7/d4o1y6vW0TUlaw1VVNpegszW2AM8k4fOPXHP92ldcpooL2y+H4n1XdmhfXgdbj/SJm3SMeXhOf3O3t+XHGP8AarlPitcibQMCaWTN+jYZ4jn9yRn5Oc9uOPxrptRu77Zc7tO1b/Wtne1r1+znrh+uPTjHvXL/ABUnupdBYXFpqEK/2gh3XBgK58k8fu2J3Y/DHvSqNcptlkEsVSen3ryOh0+CQWFwTZwjD35z5CDGJ2yfv9ug9O27rRr0Eg0LUz9jhGLS8OfITjB5P3+3Qenbd1qrY2919hnKSWCjdfddKkzkTtznfx3wf4Bwc0mtwXQ0XUS8lgVFreEhdKkU8Hsd/B9D/D0NO75TNL98veXxPo+7Ne+gkVbjNnCmJGHECDH7nOOHOOOe/PPXior62l/tXTx9ggz9vI2/Z0xn7LIcY8zp3xnGec54qC+t7wLcYl08YkbGNJlTH7nPeTj1x2PzdKjvLe5/tSwDPp5/04hcaPKAP9Gc8r5nI6/L1z83Tim27bGNNafEvhfSXY0LaCQzWYFnC26OMgGBDuyknJ+fnOM84zgdMAGnawSHUpSLOE5tLE58hOcyy4P3+/Q+vfb1otre8MtnmXTzmOPOdJlbPySdR5nzfUdcA/wmqltBdG/k/eWG/wCy2RJOlSEHMkn+3165P8XQYxQ277FJfF7y2XR9zXSCTdL/AKHCcSIP9QnH75hj7/rx9BjgDJp6fBILC4Js4Rh7858hBjE7ZP3+3Qenbd1oS3vN0v73T/8AWJ/zCZT/AMtmH/PTjjjHcfL1FVbG3uvsM5SSwUbr7rpUmciduc7+O+D/AADg5ou7gl7r95bro+zLWvQSDQtTP2OEYtLw58hOMHk/f7dB6dt3Wrt7bsqXW60iTEjAbbdBg+TnH+sOOPm4zzz14rH1uC6Gi6iXksCotbwkLpUing9jv4Pof4ehq3fW94FuMS6eMSNjGkypj9znvJx647H5ulCbuCXur3lvLo/LyJ762l/tXTx9ggz9vI2/Z0xn7LIcY8zp3xnGec54qW2gkM1mBZwtujjIBgQ7spJyfn5zjPOM4HTABz7y3uf7UsAz6ef9OIXGjygD/RnPK+ZyOvy9c/N04qS2t7wy2eZdPOY4850mVs/JJ1HmfN9R1wD/AAmhN66EyXuL3l8PaXdhawSHUpSLOE5tLE58hOcyy4P3+/Q+vfb1q4kEm6X/AEOE4kQf6hOP3zDH3/Xj6DHAGTkW0F0b+T95Yb/stkSTpUhBzJJ/t9euT/F0GMVbS3vN0v73T/8AWJ/zCZT/AMtmH/PTjjjHcfL1FCbKqrV+8unR9kGnwSCwuCbOEYe/OfIQYxO2T9/t0Hp23daNegkGhamfscIxaXhz5CcYPJ+/26D07butVbG3uvsM5SSwUbr7rpUmciduc7+O+D/AODmk1uC6Gi6iXksCotbwkLpUing9jv4Pof4ehpXfKaJfvl7y+J9H3Zr30EircZs4UxIw4gQY/c5xw5xxz35568VFfW0v9q6ePsEGft5G37OmM/ZZDjHmdO+M4zznPFQX1veBbjEunjEjYxpMqY/c57yceuOx+bpUd5b3P9qWAZ9PP+nELjR5QB/oznlfM5HX5eufm6cU23bYxprT4l8L6S7GhbQSGazAs4W3RxkAwId2Uk5Pz85xnnGcDpgA07WCQ6lKRZwnNpYnPkJzmWXB+/36H177etFtb3hls8y6ecxx5zpMrZ+STqPM+b6jrgH+E1UtoLo38n7yw3/ZbIknSpCDmST/AG+vXJ/i6DGKG3fYpL4veWy6Pua6QSbpf9DhOJEH+oTj98wx9/14+gxwBk09PgkFhcE2cIw9+c+Qgxidsn7/AG6D07butCW95ul/e6f/AKxP+YTKf+WzD/npxxxjuPl6iqtjb3X2GcpJYKN1910qTORO3Od/HfB/gHBzRd3BL3X7y3XR9mWtegkGhamfscIxaXhz5CcYPJ+/26D07butXL6CRVuM2cKYkYcQIMfuc44c4457889eKyNbguhouol5LAqLW8JC6VIp4PY7+D6H+Hoat31veBbjEunjEjYxpMqY/c57yceuOx+bpQm7gl7q95by6PyJ762l/tXTx9ggz9vI2/Z0xn7LIcY8zp3xnGec54qW2gkM1mBZwtujjIBgQ7spJyfn5zjPOM4HTABz7y3uf7UsAz6ef9OIXGjygD/RnPK+ZyOvy9c/N04qS2t7wy2eZdPOY4850mVs/JJ1HmfN9R1wD/CaE3roTJe4veXw9pd2FrBIdSlIs4Tm0sTnyE5zLLg/f79D699vWriQSbpf9DhOJEH+oTj98wx9/wBePoMcAZORbQXRv5P3lhv+y2RJOlSEHMkn+3165P8AF0GMVbS3vN0v73T/APWJ/wAwmU/8tmH/AD0444x3Hy9RQmyqq1fvLp0fZBp8EgsLgmzhGHvznyEGMTtk/f7dB6dt3WjXoJBoWpn7HCMWl4c+QnGDyfv9ug9O27rVWxt7r7DOUksFG6+66VJnInbnO/jvg/wDg5pNbguhouol5LAqLW8JC6VIp4PY7+D6H+HoaV3ymiX75e8vifR92a99BIq3GbOFMSMOIEGP3OccOccc9+eevFRX1tL/AGrp4+wQZ+3kbfs6Yz9lkOMeZ074zjPOc8VBfW94FuMS6eMSNjGkypj9znvJx647H5ulR3lvc/2pYBn08/6cQuNHlAH+jOeV8zkdfl65+bpxTbdtjGmtPiXwvpLsaFtBIZrMCzhbdHGQDAh3ZSTk/PznGecZwOmADTtYJDqUpFnCc2lic+QnOZZcH7/fofXvt60W1veGWzzLp5zHHnOkytn5JOo8z5vqOuAf4TVS2gujfyfvLDf9lsiSdKkIOZJP9vr1yf4ugxiht32KS+L3lsuj7mukEm6X/Q4TiRB/qE4/fMMff9ePoMcAZNPT4JBYXBNnCMPfnPkIMYnbJ+/26D07butCW95ul/e6f/rE/wCYTKf+WzD/AJ6cccY7j5eoqrY2919hnKSWCjdfddKkzkTtznfx3wf4Bwc0XdwS91+8t10fZlrXoJBoWpn7HCMWl4c+QnGDyfv9ug9O27rVy+gkVbjNnCmJGHECDH7nOOHOOOe/PPXisjW4LoaLqJeSwKi1vCQulSKeD2O/g+h/h6Grd9b3gW4xLp4xI2MaTKmP3Oe8nHrjsfm6UJu4Je6veW8uj8ie+tpf7V08fYIM/byNv2dMZ+yyHGPM6d8ZxnnOeKltoJDNZgWcLbo4yAYEO7KScn5+c4zzjOB0wAc+8t7n+1LAM+nn/TiFxo8oA/0Zzyvmcjr8vXPzdOKktre8MtnmXTzmOPOdJlbPySdR5nzfUdcA/wAJoTeuhMl7i95fD2l3YWsEh1KUizhObSxOfITnMsuD9/v0Pr329auJBJul/wBDhOJEH+oTj98wx9/14+gxwBk5FtBdG/k/eWG/7LZEk6VIQcySf7fXrk/xdBjFW0t7zdL+90//AFif8wmU/wDLZh/z0444x3Hy9RQmyqq1fvLp0fZBp8EgsLgmzhGHvznyEGMTtk/f7dB6dt3Wl122l/sDU2+xRBRaXmWECcYJ77+CO3p23daqWNvdfYZyklgo3X3XSpM5E7c538d8H+AcHNJrcF0NF1EvJYFRa3hIXSpFPB7HfwfQ/wAPQ0rvlNEv3y95fE+j7s176CRVuM2cKYkYcQIMfuc44c4457889eKivraX+1dPH2CDP28jb9nTGfsshxjzOnfGcZ5znioL63vAtxiXTxiRsY0mVMfuc95OPXHY/N0qO8t7n+1LAM+nn/TiFxo8oA/0Zzyvmcjr8vXPzdOKbbtsY01p8S+F9JdjQtoJDNZgWcLbo4yAYEO7KScn5+c4zzjOB0wAadrBIdSlIs4Tm0sTnyE5zLLg/f79D699vWi2t7wy2eZdPOY4850mVs/JJ1HmfN9R1wD/AAmqltBdG/k/eWG/7LZEk6VIQcySf7fXrk/xdBjFDbvsUl8XvLZdH3NdIJN0v+hwnEiD/UJx++YY+/68fQY4AyaenwSCwuCbOEYe/OfIQYxO2T9/t0Hp23daEt7zdL+90/8A1if8wmU/8tmH/PTjjjHcfL1FVbG3uvsM5SSwUbr7rpUmciduc7+O+D/AODmi7uCXuv3luuj7Mta9BINC1M/Y4Ri0vDnyE4weT9/t0Hp23dauX0EircZs4UxIw4gQY/c5xw5xxz35568Vka3BdDRdRLyWBUWt4SF0qRTwex38H0P8PQ1bvre8C3GJdPGJGxjSZUx+5z3k49cdj83ShN3BL3V7y3l0fkT31tL/AGrp4+wQZ+3kbfs6Yz9lkOMeZ074zjPOc8VLbQSGazAs4W3RxkAwId2Uk5Pz85xnnGcDpgA595b3P9qWAZ9PP+nELjR5QB/oznlfM5HX5eufm6cVJbW94ZbPMunnMcec6TK2fkk6jzPm+o64B/hNCb10JkvcXvL4e0u7C1gkOpSkWcJzaWJz5Cc5llwfv9+h9e+3rVxIJN0v+hwnEiD/AFCcfvmGPv8Arx9BjgDJyLaC6N/J+8sN/wBlsiSdKkIOZJP9vr1yf4ugxiraW95ul/e6f/rE/wCYTKf+WzD/AJ6cccY7j5eooTZVVav3l06Psg0+CQWFwTZwjD35z5CDGJ2yfv8AboPTtu60a9BINC1M/Y4Ri0vDnyE4weT9/t0Hp23daq2NvdfYZyklgo3X3XSpM5E7c538d8H+AcHNJrcF0NF1EvJYFRa3hIXSpFPB7HfwfQ/w9DSu+U0S/fL3l8T6PuzXvoJFW4zZwpiRhxAgx+5zjhzjjnvzz14rlPitC8egZa1iiAv0GViVMHySccOeO+OnfPat++t7wLcYl08YkbGNJlTH7nPeTj1x2PzdK5n4nwzx6GTM1oy/bkAEOnvbkfuj/EzHA/2evelUb5TXLF/tNL3vwfkdNp6t9guP3sx+e/8A+WU3/PdvVu/fPA/iyaNeVv7C1P8Aezf8el51im9f97v3zwP4smqljaWz2NwTcPndfDC6tP8A892xxnkn0/j6nmjW7S2TRdRZbhywtbwgHVp2yc8cE4OfQ8N1NPXlMkl7Zav4n0Xd+Zr3ykLcfvZjiRusUwz+592/DnnHP3eKivkb+1dO/fz/APH+efJuM/8AHrJz97Oe2OuOc44rlr7xP4WMVww1Wcg6y2ijGoXjk3flbfLwRyM/x/dPTOOau2WoaNrGpA6ZfvMtprMtlcFtVul2Sx2z7gC2DgHHzjrnaCRTbdjnpyg9FJ/C/wCXt6nQ2yt51n+9mH7uPpFMcfJJ0w3P4YHJxwDmnaq39pS/vZh/olj/AMspv+esv+127Y4P8ODRbWVqJbMm4kGI4851idcfJJ1Ofl+g6cD+I1VtrS2+3yIZ3wLWyP8AyFpwc+ZJnPPbHTonUdTQ73RolH3tXsui7+prIp3S/vZv9Yn/ACym/wCezf7X48854HzZNU9PVvsFx+9mPz3/APyym/57t6t3754H8WTQlla7pf8ASJP9Yn/MYnH/AC2Y+vPHOew+bqaqWNpbPY3BNw+d18MLq0//AD3bHGeSfT+PqeaNbglHler3XRdn5lvXlb+wtT/ezf8AHpedYpvX/e7988D+LJq5fKQtx+9mOJG6xTDP7n3b8Oecc/d4rI1u0tk0XUWW4csLW8IB1adsnPHBODn0PDdTVu+srUrcYuJDmRumsTvn9zju3Ppnufl6UK9wSjyrV7y6Ly8ye+Rv7V079/P/AMf558m4z/x6yc/ezntjrjnOOKltlbzrP97MP3cfSKY4+STphufwwOTjgHOfeWtquqWOLhsNfHJOsznj7M/IbORyMbuv8PSpLaytRLZk3EgxHHnOsTrj5JOpz8v0HTgfxGhX1JklyLV/D2Xd+YWqt/aUv72Yf6JY/wDLKb/nrL/tdu2OD/Dg1cRTul/ezf6xP+WU3/PZv9r8eec8D5smsm2tLb7fIhnfAtbI/wDIWnBz5kmc89sdOidR1NWksrXdL/pEn+sT/mMTj/lsx9eeOc9h83U0K5VVK71fTouy8w09W+wXH72Y/Pf/APLKb/nu3q3fvngfxZNGvK39han+9m/49LzrFN6/73fvngfxZNVLG0tnsbgm4fO6+GF1af8A57tjjPJPp/H1PNGt2lsmi6iy3Dlha3hAOrTtk544Jwc+h4bqaWvKaJL2y1fxPou78zXvlIW4/ezHEjdYphn9z7t+HPOOfu8VFfI39q6d+/n/AOP88+TcZ/49ZOfvZz2x1xznHFQX1lalbjFxIcyN01id8/ucd259M9z8vSo7y1tV1SxxcNhr45J1mc8fZn5DZyORjd1/h6U3exjTStu/hfRdvU0LZW86z/ezD93H0imOPkk6Ybn8MDk44BzTtVb+0pf3sw/0Sx/5ZTf89Zf9rt2xwf4cGi2srUS2ZNxIMRx5zrE64+STqc/L9B04H8RrDv7/AEbRtQtI9TvpIftv9n2dv/xMrkl5nklwp252/dPXCp1ByeR3uV7qUnd7Lou68zqEU7pf3s3+sT/llN/z2b/a/HnnPA+bJqnp6t9guP3sx+e//wCWU3/PdvVu/fPA/iya5KXxt4Rgv5rM6lqEt0b6WzEVvPqEzNLBJvlUBFO7arqd3TB3DJyBu6Olne6MbmOa4VJheMqvqVzG4BmO0NG2CGx/CwBbktzRd3FFwcXaT3XRdn5mhryt/YWp/vZv+PS86xTev+93754H8WTVy+Uhbj97McSN1imGf3Pu34c845+7xWRrdpbJouostw5YWt4QDq07ZOeOCcHPoeG6mrd9ZWpW4xcSHMjdNYnfP7nHdufTPc/L0oV7jSjyrV7y6Ly8ye+Rv7V079/P/wAf558m4z/x6yc/ezntjrjnOOKltlbzrP8AezD93H0imOPkk6Ybn8MDk44Bzn3lrarqlji4bDXxyTrM54+zPyGzkcjG7r/D0qS2srUS2ZNxIMRx5zrE64+STqc/L9B04H8RoV9SZJci1fw9l3fmFqrf2lL+9mH+iWP/ACym/wCesv8Atdu2OD/Dg1cRTul/ezf6xP8AllN/z2b/AGvx55zwPmyayba0tvt8iGd8C1sj/wAhacHPmSZzz2x06J1HU1aSytd0v+kSf6xP+YxOP+WzH1545z2HzdTQrlVUrvV9Oi7LzDT1b7BcfvZj89//AMspv+e7erd++eB/Fk0a8rf2Fqf72b/j0vOsU3r/AL3fvngfxZNVLG0tnsbgm4fO6+GF1af/AJ7tjjPJPp/H1PNGt2lsmi6iy3Dlha3hAOrTtk544Jwc+h4bqaWvKaJL2y1fxPou78zXvlIW4/ezHEjdYphn9z7t+HPOOfu8VFfI39q6d+/n/wCP88+TcZ/49ZOfvZz2x1xznHFQX1lalbjFxIcyN01id8/ucd259M9z8vSuVTxf4VvptAu7HU7qeDUrm5nttt5fF5UgtnEpUbd4IOAOAzfdUEU3exhFwitZP4X/AC9vU7a2VvOs/wB7MP3cfSKY4+STphufwwOTjgHNO1Vv7Sl/ezD/AESx/wCWU3/PWX/a7dscH+HBrn/DHiLw9rmt/wBm6fd6l9ts4YjcR3Fxf2vlfI+NzSKoUncCFz0zjI3Ea1taW32+RDO+Ba2R/wCQtODnzJM557Y6dE6jqaG3cuPK1JpvZdF/N6msindL+9m/1if8spv+ezf7X48854HzZNU9PVvsFx+9mPz3/wDyym/57t6t3754H8WTQlla7pf9Ik/1if8AMYnH/LZj688c57D5upqpY2ls9jcE3D53XwwurT/892xxnkn0/j6nmjW4JR5Xq910XZ+Zb15W/sLU/wB7N/x6XnWKb1/3u/fPA/iyauXykLcfvZjiRusUwz+592/DnnHP3eKyNbtLZNF1FluHLC1vCAdWnbJzxwTg59Dw3U1bvrK1K3GLiQ5kbprE75/c47tz6Z7n5elCvcEo8q1e8ui8vMnvkb+1dO/fz/8AH+efJuM/8esnP3s57Y645zjipbZW86z/AHsw/dx9Ipjj5JOmG5/DA5OOAc595a2q6pY4uGw18ck6zOePsz8hs5HIxu6/w9KktrK1EtmTcSDEcec6xOuPkk6nPy/QdOB/EaFfUmSXItX8PZd35haq39pS/vZh/olj/wAspv8AnrL/ALXbtjg/w4NXEU7pf3s3+sT/AJZTf89m/wBr8eec8D5smsm2tLb7fIhnfAtbI/8AIWnBz5kmc89sdOidR1NWksrXdL/pEn+sT/mMTj/lsx9eeOc9h83U0K5VVK71fTouy8w09W+wXH72Y/Pf/wDLKb/nu3q3fvngfxZNGvK39han+9m/49LzrFN6/wC93754H8WTVSxtLZ7G4JuHzuvhhdWn/wCe7Y4zyT6fx9TzUXiVLGy8OavdTXTrFBZXsjE6rO4AHP3cndwOn8fU0teUv3VWTbfxPou78zcvlIW4/ezHEjdYphn9z7t+HPOOfu8VFfI39q6d+/n/AOP88+TcZ/49ZOfvZz2x1xznHFcw/iTwxd3DW8OrSiSaw/tlDJqV2qfZDDgSlnwo5PRiG7EAc1a0rUdI1/8As3UNLubtrOa+Ox7i/vIC6/ZWIZfNCttORiQDnlc4zTbdjGm4PZv4X0Xb1OitlbzrP97MP3cfSKY4+STphufwwOTjgHNO1Vv7Sl/ezD/RLH/llN/z1l/2u3bHB/hwaLaytRLZk3EgxHHnOsTrj5JOpz8v0HTgfxGqttaW32+RDO+Ba2R/5C04OfMkznntjp0TqOpod7otKPvavZdF39TWRWzMfOmwHUk+VN085+T83brzz2HzZNU9PVvsFx+9mPz3/wDyym/57t6t3754H8WTSxWlsrzFbmUEunI1iccec+f4uRg9ewO7qap2NpbPY3BNw+d18MLq0/8Az3bHGeSfT+PqeaNbgkrPV7rouz8y3ryt/YWp/vZv+PS86xTev+93754H8WTVy+Uhbj97McSN1imGf3Pu34c845+7xWRrdpbJouostw5YWt4QDq07ZOeOCcHPoeG6mrd9ZWpW4xcSHMjdNYnfP7nHdufTPc/L0oV7glHlWr3l0Xl5k98jf2rp37+f/j/PPk3Gf+PWTn72c9sdcc5xxUtsredZ/vZh+7j6RTHHySdMNz+GByccA5z7y1tV1SxxcNhr45J1mc8fZn5DZyORjd1/h6VJbWVqJbMm4kGI4851idcfJJ1Ofl+g6cD+I0K+pMkuRav4ey7vzC1Vv7Sl/ezD/RLH/llN/wA9Zf8Aa7dscH+HBq4indL+9m/1if8ALKb/AJ7N/tfjzzngfNk1k21pbfb5EM74FrZH/kLTg58yTOee2OnROo6mrSWVrul/0iT/AFif8xicf8tmPrzxznsPm6mhXKqpXer6dF2XmGnq32C4/ezH57//AJZTf8929W7988D+LJo15W/sLU/3s3/HpedYpvX/AHu/fPA/iyaqWNpbPY3BNw+d18MLq0//AD3bHGeSfT+PqeaNbtLZNF1FluHLC1vCAdWnbJzxwTg59Dw3U0teU0SXtlq/ifRd35mvfKQtx+9mOJG6xTDP7n3b8Oecc/d4rlPispGgcySt/p6DDRyr/wAsTz87EZ9jz744rfvrK1K3GLiQ5kbprE75/c47tz6Z7n5elcz8TreCLQy0MzOxvk4Ooy3HHlHkK5wf97r26Uql+U1yxL6zS1f3Ly8zbstV05LG4VtRsAxa+IB1M5OZyRx3yOQP4hyaNb1XTpNF1FI9RsGdrW8VVXUyxJJ4AHcnsP4upq3p92psLgfaJjl78YLw87p2Pb1745P8PFY3i/xp4f07S9Xtb7xDaQXSWd2GtpLy2835vmA2A7iWBBwBk5G3Ip68pg5U4VU5ae8/teb8jgb7wg5triMa74fJPjhvEmRqbPm22btmCvMnbPrxmuo8FWUHh3UNT+16vo8wv/FF3qkbQaq2Eilt227jgYIPBbnnjPNT2Xxc8Fa6l79j8URrsfcftrR2u7dCyjHmBdx+Ug7c4GO5Gdm98X6O3ivw/p0WrtLe39w97bJFJA/mQraP+83LlQDngkgMAcZIOBp2OOkqEdV2f2urVuxfttY0wS2edT08YjjznUyuPkk6n+H6DpwP4jVS21bThfyMdRsAptbJQTqZHIkkyPYjIyP4c5Fa9tdqs1mftEw2xxjIeHjCSDjP1788nPOKp2t2BqUo+0TDFpYjAeHjbLKe/p27j+Lim07nUlH3tHsvtefoCaxpm6X/AImen/6xP+YmR/y2Y/j657D5upqpZarpyWNwrajYBi18QDqZyczkjjvkcgfxDk1PqXibSdHb/iba3b2HnSKY/tN3bReZtmZjjcRnG4HjgE8/KRVOXxNpOkWDjVtbt7Hzn1ARi6u7aLzP35JxkjPUZxzyNvFGtxXpqLuuq+15PyJdb1XTpNF1FI9RsGdrW8VVXUyxJJ4AHcnsP4upq3faxphW4xqennMjdNTL5/c479eeM9z8vSuU8X/FDwfYaBd+d4otpjcQ3VuiWs0NyxdySMrFuIU45YgDOMHmtoeO/DWpiRbLxNY3Dyl5VjF7alyotzklQcjABzxwAf4qFe5KqUbJeb+16eRdvNW01tUsWXUtPKrfFmI1U4A+zOMlvTJA3ep21Jbaxpgls86np4xHHnOplcfJJ1P8P0HTgfxGqOk+LNN8RzWd9pOoyzW8erzQM6zWxO6OCWMtwSMHAKnoUZT1NbVtdqs1mftEw2xxjIeHjCSDjP1788nPOKFfUb5HTTSfw/zeb8jIttW04X8jHUbAKbWyUE6mRyJJMj2IyMj+HORVtNY0zdL/AMTPT/8AWJ/zEyP+WzH8fXPYfN1NUtQ8QWGhpfajquoSW1la2Nk8sheE7QssvAHUnphQCxJAI5FcfZ/HXwUxlW+1PVdNu/OCyWt3ZbZYmWdiQ+1SoPOcA8EnOMYArhXnTjK0tNvteS8jsrLVdOSxuFbUbAMWviAdTOTmckcd8jkD+IcmjW9V06TRdRSPUbBna1vFVV1MsSSeAB3J7D+Lqa4m3+N3gSC1mil8RXW9zdMALRmBEspdckR9wQWHUHjjkVeX4teDvEFlqFhpniF2upLK68tLiMW4kLthVUyKoZiT91ctn7owDS15Rxq0XWVn9r+bzfkdnfaxphW4xqennMjdNTL5/c479eeM9z8vSo7zVtNbVLFl1LTyq3xZiNVOAPszjJb0yQN3qdtT6hIJb+Sct5m1ZAsrGDeu6JQRkHOGwuQox8g/ixjl/H/xG0zwr4h0iK9k1Cf/AEl725a38iRra3EPk+cyrkn55AOARtVz1XFN3sRGVOKu09n1fb0/E321azaKFbTV9LhufIQRyTagzIj+XJgsoZTgEjKgj0BG4mvF/DvgCSHQPFNjf65oFvfXqade6ZcWWoLEtnexhwZFCQoqHcBnau5UbG5j8x9y0fWbO/i0+7sNRFzamNAk1vPbuh2rIpCtnHByOeRyDzio7W7A1KUfaJhi0sRgPDxtllPf07dx/FxQ07hKlTqXbT0S+13foeSWHgC0h1DwTPP4g0t30p7mfWLlNXeK5vbm4OGkSZArn5l5YkHYFznJFeoWWq6cljcK2o2AYtfEA6mcnM5I475HIH8Q5Na6XYDS/wCkTDMiH78POJmP9c8cZPPy4rlvD/jjQ9R1jVvDtlqs02r2X2554AqbVDT/AN/G1vvLkKSc9Ohos0xxjTgmrdV9ryfkaWt6rp0mi6ikeo2DO1reKqrqZYkk8ADuT2H8XU1bvtY0wrcY1PTzmRumpl8/ucd+vPGe5+XpRr12p0LUx9omObS8GN8PO457evfuf4eKr+NvE9l4d8O6rrGpXF21nbMXfyxFIzboxGowvcsyrnhRnkg80a3KvCME2tPe+16eRJeatprapYsupaeVW+LMRqpwB9mcZLemSBu9TtqS21jTBLZ51PTxiOPOdTK4+STqf4foOnA/iNcZovxT06+1NLbxNP8A8I3rlhqR+12V5e221QbaQI6SkKsgIxyBgZHqpbr9L8TaTd2sN/Z61bz2NtGgmuYbu2aOLbHIWBbO1cBgfm5APPVaSvqZudOUEl/L/N5vyILbVtOF/Ix1GwCm1slBOpkciSTI9iMjI/hzkVbTWNM3S/8AEz0//WJ/zEyP+WzH8fXPYfN1NY3hHxloviW/1JtD1Z7tbKOztZihiUK6SSE7dwG5ecqwyDzkkU7xB4/0Dw5rFhp2r6rJBd6lcIsShoW2DzpGDyY+6pIwG6bm5+QEhq9i606avJ7afa8l5Fyy1XTksbhW1GwDFr4gHUzk5nJHHfI5A/iHJo1vVdOk0XUUj1GwZ2tbxVVdTLEkngAdyew/i6mren3amwuB9omOXvxgvDzunY9vXvjk/wAPFcV4/wDiE9jc6vo2k2c2pvZ6XdXmpSfbIIhbwvIBhflO+TbukMZKEqAVJyKWvKXOdOnVUpq3vP7T7vyO1vtY0wrcY1PTzmRumpl8/ucd+vPGe5+XpXl+geDLXw/8QrvVbDxDpY02O4mXRLR9SMkGnGeB3mbYoTanmbFGxlyuVYknI7uL4g+F9XiQ2Pieyme8cNDC95bLK5eDCgx5DBjkLtxntjdxW5fXy/2rp7fap/8Aj/LZ8y3z/wAesgz6Z7emPehp2MYRp1LNK9k/teXoeb/DXRz4c8RfbJdV0Ox0+6tImurG11ya4W5vj5he6aSUB4mx8pQFs5GSa6XXPFWmaFpmr6vJeWUy2el20yRLqm0zOjSsIl9GJ2jAzt3AgEnFdRbXarNZn7RMNscYyHh4wkg4z9e/PJzzivP/AIr20eueEtR0WS+kgGopo9lvJhYLuvcH5cgnaCTjIPHzEDmm00DjGnSnyJ6JdfP0Om0DxTpOr6Pa6lHeW1vHexwXKxT6jskQPIW2sMnkA8+n3upp9lqunJY3CtqNgGLXxAOpnJzOSOO+RyB/EOTXmvg8fE//AIRvSvD4XS/C8GnwxW02otNBeyyKjnyzDEG2gjbht7EHduGBgCleWEXwrvYfFWizXtxpl7Lcaf4ie8vRNI6NcbY7sgBi0gJO44+bd8gG5mBrcSqJQ5nF2ur626PpY9X1vVdOk0XUUj1GwZ2tbxVVdTLEkngAdyew/i6mrd9rGmFbjGp6ecyN01Mvn9zjv154z3Py9KNeu1OhamPtExzaXgxvh53HPb179z/DxVy+vA63H+kTNukY8vCc/udvb8uOMf7VCTubJR5Vo95fa9PIz7zVtNbVLFl1LTyq3xZiNVOAPszjJb0yQN3qdtSW2saYJbPOp6eMRx5zqZXHySdT/D9B04H8Rqe+vl/tXT2+1T/8f5bPmW+f+PWQZ9M9vTHvUttdqs1mftEw2xxjIeHjCSDjP1788nPOKEnqTJR5Fo/h/m835HP6Z4j0W51jUIYdVsDLawWEMytqLKVbcz9D1G115GQvODkEC5/wkmhJfNaPrekrdSOjJCdXw7L5znIGckYBOewG7qTXiHw50vxumu+JNX8KanpFjpHiK7W68+9QtOsH2iXyZo4mA5A3OFYgEFScA5rvbX4V+F5vDd3p2v8AnaxqV2UN1rFy8LXkkm/BdZWLMgCquFDEcfNuBJYVzFzlPXl6rr00t06r/huh19lqunJY3CtqNgGLXxAOpnJzOSOO+RyB/EOTTfEGo6Vc6BqkDX2nTCWzvIzGdRL79xxt2/xZ7D+Pqa5P4OeIryXRNV8Na9eTza9oElza3UxlRxcLI+9Jd7AZ3fMDyzHaGz82K7nXrtToWpj7RMc2l4Mb4edxz29e/c/w8UrPlOinKFScZcr1l3835Hicvwutl8HeK9Nn8U6bd6lcyJaaZdXOpC4+z2EGJYYfuKVyRtbb8oIXC8c994WW403X7mfVPEGnyWE+pI9rYjX5rwWirZurubmUB2DsR1GFI2j7xrs9b1e0s7S6uL7UltrYSndNc3FvHGMxbAWbIAySF9OcfeqrD4h07Vr2wudK1hL2BdSYNLbXNrIA32RxyVJGeR7YPrQ0zClSpRkrLXlf2vL09QtvEGii/s7Y6xpYuBBHIYjq21gu2QZI6qM8ccA4H8RqG21bThfyMdRsAptbJQTqZHIkkyPYjIyP4c5FeW+E9XsW/aIm1RdSupRdx3GiwghQIntre1d1XfgAbjMOeDjIyWye61H4ieFtDub6XUfEltGLa2s4pIoriCWVXSaQMojXLkqSOMZH8WBTdyoVadpuStt9rzXl8zo01jTN0v8AxM9P/wBYn/MTI/5bMfx9c9h83U1UstV05LG4VtRsAxa+IB1M5OZyRx3yOQP4hya5K/8AGPi7VYLvUfBenJFpkEZmH9tII59QcTsyiGNWDINuW3OOS6jaF5GloXxF8M3OitLca/BYTSfbi9pqF1bW88LNOx2SRswZW9R1z93Io1uNVaVndNar7Xk/L+tzb1vVdOk0XUUj1GwZ2tbxVVdTLEkngAdyew/i6mrd9rGmFbjGp6ecyN01Mvn9zjv154z3Py9KZ4k1CKLw7qsk126RrZ3pZnlgCgE55Oeh6n/x3iodO8W6N4kgv30TWUvxFPIkgjmgYqRGyZIHOCVYBh8rLypJINCvctOmlGLWt5fa9PIr6z4m0m38RaBbDUdOd7rUpBxq7fKi2UpL59M7V3erAVo22saYJbPOp6eMRx5zqZXHySdT/D9B04H8RryD4j6xq83x88OXek6iv9n6HPZx3DFoGeOS9kEMicAgloVHJ4UDOQSM+ia98RNE8NavYade3OqTaq1mlxDZWNqLiWVVWUYTapXOQRhiCBktjg0K5zRqRaamna1l73/A11v+XQ0LbVtOF/Ix1GwCm1slBOpkciSTI9iMjI/hzkVbTWNM3S/8TPT/APWJ/wAxMj/lsx/H1z2HzdTXm5h8SeO9bkg1aWfQvBctlaJcae0kK3t9FnKo5UkwrkyggMHwNrgbsquhXt78K5ZdL1D994Hm1BI9MuraSLfpqvcFglzvOPLDO5Eu44IG7h1AFc1q1I3u4u2mvN5LyO8stV05LG4VtRsAxa+IB1M5OZyRx3yOQP4hyaNb1XTpNF1FI9RsGdrW8VVXUyxJJ4AHcnsP4upp+h6zZ3+kvLZakLmKZr8xvFPburg3B6EHkHjOP+A8VY167U6FqY+0THNpeDG+Hncc9vXv3P8ADxSs+U6IuDrJpfaf2vN+QX2saYVuManp5zI3TUy+f3OO/XnjPc/L0rmfifqFldaGUtby0nf7cjbYb4znHlEZx3Gf4vwrsr68Drcf6RM26Rjy8Jz+529vy44x/tVynxWuRNoGBNLJm/RsM8Rz+5Iz8nOe3HH40pp8ptlij9apWT+/08jbsrq9WwuB9h1VhnUCTutsf687gfnz14bHf7vFZvifS7W+gutRvvDksuoQWd4I7yeCzeSIBieH3FgAWYnHOSdvU1rafBILC4Js4Rh7858hBjE7ZP3+3Qenbd1o16CQaFqZ+xwjFpeHPkJxg8n7/boPTtu607e7uYKUPbLSPxPv3fmU/FWl2uthzrnhmbUDBLJ5ZvYLKbyyYATjLHBO1SccYUfxAVx/jr4fW91a2w8IeG4tD8Q2+pR3FhdpZ2SbZooTKqtsYcEryDlcc7WYAH0i+gkVbjNnCmJGHECDH7nOOHOOOe/PPXior62l/tXTx9ggz9vI2/Z0xn7LIcY8zp3xnGec54oa03OePspKzjH4X37ep5nong3xvaWtlcW/i7xVF4iuEjknklFpd2a7hKxWGCRwFAHCnK8BvlGQofKnxZjvoLbTrvS54GsrKOe+mskjuI13uEkSMTNGzZ3EZKgkYKqOvp1tBIZrMCzhbdHGQDAh3ZSTk/PznGecZwOmADTtYJDqUpFnCc2lic+QnOZZcH7/AH6H177etDjruChTXNa2y79/X+mctoHgmys4dRk1jRL3W9X1Foxqd/ex2kjXbfaDwUZyqJlE2xr8o2LnOAak0zwloNtE9zB4Kt1nhkvJI5ksbBWjZJztIOQQV4GRyCPl4rsUgk3S/wChwnEiD/UJx++YY+/68fQY4AyaenwSCwuCbOEYe/OfIQYxO2T9/t0Hp23dadtdyoqkou0Y7rv2fmZN9pVpZW+t6hZ+G5bO/u7S+FzeRwWaSSAtljI6ncwzgt1Ofu1VvvBfhtFuMeAbRdsjDnT9PGP3O7sfx44x/tV0GvQSDQtTP2OEYtLw58hOMHk/f7dB6dt3Wrl9BIq3GbOFMSMOIEGP3OccOccc9+eevFCWu406fKvdjvL9PM8kl+H143jWDS5vD7R+BBrT6otgrWuZ7o2ahI/KGFVUMcjkbijK4UgnNdDovw70LTL3zdH0LxJpj33lzTDTtW+yh2KykEKk6gAc7RgYBYcZFdrfW0v9q6ePsEGft5G37OmM/ZZDjHmdO+M4zznPFS20EhmswLOFt0cZAMCHdlJOT8/OcZ5xnA6YAKS31MVTowhdKOqv18/M4jTfBulQ+JYdWk0PWb7Uba0svs81/eJePBmZmBjM0rbeVG3HIO7OAxz2Ud3fb5/+Jdq3+tjzhrXr9ofr8/XOfbOc8YqC1gkOpSkWcJzaWJz5Cc5llwfv9+h9e+3rVxIJN0v+hwnEiD/UJx++YY+/68fQY4AyWl5m1T2cW0ox6fkvMz7K6vVsLgfYdVYZ1Ak7rbH+vO4H589eGx3+7xVLxhZx6z4fvIdY0G5u4YobyZBdx2cqROCRvALEgjJyQM8/LxWjp8EgsLgmzhGHvznyEGMTtk/f7dB6dt3WjXoJBoWpn7HCMWl4c+QnGDyfv9ug9O27rSt7u5pem6yTUfif5vzOD1H4X6TZ6vd6r4f07xH4cvHE9vM2mXNrEsiPBkqU3Mq45I2AY6j5gCOg8NeGLLwi1hZaLomqQsb4iaeQ2j3F032aU5kk3fO3zueflAJAwcCuovoJFW4zZwpiRhxAgx+5zjhzjjnvzz14qK+tpf7V08fYIM/byNv2dMZ+yyHGPM6d8ZxnnOeKGtNzCmqS1Sj8L79vU4m++HHhvUzp4j8JXenXKLFLBd6V9ls54pNshWRHjccgqGG7P3eRnFZVn8N1kuZItR1T4h6nZyWdss1nc61EY5kkaRdrhXUlOu1c8HO7g8+oW0EhmswLOFt0cZAMCHdlJOT8/OcZ5xnA6YANO1gkOpSkWcJzaWJz5Cc5llwfv9+h9e+3rTa13Hy0m5Pljpbv39Tirr4baVNcytp+n+KNHtmuA1xZ6VqENrb3AaXYyvEsm0AiNR8gXkZJxgjm/EsSfDk+Gdf0fS7+00qza80K/XETKLKS4baWcFivly4JJA3s2A4yCfZUgk3S/wChwnEiD/UJx++YY+/68fQY4AycsaXBqGi3drqGlWVzau98XimtI3Q7bgnJBcj5SBjjjtnrStruJwpuD5VFO679n5nl2nxfE/xF4MXXLnxbNaW2o2FzefZbfR7OSJIXO4qHaQSYwRkldw6Dd1PVHwPu1dNc8UJ4i8Q63at+7lvpLVbe3lFsNzxW6OEQkqrfxEbFIO8ZPX69BINC1M/Y4Ri0vDnyE4weT9/t0Hp23dasXENwIrk3FhbQsJpBiONSABESOd3Hy4YjBAPQnHIlruEIUkouyer7+X96xk+JtKttd1TThrfhufUPLvnVFvILKY82xJUbiQCdqk/w4QfxAVRHhHQLu9gmufA1vPPOqSSSPY6ezSMyyEsSx5JIzluTg55xXR31tL/aunj7BBn7eRt+zpjP2WQ4x5nTvjOM85zxUttBIZrMCzhbdHGQDAh3ZSTk/PznGecZwOmACJb6jk6fItI/D/n5nF6r4Q0fX9aS+1Lw1fPfxRafcJdW7wW9wrhpEV/NjkV+gAX5s5Rd33VNUpfhvo//AAjniPTLLQNRW71dDFcajdNb3Vw0jzEb3d5dzHfGj7QwBdc8cGu1tYJDqUpFnCc2lic+QnOZZcH7/fofXvt61cSCTdL/AKHCcSIP9QnH75hj7/rx9BjgDJaXmOsqTk3yx6d+y8zxP4deKvGfjhIktrrV7DTtMsbhNXmjsbVZbm+kdmkVDKCiouY2bA3AsRtAZSvb6J4VtfCHhvXY9N07W3ub6G9lvdQvZraWe4bON0r7skDPOB1JIBLMT1OnwSCwuCbOEYe/OfIQYxO2T9/t0Hp23daTXoJBoepZs4h/od4c+QnGDyc7+3Qenbd1pW93cdKMIVlzWb5nr830vYxtZ8J6Fc3F9dXfgiGa5lnkeWaaxsGd3MJclmzkkn5ifx+9XGSaH8RvCutT2PgKw02PQ5NWku7GDVJE3wyyW5Z4lWIhEjGZSqjjBHfOfWb6CRVuM2cKYkYcQIMfuc44c4457889eKivraX+1dPH2CDP28jb9nTGfsshxjzOnfGcZ5znihrTciKpu2kV7r79vXY4+w8Z+KrKBbzxB4B8QW0MKQeSulXVpqMrqVlAOwbW79g3G4nGBXE/8JRb/Ef4meDovDz3N/o+mwRardwkwpIJYZXihK8ggrJLna+MqwJDDFe120EhmswLOFt0cZAMCHdlJOT8/OcZ5xnA6YAOZp+mxQ61eXEOl2iTXFrYNNKtrGGl+eRVLNvyxIGMnqBj5RTa1RmobrmTWl7rz8rF6O7vt8//ABLtW/1secNa9ftD9fn65z7ZznjFUI3uJ9Ivbe40zUbi3lGopIj/AGVkZWnberAtyOcMP++citRIJN0v+hwnEiD/AFCcfvmGPv8Arx9BjgDJp6fBILC4Js4Rh7858hBjE7ZP3+3Qenbd1otrudClDlekd137PzPNLLTviL4V0i70Sxs7TUPCNpaXkNo99dLHepBk5EjLvU7MhcKBkKNu3oN2+8T/ABGFxcR3Pw7m8gTsJJU160b/AJY4JAKKT8nPbjjg8112vQSDQtTP2OEYtLw58hOMHk/f7dB6dt3Wrl9BIq3GbOFMSMOIEGP3OccOccc9+eevFCWu5k4RcY8rS+Lb5d7nM2/iDxPNPpj6t4N1+0v/AO0GLw295p865+zSABXMiZbbg8qABkcnGeF8YfEh5tD1/wAM67omsaXr1xpv2awsyYZzeJNHJFCYiv3yWkAKpuI+fklTj1u+tpf7V08fYIM/byNv2dMZ+yyHGPM6d8ZxnnOeKz7vwvp2ra3oGo6hpFvdXmnIHtGkiBVS6NlinmBWPyAgsMgqCNpHIluZThaCtJP3ey8/6RF4fin0qG1sbSx1fyLXTtNt41L2pYIjyBCTu59u+Qd3GK1Y7u+3z/8AEu1b/Wx5w1r1+0P1+frnPtnOeMVBawSHUpSLOE5tLE58hOcyy4P3+/Q+vfb1q4kEm6X/AEOE4kQf6hOP3zDH3/Xj6DHAGSJabnVUdNO1o/Z79l5nn3ibSfE8t3Dr/g+HyNYt4tStZ1v4Ldoru3e6DNG7rIHXYQzcA/McD5SScfU7X4watpd7Frd7pOiWkNvczGbTIRPJLg4kjYO+AhJJJ6/LwDnB9N0+CQWFwTZwjD35z5CDGJ2yfv8AboPTtu60uuwyroOqYtIlBs7zOIVHAPP8fY9PTtu61Nvd3BxpyrW01l59/U4HT/hT4e0i5vb290LW9cv2LQm51ye1u2CCAFVwW2/LtGDjIXgHoK1NZ8CaLd+L4tXHh7WbLVLm6eCaewu4rOSZWheRgfJlUF2b5ix6gYJJ4rtb6CRVuM2cKYkYcQIMfuc44c4457889eKivraX+1dPH2CDP28jb9nTGfsshxjzOnfGcZ5znim1puZ01SStyx+F9+3qeL/FFF8BW3gzXtIguNFtdEtLu0s0McUhE9zaTGJlwWBXzE+Yv8x3knPNdn4G8GaX4Y/s8Wfht21CzsbHF6ttZrM0jPIHlDFiw38gfMTxhvlArsn0uC+l0wXelWV15RhnhE1pG+2QJJtcZf73U7uDx2wAY7WCQ6lKRZwnNpYnPkJzmWXB+/36H177etNrXcUIU4znK0elvLVLuTx3d9vn/wCJdq3+tjzhrXr9ofr8/XOfbOc8Yrl5PDGjaj9tvdR8HR315K968lxPZ2MjsVmI+ZmO47RwfTHy8V1qQSbpf9DhOJEH+oTj98wx9/14+gxwBk09PgkFhcE2cIw9+c+Qgxidsn7/AG6D07butFtdzXmpuL0juu/Z+Zy2seDPDiaRfsvgW0iZba7YSf2fYDYVOA3HPHfHI/h4rW8S+H9L1a7ur3V/CH228LlGnu7WxkfAgyAWyTx144x0+atPXoJBoWpn7HCMWl4c+QnGDyfv9ug9O27rVy+gkVbjNnCmJGHECDH7nOOHOOOe/PPXihLXcS9lyr3Y7y/TzPMviFBpngXwVpotNIu9G0bTfEGn3Mm1Lc/6toyWOxizybV6nOcckmtT4R6Zq2l6cmqarp2qtr2uSJqF46mDK7kkEUS+Y+9USMBQj/d+ccfKK7S+tpf7V08fYIM/byNv2dMZ+yyHGPM6d8ZxnnOeKltoJDNZgWcLbo4yAYEO7KScn5+c4zzjOB0wAUlvqRL2fKpWj8Pnbd+Zn2t1e/bnYWOq82lgNoa24HmybTy/TPTvkHdxipbhp7y3vbW70jUZ7adljmik+yMsitO4KsC+CDkjHTOc/LiktYJDqUpFnCc2lic+QnOZZcH7/fofXvt61cSCTdL/AKHCcSIP9QnH75hj7/rx9BjgDJaXmaVZQu9I/Z79l5nDp4G8NXGl3kcvga3ZXF8pdLOxRlAmK8MCGUqOMqQQR8hxW0LM6J4Mm0nTtN1iDT7WwvIYllnglEcYOMFmkZio6EckYAXgYrS0+CQWFwTZwjD35z5CDGJ2yfv9ug9O27rRr0Eg0LUz9jhGLS8OfITjB5P3+3Qenbd1pW93cuPs1XVox+J/m/Mn1G7vtlzu07Vv9a2d7WvX7OeuH649OMe9cv8AFSe6l0FhcWmoQr/aCHdcGArnyTx+7Yndj8Me9dbfQSKtxmzhTEjDiBBj9znHDnHHPfnnrxXKfFaF49Ay1rFEBfoMrEqYPkk44c8d8dO+e1Ka93c2yyUHiqVkvx8vM1bG3uvsM5SSwUbr7rpUmciduc7+O+D/AADg5pNbguhouol5LAqLW8JC6VIp4PY7+D6H+Hoat6erfYLj97Mfnv8A/llN/wA929W7988D+LJo15W/sLU/3s3/AB6XnWKb1/3u/fPA/iyadvdIVV+2Sv8AafRd35BfW94FuMS6eMSNjGkypj9znvJx647H5ulR3lvc/wBqWAZ9PP8ApxC40eUAf6M55XzOR1+Xrn5unFaF8pC3H72Y4kbrFMM/ufdvw55xz93ior5G/tXTv38//H+efJuM/wDHrJz97Oe2OuOc44ptaGNOq7b/AGX0Xb0ILa3vDLZ5l085jjznSZWz8knUeZ831HXAP8JqpbQXRv5P3lhv+y2RJOlSEHMkn+3165P8XQYxWvbK3nWf72Yfu4+kUxx8knTDc/hgcnHAOadqrf2lL+9mH+iWP/LKb/nrL/tdu2OD/Dg0Nalqq/e16Lou/oCW95ul/e6f/rE/5hMp/wCWzD/npxxxjuPl6iqtjb3X2GcpJYKN1910qTORO3Od/HfB/gHBzWsindL+9m/1if8ALKb/AJ7N/tfjzzngfNk1T09W+wXH72Y/Pf8A/LKb/nu3q3fvngfxZNFtRKq7PXqui7PyKmtwXQ0XUS8lgVFreEhdKkU8Hsd/B9D/AA9DVu+t7wLcYl08YkbGNJlTH7nPeTj1x2PzdKNeVv7C1P8Aezf8el51im9f97v3zwP4smrl8pC3H72Y4kbrFMM/ufdvw55xz93ihLUFVfKtesui8vIz7y3uf7UsAz6ef9OIXGjygD/RnPK+ZyOvy9c/N04qS2t7wy2eZdPOY4850mVs/JJ1HmfN9R1wD/Canvkb+1dO/fz/APH+efJuM/8AHrJz97Oe2OuOc44qW2VvOs/3sw/dx9Ipjj5JOmG5/DA5OOAciW5Mqr5Fr9nsu78jItoLo38n7yw3/ZbIknSpCDmST/b69cn+LoMYq2lvebpf3un/AOsT/mEyn/lsw/56cccY7j5eootVb+0pf3sw/wBEsf8AllN/z1l/2u3bHB/hwauIp3S/vZv9Yn/LKb/ns3+1+PPOeB82TQkVVqu717dF2XkZNjb3X2GcpJYKN1910qTORO3Od/HfB/gHBzSa3BdDRdRLyWBUWt4SF0qRTwex38H0P8PQ1b09W+wXH72Y/Pf/APLKb/nu3q3fvngfxZNGvK39han+9m/49LzrFN6/73fvngfxZNK3umiqv2yV/tPou78gvre8C3GJdPGJGxjSZUx+5z3k49cdj83So7y3uf7UsAz6ef8ATiFxo8oA/wBGc8r5nI6/L1z83TitC+Uhbj97McSN1imGf3Pu34c845+7xUV8jf2rp37+f/j/ADz5Nxn/AI9ZOfvZz2x1xznHFNrQxp1Xbf7L6Lt6EFtb3hls8y6ecxx5zpMrZ+STqPM+b6jrgH+E1UtoLo38n7yw3/ZbIknSpCDmST/b69cn+LoMYrXtlbzrP97MP3cfSKY4+STphufwwOTjgHNO1Vv7Sl/ezD/RLH/llN/z1l/2u3bHB/hwaGtS1Vfva9F0Xf0BLe83S/vdP/1if8wmU/8ALZh/z0444x3Hy9RVWxt7r7DOUksFG6+66VJnInbnO/jvg/wDg5rWRTul/ezf6xP+WU3/AD2b/a/HnnPA+bJqnp6t9guP3sx+e/8A+WU3/PdvVu/fPA/iyaLaiVV2evVdF2fkVNbguhouol5LAqLW8JC6VIp4PY7+D6H+Hoat31veBbjEunjEjYxpMqY/c57yceuOx+bpRryt/YWp/vZv+PS86xTev+93754H8WTVy+Uhbj97McSN1imGf3Pu34c845+7xQlqCqvlWvWXReXkZ95b3P8AalgGfTz/AKcQuNHlAH+jOeV8zkdfl65+bpxUltb3hls8y6ecxx5zpMrZ+STqPM+b6jrgH+E1PfI39q6d+/n/AOP88+TcZ/49ZOfvZz2x1xznHFS2yt51n+9mH7uPpFMcfJJ0w3P4YHJxwDkS3JlVfItfs9l3fkZFtBdG/k/eWG/7LZEk6VIQcySf7fXrk/xdBjFW0t7zdL+90/8A1if8wmU/8tmH/PTjjjHcfL1FFqrf2lL+9mH+iWP/ACym/wCesv8Atdu2OD/Dg1cRTul/ezf6xP8AllN/z2b/AGvx55zwPmyaEiqtV3evbouy8jJsbe6+wzlJLBRuvuulSZyJ25zv474P8A4OaTW4LoaLqJeSwKi1vCQulSKeD2O/g+h/h6Grenq32C4/ezH57/8A5ZTf8929W7988D+LJo15W/sLU/3s3/HpedYpvX/e7988D+LJpW900VV+2Sv9p9F3fkF9b3gW4xLp4xI2MaTKmP3Oe8nHrjsfm6VHeW9z/algGfTz/pxC40eUAf6M55XzOR1+Xrn5unFaF8pC3H72Y4kbrFMM/ufdvw55xz93ior5G/tXTv38/wDx/nnybjP/AB6yc/ezntjrjnOOKbWhjTqu2/2X0Xb0ILa3vDLZ5l085jjznSZWz8knUeZ831HXAP8ACaqW0F0b+T95Yb/stkSTpUhBzJJ/t9euT/F0GMVr2yt51n+9mH7uPpFMcfJJ0w3P4YHJxwDmnaq39pS/vZh/olj/AMspv+esv+127Y4P8ODQ1qWqr97Xoui7+gJb3m6X97p/+sT/AJhMp/5bMP8AnpxxxjuPl6iqtjb3X2GcpJYKN1910qTORO3Od/HfB/gHBzWsindL+9m/1if8spv+ezf7X48854HzZNU9PVvsFx+9mPz3/wDyym/57t6t3754H8WTRbUSquz16rouz8iprcF0NF1EvJYFRa3hIXSpFPB7HfwfQ/w9DVu+t7wLcYl08YkbGNJlTH7nPeTj1x2PzdKNeVv7C1P97N/x6XnWKb1/3u/fPA/iyauXykLcfvZjiRusUwz+592/DnnHP3eKEtQVV8q16y6Ly8jPvLe5/tSwDPp5/wBOIXGjygD/AEZzyvmcjr8vXPzdOKktre8MtnmXTzmOPOdJlbPySdR5nzfUdcA/wmp75G/tXTv38/8Ax/nnybjP/HrJz97Oe2OuOc44qW2VvOs/3sw/dx9Ipjj5JOmG5/DA5OOAciW5Mqr5Fr9nsu78jItoLo38n7yw3/ZbIknSpCDmST/b69cn+LoMYq2lvebpf3un/wCsT/mEyn/lsw/56cccY7j5eootVb+0pf3sw/0Sx/5ZTf8APWX/AGu3bHB/hwauIp3S/vZv9Yn/ACym/wCezf7X48854HzZNCRVWq7vXt0XZeRk2NvdfYZyklgo3X3XSpM5E7c538d8H+AcHNJrcF0NF1EvJYFRa3hIXSpFPB7HfwfQ/wAPQ1b09W+wXH72Y/Pf/wDLKb/nu3q3fvngfxZNGvK39han+9m/49LzrFN6/wC93754H8WTSt7poqr9slf7T6Lu/IL63vAtxiXTxiRsY0mVMfuc95OPXHY/N0qO8t7n+1LAM+nn/TiFxo8oA/0Zzyvmcjr8vXPzdOK0L5SFuP3sxxI3WKYZ/c+7fhzzjn7vFRXyN/aunfv5/wDj/PPk3Gf+PWTn72c9sdcc5xxTa0MadV23+y+i7ehBbW94ZbPMunnMcec6TK2fkk6jzPm+o64B/hNVLaC6N/J+8sN/2WyJJ0qQg5kk/wBvr1yf4ugxite2VvOs/wB7MP3cfSKY4+STphufwwOTjgHNO1Vv7Sl/ezD/AESx/wCWU3/PWX/a7dscH+HBoa1LVV+9r0XRd/QEt7zdL+90/wD1if8AMJlP/LZh/wA9OOOMdx8vUVVsbe6+wzlJLBRuvuulSZyJ25zv474P8A4Oa1kU7pf3s3+sT/llN/z2b/a/HnnPA+bJqnp6t9guP3sx+e//AOWU3/PdvVu/fPA/iyaLaiVV2evVdF2fkVNbguhouol5LAqLW8JC6VIp4PY7+D6H+Hoat31veBbjEunjEjYxpMqY/c57yceuOx+bpRryt/YWp/vZv+PS86xTev8Avd++eB/Fk1cvlIW4/ezHEjdYphn9z7t+HPOOfu8UJagqr5Vr1l0Xl5GfeW9z/algGfTz/pxC40eUAf6M55XzOR1+Xrn5unFSW1veGWzzLp5zHHnOkytn5JOo8z5vqOuAf4TU98jf2rp37+f/AI/zz5Nxn/j1k5+9nPbHXHOccVLbK3nWf72Yfu4+kUxx8knTDc/hgcnHAORLcmVV8i1+z2Xd+RkW0F0b+T95Yb/stkSTpUhBzJJ/t9euT/F0GMVbS3vN0v73T/8AWJ/zCZT/AMtmH/PTjjjHcfL1FFqrf2lL+9mH+iWP/LKb/nrL/tdu2OD/AA4NXEU7pf3s3+sT/llN/wA9m/2vx55zwPmyaEiqtV3evbouy8jJsbe6+wzlJLBRuvuulSZyJ25zv474P8A4OaTW4LoaLqJeSwKi1vCQulSKeD2O/g+h/h6Grenq32C4/ezH57//AJZTf8929W7988D+LJo15W/sLU/3s3/HpedYpvX/AHu/fPA/iyaVvdNFVftkr/afRd35BfW94FuMS6eMSNjGkypj9znvJx647H5ulcz8T4Z49DJma0ZftyACHT3tyP3R/iZjgf7PXvXZXykLcfvZjiRusUwz+592/DnnHP3eK5T4rKRoHMkrf6egw0cq/wDLE8/OxGfY8++OKVRe6a5ZUbxNJfovLyPOl13VlUquqX4U78gXD4O45bv3PJ9TRJruryxvHJql+8bqysrXDkMG+8CM9D39aKKx6HrL416v9RX1/WH3b9W1Btxyc3LnJxt9fTj6UNr+sM6u2ragXV/MVjcvkNt25HPXaSM+hxRRTexnHb5P8gXX9YUqV1bUAUACkXL8AAgY59z+ZpF13VlbcuqX4baq5Fw/RSSo69ASSPTNFFD3K7/L8xRr+sDONW1Dkgn/AEl+SDuHf1JP1NIuu6sqlV1S/CnfkC4fB3HLd+55PqaKKOoL9f0CTXdXljeOTVL943VlZWuHIYN94EZ6Hv60r6/rD7t+rag245Oblzk42+vpx9KKKFuC2Xz/AEBtf1hnV21bUC6v5isbl8htu3I567SRn0OKF1/WFKldW1AFAApFy/AAIGOfc/maKKES/h+X+Yi67qytuXVL8NtVci4fopJUdegJJHpmlGv6wM41bUOSCf8ASX5IO4d/Uk/U0UUIqe/3foIuu6sqlV1S/CnfkC4fB3HLd+55PqaJNd1eWN45NUv3jdWVla4chg33gRnoe/rRRS6FL416v9RX1/WH3b9W1Btxyc3LnJxt9fTj6UNr+sM6u2ragXV/MVjcvkNt25HPXaSM+hxRRTexnHb5P8gXX9YUqV1bUAUACkXL8AAgY59z+ZpF13VlbcuqX4baq5Fw/RSSo69ASSPTNFFD3K7/AC/MUa/rAzjVtQ5IJ/0l+SDuHf1JP1NIuu6sqlV1S/CnfkC4fB3HLd+55PqaKKOoL9f0CTXdXljeOTVL943VlZWuHIYN94EZ6Hv60r6/rD7t+rag245Oblzk42+vpx9KKKFuC2Xz/QG1/WGdXbVtQLq/mKxuXyG27cjnrtJGfQ4oXX9YUqV1bUAUACkXL8AAgY59z+ZoooRL+H5f5iLrurK25dUvw21VyLh+iklR16AkkemaUa/rAzjVtQ5IJ/0l+SDuHf1JP1NFFCKnv936CLrurKpVdUvwp35AuHwdxy3fueT6miTXdXljeOTVL943VlZWuHIYN94EZ6Hv60UUuhS+Ner/AFFfX9Yfdv1bUG3HJzcucnG319OPpQ2v6wzq7atqBdX8xWNy+Q23bkc9dpIz6HFFFN7Gcdvk/wAgXX9YUqV1bUAUACkXL8AAgY59z+ZpF13VlbcuqX4baq5Fw/RSSo69ASSPTNFFD3K7/L8xRr+sDONW1Dkgn/SX5IO4d/Uk/U0i67qyqVXVL8Kd+QLh8Hcct37nk+pooo6gv1/QJNd1eWN45NUv3jdWVla4chg33gRnoe/rSvr+sPu36tqDbjk5uXOTjb6+nH0oooW4LZfP9AbX9YZ1dtW1Aur+YrG5fIbbtyOeu0kZ9Dihdf1hSpXVtQBQAKRcvwACBjn3P5miihEv4fl/mIuu6srbl1S/DbVXIuH6KSVHXoCSR6ZpRr+sDONW1Dkgn/SX5IO4d/Uk/U0UUIqe/wB36CLrurKpVdUvwp35AuHwdxy3fueT6miTXdXljeOTVL943VlZWuHIYN94EZ6Hv60UUuhS+Ner/UV9f1h92/VtQbccnNy5ycbfX04+lDa/rDOrtq2oF1fzFY3L5DbduRz12kjPocUUU3sZx2+T/IF1/WFKldW1AFAApFy/AAIGOfc/maRdd1ZW3Lql+G2quRcP0UkqOvQEkj0zRRQ9yu/y/MUa/rAzjVtQ5IJ/0l+SDuHf1JP1NIuu6sqlV1S/CnfkC4fB3HLd+55PqaKKOoL9f0CTXdXljeOTVL943VlZWuHIYN94EZ6Hv60r6/rD7t+rag245Oblzk42+vpx9KKKFuC2Xz/QG1/WGdXbVtQLq/mKxuXyG27cjnrtJGfQ4oXX9YUqV1bUAUACkXL8AAgY59z+ZoooRL+H5f5iLrurK25dUvw21VyLh+iklR16AkkemaUa/rAzjVtQ5IJ/0l+SDuHf1JP1NFFCKnv936CLrurKpVdUvwp35AuHwdxy3fueT6miTXdXljeOTVL943VlZWuHIYN94EZ6Hv60UUuhS+Ner/UV9f1h92/VtQbccnNy5ycbfX04+lRXurajfRGO9v7u5jL+ZtmmZxuxjOCeuOM0UUS2Lwn8WH9dj//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram showing an acute anterior myocardial infarction (Q waves and ST elevations in leads V2 to V4, and ST elevations alone in leads I and aVL) and right bundle branch block (terminal R wave in lead V1 and terminal S wave in leads I and V6).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_0_3080=[""].join("\n");
var outline_f3_0_3080=null;
var title_f3_0_3081="Medical therapy of hypercortisolism (Cushings syndrome)";
var content_f3_0_3081=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/0/3081/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/0/3081/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/0/3081/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/0/3081/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/0/3081/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/0/3081/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/0/3081/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypercortisolism of Cushing&rsquo;s syndrome is primarily treated surgically, regardless of its cause (ie, due to corticotropin (ACTH)-producing pituitary tumor (Cushing's disease), ectopic ACTH secretion by a nonpituitary tumor, or cortisol secretion by an adrenal adenoma or carcinoma). However, when surgery is delayed, contraindicated, or unsuccessful, medical therapy is often required. Adrenal enzyme inhibitors are the most commonly used drugs, but adrenolytic agents, drugs that target the pituitary, and glucocorticoid-receptor antagonists also have been used.",
"   </p>",
"   <p>",
"    The pharmacologic management of hypercortisolemia in Cushing&rsquo;s syndrome will be reviewed here. An overview of the treatment options for Cushing's syndrome and additional details about drugs that inhibit cortisol synthesis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1016?source=see_link\">",
"     \"Overview of the treatment of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26295?source=see_link\">",
"     \"Pharmacology and toxicity of adrenal enzyme inhibitors and adrenolytic agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19496?source=see_link\">",
"     \"Persistent or recurrent Cushing&rsquo;s disease: Surgical adrenalectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"   </p>",
"   <p>",
"    The main indications for medical therapy of Cushing&rsquo;s syndrome include (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1016?source=see_link\">",
"     \"Overview of the treatment of Cushing's syndrome\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management of hypercortisolism when surgery is contraindicated",
"     </li>",
"     <li>",
"      Control of hypercortisolism in preparation for surgery",
"     </li>",
"     <li>",
"      Persistence or recurrence of hypercortisolism after surgery",
"     </li>",
"     <li>",
"      Control of hypercortisolism while waiting for the effect of pituitary radiation in patients with ACTH-secreting pituitary tumors (Cushing&rsquo;s disease)",
"     </li>",
"     <li>",
"      Treatment of occult ectopic ACTH syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ADRENAL ENZYME INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aminoglutethimide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    , trilostane,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    inhibit one or more enzymes involved in cortisol synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. However, aminoglutethimide is no longer available in the world market, trilostane is a very weak inhibitor, and fluconazole has rarely been used clinically; these will not be considered further. These agents are usually used in patients with ACTH-dependent Cushing&rsquo;s syndrome. They are sometimes used in patients with adrenal cancer when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    is not able to control hormone excess. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40762?source=see_link\">",
"     \"Treatment of adrenocortical carcinoma\"",
"    </a>",
"    .) Patients with benign adrenal sources of cortisol are generally treated with adrenalectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=see_link\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34390?source=see_link\">",
"     \"Treatment of adrenocortical adenomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When used in patients with Cushing&rsquo;s disease, an increase in corticotropin (ACTH) secretion can sometimes override the blockade so that hypercortisolemia persists. Combinations of these drugs often have additive or synergistic therapeutic effects at lower individual doses, thereby minimizing side effects. The mechanism of action of the different drugs that can be used is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26295?source=see_link\">",
"     \"Pharmacology and toxicity of adrenal enzyme inhibitors and adrenolytic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Oral drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral, rather than intravenous, drugs are most often used for the control of cortisol secretion; however, the availability of these drugs varies in different countries. In the United States, the most commonly used drug is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ; in the UK,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    has been used more commonly. Metyrapone or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    may be added to ketoconazole if needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16432801\">",
"    <span class=\"h3\">",
"     Ketoconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     Ketoconazole",
"    </a>",
"    (Nizoral) inhibits the first step in cortisol biosynthesis (side-chain cleavage) and, to a lesser extent, the conversion of 11-deoxycortisol to cortisol; it is an even more potent inhibitor of C17-20 desmolase, decreasing androstenedione and testosterone production. It also inhibits ACTH secretion in vitro at therapeutic doses (200 to 400 mg two or three times a day) by impairing corticotroph adenylate cyclase activation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/6\">",
"     6",
"    </a>",
"    ]. However, the contribution of this effect to its action in patients with Cushing&rsquo;s disease has not been demonstrated.",
"   </p>",
"   <p>",
"    The side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    include headache, sedation, nausea, and vomiting. In men, inhibition of androgen production may lead to gynecomastia, decreased libido, and impotence. Because of this, some practitioners do not use ketoconazole as the first-line drug for men requiring long-term medical therapy of Cushing&rsquo;s syndrome. Others opt to use ketoconazole and replace testosterone if needed. Ketoconazole also decreases estradiol and testosterone production in women; this effect usually is not clinically apparent because of the oligomenorrhea or amenorrhea seen in most women with Cushing&rsquo;s syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/7\">",
"     7",
"    </a>",
"    ]. Unfortunately, ketoconazole is also a rare cause of reversible hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, liver function should be monitored at regular intervals. In clinical practice, this is usually done every one to two weeks at the outset of therapy and decreased to monthly or less after no increase is seen.",
"   </p>",
"   <p>",
"    The frequency of monitoring is increased in those patients who have elevated liver function tests at baseline, which is common in Cushing&rsquo;s syndrome. We recommend discontinuation of the agent if hepatocellular enzyme levels are three times the upper normal range, but this approach has not been systematically assessed.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     Ketoconazole",
"    </a>",
"    is teratogenic and toxic to animal embryos but has been used successfully and without harm to fetuses from as early as the seventh week of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. However, ketoconazole is not the treatment of choice during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4725?source=see_link&amp;anchor=H5#H5\">",
"     \"Cushing's syndrome in pregnancy\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16432822\">",
"    <span class=\"h3\">",
"     Metyrapone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     Metyrapone",
"    </a>",
"    (Metopirone&reg;) is an 11-beta-hydroxylase (P450c11) inhibitor that blocks the final step in cortisol biosynthesis (",
"    <a class=\"graphic graphic_figure graphicRef56413 \" href=\"UTD.htm?42/12/43212\">",
"     figure 1",
"    </a>",
"    ). It also increases adrenal androgen production, which can cause an increase in hirsutism in women; thus, we do not suggest metyrapone as the first-line drug for women requiring long-term control of hypercortisolism.",
"   </p>",
"   <p>",
"    Salt retention and hypertension also can occur because of increased production of deoxycorticosterone. Less frequently,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    may also inhibit ACTH secretion directly at high doses [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/11\">",
"     11",
"    </a>",
"    ]. When given in a dose of about 4",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    metyrapone decreases cortisol secretion, but usually not to normal, in patients with Cushing's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/12\">",
"     12",
"    </a>",
"    ]. Thus, like the other adrenal enzyme inhibitors, metyrapone is most useful as adjunctive therapy in patients with mild disease or after pituitary irradiation, which prevents a further increase in ACTH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/1,13-16\">",
"     1,13-16",
"    </a>",
"    ]. A dose of 500 to 750 mg three or four times a day is usually required in these patients. Metyrapone has also been used in pregnancy but its efficacy is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     Metyrapone",
"    </a>",
"    (Metopirone&reg;) is currently available in North America through its new distributor HRA Pharma (Paris, France) via its specialty pharmacy Direct Success Inc. with order forms available on the",
"    <a class=\"external\" href=\"file://www.metopirone.us/\">",
"     web",
"    </a>",
"    or by phone at 1-855-674-7663; order forms can be faxed to 1-855-674-6767.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Intravenous etomidate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     Etomidate",
"    </a>",
"    is an intravenous substituted imidazole anesthetic drug that blocks 11-beta-hydroxylation of deoxycortisol to produce cortisol (",
"    <a class=\"graphic graphic_figure graphicRef70372 \" href=\"UTD.htm?0/7/123\">",
"     figure 2",
"    </a>",
"    ). It may be useful in hospitalized patients when infused intravenously in a low, nonhypnotic dose of 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour, and has been effective in about 30 adults and children who were acutely ill [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/20\">",
"     20",
"    </a>",
"    ]. It lowers serum cortisol to normal (ie, 10",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [28",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    within about 10 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/4\">",
"     4",
"    </a>",
"    ] and is the only available agent for patients unable to take medication by mouth.",
"   </p>",
"   <p>",
"    In normal subjects given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    for five hours, plasma ACTH concentrations remain within the normal range. However, ACTH secretion might rise and overcome the etomidate blockade with more chronic administration in patients with Cushing's disease. Sedation, a theoretical side effect of this drug, was not observed in the few patients studied to date.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6330531\">",
"    <span class=\"h1\">",
"     ADRENOLYTIC AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6330785\">",
"    <span class=\"h2\">",
"     Mitotane",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     Mitotane",
"    </a>",
"    is an adrenocorticolytic drug that is used primarily for the treatment of adrenal carcinoma, which will not be considered further here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40762?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of adrenocortical carcinoma\", section on 'Adjuvant mitotane'",
"    </a>",
"    .) It can also be used to achieve medical adrenalectomy with or without pituitary irradiation in patients with Cushing&rsquo;s disease or as an adjunctive medication in patients with ectopic ACTH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Mitotane&rsquo;s mechanisms of action are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26295?source=see_link\">",
"     \"Pharmacology and toxicity of adrenal enzyme inhibitors and adrenolytic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6330792\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    should be started with 0.5 g given at bedtime, adding single 0.5 g doses at mealtimes every week or so, as the patient's tolerance permits, to reach a maximal dose of 2 to 3",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    one-half of which is taken at bedtime to reduce nausea.",
"   </p>",
"   <p>",
"    Thereafter, the concentrations are maintained by doses of 1 to 2 g daily.",
"   </p>",
"   <p>",
"    The usual duration of adjunctive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    therapy after radiotherapy in patients with Cushing's disease is six to nine months. Mitotane should not be given to pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     Mitotane",
"    </a>",
"    is taken up by fatty tissues and persists in plasma long after the drug is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/25\">",
"     25",
"    </a>",
"    ]. As a result, cortisol levels may remain suppressed so that replacement glucocorticoid (if used) may have to be tapered over a period of several weeks to months after mitotane is discontinued.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     Mitotane",
"    </a>",
"    tends to spare the zona glomerulosa [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/26\">",
"     26",
"    </a>",
"    ]. As a result, mineralocorticoid replacement usually is required only with chronic, high-dose therapy used for adrenal carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40762?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of adrenocortical carcinoma\", section on 'Adjuvant mitotane'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6330813\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;At daily doses of 2 to 3 g, the major side effects are nausea, vomiting, and anorexia. Additional side effects that occur with the higher doses used for adrenal carcinoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40762?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of adrenocortical carcinoma\", section on 'Adjuvant mitotane'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H930417\">",
"    <span class=\"h2\">",
"     Results",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach is effective in patients with Cushing's disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study followed 46 patients who were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      and pituitary irradiation for 5 to 15 years [",
"      <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/21\">",
"       21",
"      </a>",
"      ]. A cure rate of 80 percent was initially reported, but only a minority of patients became hypocortisolemic. Eight of the patients thought to be cured eventually required pituitary surgery, and another nine required bilateral surgical adrenalectomy; the sustained cure rate was 59 percent. Four patients subsequently developed Nelson's syndrome.",
"     </li>",
"     <li>",
"      Similar findings were reported in a study of 46 patients treated with higher doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      but no pituitary irradiation [",
"      <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/22\">",
"       22",
"      </a>",
"      ]. No cases of Nelson's syndrome were noted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1553178\">",
"    <span class=\"h1\">",
"     SUGGESTED APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two approaches to the use of these agents in Cushing&rsquo;s syndrome. The first is a &ldquo;block and replace&rdquo; strategy in which the goal is total ablation of cortisol secretion, with the addition of replacement glucocorticoid therapy when cortisol levels are extremely low. The second is a &ldquo;normalization&rdquo; strategy in which the goal is to reduce cortisol levels to normal. The &ldquo;block and replace&rdquo; strategy is almost always needed in patients with wide variability in cortisol production and urinary free cortisol because attempts to normalize cortisol secretion with an invariant treatment will result in over- and under-suppression on different days. Conversely, the normalization strategy works best in patients with relatively invariant hypercortisolism. Thus, it is important to collect sufficient basal urine cortisol results to judge the extent of variability. Compared to the normalization approach, the block and replace approach generally requires higher doses and sometimes additional drugs, and thus is more costly and exposes the patient to the risk of additional adverse effects.",
"   </p>",
"   <p>",
"    We suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    as the first drug used. Its effect can be assessed within 24 to 48 hours by measuring serum cortisol or 24-hour urine cortisol excretion and its dose adjusted frequently. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/132?source=see_link\">",
"     \"Measurement of cortisol in serum and saliva\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41319?source=see_link\">",
"     \"Measurement of urinary excretion of endogenous and exogenous glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       Ketoconazole",
"      </a>",
"      should be started at a dose of 200 mg two or three times daily and increased rapidly to 400 mg three times daily; higher doses are seldom more effective.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       Ketoconazole",
"      </a>",
"      requires an acidic environment for maximal absorption. The bioavailability of ketoconazole may be reduced as much as 50 percent if it is given with a proton pump inhibitor [",
"      <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/27\">",
"       27",
"      </a>",
"      ]. Such agents should be discontinued, if at all possible, if ketoconazole is used.",
"     </li>",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      does not control cortisol secretion, it should be maintained at a total dose of 1200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      should be added.",
"     </li>",
"     <li>",
"      We suggest adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      at a dose of 250 mg two or three times a day and increasing rapidly, using serum cortisol values or 24-hour urine cortisol excretion as an index of therapeutic effect, to a maximum dose of about 4.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/27\">",
"       27",
"      </a>",
"      ]. Most patients show near-maximal responses at a daily dose of 2 g.",
"     </li>",
"     <li>",
"      An alternative is the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      , but its effects occur slowly. (See",
"      <a class=\"local\" href=\"#H6330785\">",
"       'Mitotane'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In one study of 11 cases of severe hypercortisolism in whom adrenalectomy was not feasible, triple drug therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      normalized urinary free cortisol [",
"      <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These drugs tend to act synergistically; using them in combination often allows one to obtain the greatest therapeutic benefit with the lowest incidence of side effects. It is seldom necessary to use maximum doses. Particularly in patients with severe hypercortisolism, it is important to control cortisol synthesis quickly. In these patients, the doses should be increased as rapidly as laboratory results are available. Patients with mild-moderate hypercortisolism may be advanced more slowly, ideally within one month.",
"   </p>",
"   <p>",
"    An alternative approach is to begin treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    using the doses described above, and to add",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    if cortisol is not adequately controlled.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     Mitotane",
"    </a>",
"    is rarely given as the initial agent except in patients with adrenocortical cancer. However, if the other agents cannot be used it can be used as monotherapy.",
"   </p>",
"   <p>",
"    Unless",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    is given in adrenolytic doses, these medications do not permanently cure the hypercortisolism, leading to recurrence when the drug is discontinued. As a result, they must be continued indefinitely unless a tumor is found and excised or pituitary radiotherapy is effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1553430\">",
"    <span class=\"h2\">",
"     Replacement glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a block and replace strategy, patients must receive replacement glucocorticoid therapy. This should be started when the serum or urine cortisol is in the normal range and the treatment doses are increased to achieve complete ablation of cortisol secretion. With steroidogenesis inhibitors, any agent can be used in the usual way. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .) If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    is used, a pre-dose cortisol level can be used to assess treatment efficacy or the patient can be placed on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    for that day.",
"   </p>",
"   <p>",
"    One cannot predict when a patient will become hypocortisolemic after beginning treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    . As a result, replacement glucocorticoid, usually 5 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or 0.5 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    each day, should be begun rapidly when increased levels of cortisol in urine or saliva begin to decrease. Mitotane increases the metabolism of dexamethasone [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/29\">",
"     29",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    , and cortisol and induces an increase in CBG levels [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/30\">",
"     30",
"    </a>",
"    ]. Thus, replacement dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    usually requires a two- to three-fold increase in the usual dose after long-term therapy with mitotane. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40762?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of adrenocortical carcinoma\", section on 'Adjuvant mitotane'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    If dexamethasone is used for replacement therapy during mitotane administration, it may be necessary to increase its dose (and that of fludrocortisone, if it is required) to three to seven times the usual dose; in these cases, amelioration of symptoms of hypocortisolism or normalization of urinary free cortisol values must be used to guide glucocorticoid replacement, while symptoms and signs of volume depletion or excess (postural hypotension, systemic hypertension, or edema), serum electrolytes, and plasma renin activity are used to guide mineralocorticoid replacement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1553437\">",
"    <span class=\"h2\">",
"     Monitoring efficacy of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum cortisol",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urine cortisol excretion are used to assess efficacy of steroidogenesis inhibitors. At the outset of treatment, we recommend measurement of a morning cortisol level on the day that urine is collected for cortisol measurement. This allows the two to be correlated, with the potential later use of the morning cortisol only, as most patients find it more convenient than urine collection.",
"   </p>",
"   <p>",
"    For the &lsquo;normalization&rsquo; strategy, a serum cortisol target of 7 to 12",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (193 to 331",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    can be used while awaiting the urine result. This target range includes the upper part of the normal 24-hour mean cortisol values up to values slightly above normal. This approach minimizes the chance of adrenal insufficiency. Because of this possibility, patients on the normalization approach should receive education about adrenal insufficiency signs and symptoms and how to administer emergency doses of glucocorticoid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of adrenal insufficiency in adults\", section on 'Emergency precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urinary cortisol excretion alone is used as the optimal measure of the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    therapy alone or in combination with other agents. Mitotane increases corticosteroid binding globulin levels, so that serum cortisol levels increase [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/31\">",
"     31",
"    </a>",
"    ]. However, if serum cortisol levels are used to monitor treatment, they should be correlated with urinary cortisol excretion, at least initially.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     Metyrapone",
"    </a>",
"    administration may falsely elevate serum cortisol when measured by immunoassay, but not tandem mass spectrometry [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/32\">",
"     32",
"    </a>",
"    ]. As a result, urinary or serum cortisol measurement by tandem mass spectrometry is preferred to monitor efficacy of treatment.",
"   </p>",
"   <p>",
"    Urinary cortisol levels need to be measured frequently to adjust the dose of any steroidogenesis inhibitor or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    , but once the dose appears to be optimal, monitoring may occur less often, perhaps monthly or less frequently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     OTHER AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6331226\">",
"    <span class=\"h2\">",
"     Drugs that target pituitary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a number of pituitary-targeted therapies have been investigated, several have been ineffective, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/25/19862?source=see_link\">",
"     cyproheptadine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    . Only the somatostatin analogue,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/21/27989?source=see_link\">",
"     pasireotide",
"    </a>",
"    , and the dopamine agonist,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    (and the combination of the two), have shown potential benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458568781\">",
"    <span class=\"h3\">",
"     Cabergoline",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two studies, chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    therapy (1 to 7 mg orally per week) was associated with clinically important improvement in 24-hour urinary free cortisol (UFC) to &le;125 percent of normal in 12 of 42 patients with Cushing&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Normalization of UFC was achieved in 30 percent of patients with up to five years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/34\">",
"     34",
"    </a>",
"    ]. In a third report, for patients in whom cabergoline therapy (3",
"    <span class=\"nowrap\">",
"     g/week)",
"    </span>",
"    provided a suboptimal response, addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    (200 to 400 mg daily) achieved a normal UFC in six of nine patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458568732\">",
"    <span class=\"h3\">",
"     Pasireotide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The somatostatin analog",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/21/27989?source=see_link\">",
"     pasireotide",
"    </a>",
"    binds to somatostatin receptors and blocks the release of ACTH from the corticotropes via its high affinity for somatostatin receptor subtype 5 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/35\">",
"     35",
"    </a>",
"    ]. In one study, when given subcutaneously twice daily for six months, pasireotide decreased 24-hour urinary free cortisol (UFC) by a mean of 48 percent and normalized it in 21 of 80 (26 percent) and 12 of 82 (15 percent) of patients receiving a 900 mcg or 600 mcg dose, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/36\">",
"     36",
"    </a>",
"    ]. Response rates were similar after 12 months. In addition, a sustained response for seven years has been reported in one individual [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/37\">",
"     37",
"    </a>",
"    ]. Hyperglycemia-related adverse events occurred in 118 of 162 patients (73 percent); 74 of 162 patients (63 percent) required initiation of a glucose-lowering medication.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/21/27989?source=see_link\">",
"     Pasireotide",
"    </a>",
"    injection has been approved in a number of countries for the treatment of patients with Cushing's disease for whom surgery has been unsuccessful or who are not surgical candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/38\">",
"     38",
"    </a>",
"    ]. It was approved in the United States in December 2012 by the Food and Drug Administration [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/39\">",
"     39",
"    </a>",
"    ]. It is available in Europe and is expected to be available in the US in March 2013.",
"   </p>",
"   <p>",
"    The recommended initial dose is 0.6 mg subcutaneously twice daily. If the patient responds with normalization of UFC (measured after one to two months of therapy),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/21/27989?source=see_link\">",
"     pasireotide",
"    </a>",
"    should be continued as long as the patient continues to respond. If the response is inadequate, the dose may be increased to 0.9 mg twice daily. If there is no clinical response to 0.9 mg, treatment should either be stopped or combined therapy should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458568952\">",
"    <span class=\"h3\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a report of 17 patients with Cushing&rsquo;s disease, the somatostatin analog",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/21/27989?source=see_link\">",
"     pasireotide",
"    </a>",
"    , followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    and, if necessary,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    , achieved normalization in urinary free cortisol in five (29 percent for pasireotide alone), four (53 percent for pasireotide and cabergoline), and six patients (88 percent for three drugs), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6330490\">",
"    <span class=\"h2\">",
"     Glucocorticoid-receptor antagonists (mifepristone)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     Mifepristone",
"    </a>",
"    (RU-486) is an anti-progestational drug that is best known as an abortifacient. However, it has other potential therapeutic uses as an antiprogestin (eg, for the treatment of endometriosis and uterine myomas) and, at much higher doses, as a glucocorticoid receptor antagonist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25866?source=see_link&amp;anchor=H19#H19\">",
"     \"Therapeutic use and adverse effects of progesterone receptor antagonists and selective progesterone receptor modulators\", section on 'Cushing's syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In retrospective reports of patients with Cushing&rsquo;s syndrome,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    was rapidly effective for some symptoms of Cushing&rsquo;s syndrome, most notably, cortisol-induced psychosis, which improved within the first week of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Hyperglycemia due to hypercortisolism improved in some patients, but side effects included moderate to severe hypokalemia in 20 to 50 percent of patients. Symptoms of adrenal insufficiency developed in some patients (3 of 20 in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/41\">",
"     41",
"    </a>",
"    ]. Because mifepristone blocks cortisol action, the levels of cortisol are not changed, so that hormonal measurement cannot be used to judge either therapeutic efficacy or adrenal insufficiency. Mifepristone also blocks the action of exogenous glucocorticoids, making it difficult to treat the symptoms of adrenal insufficiency if they develop. However, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    4 mg to overcome the blockade.",
"   </p>",
"   <p>",
"    In an open-label, 24-week study of 46 patients with Cushing&rsquo;s syndrome associated with type 2 diabetes, impaired glucose tolerance, or hypertension, administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    300 to 1200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    improved clinical and metabolic status in most (40 of 46 patients, 87 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/43\">",
"     43",
"    </a>",
"    ]. Sixty percent (15 of 25) of patients in the",
"    <span class=\"nowrap\">",
"     diabetes/impaired",
"    </span>",
"    glucose tolerance experienced a significant decrease in the AUC for glucose on an oral glucose tolerance test. In addition, mean fasting glucose decreased from 149 to 105",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8.3 to 5.8",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and A1C decreased from 7.4 to 6.3 percent. A diastolic blood pressure decrease of at least 5 mm Hg was seen in 8 of 21 (38 percent) of the hypertensive group. In the combined cohort, improvements in depression, cognition, and quality of life were also observed. Adverse events occurred in most patients (40 of 46, 87 percent), and included fatigue, nausea, headache, hypokalemia, arthralgias, edema, and endometrial thickening in women.",
"    <br/>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     Mifepristone",
"    </a>",
"    (Korlym) has been approved in the United States as a once-daily oral medication (300 mg) to control hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing&rsquo;s syndrome and type 2 diabetes or glucose intolerance who have failed surgery or are not candidates for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/44\">",
"     44",
"    </a>",
"    ]. Because patients were not categorized as clinically normal, the role of mifepristone apart from treatment of hyperglycemia is not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?3/0/3081/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     Mifepristone",
"    </a>",
"    may also be a reasonable short-term intervention for patients with Cushing&rsquo;s syndrome who have an acute crisis, such as cortisol-induced psychosis, as symptoms improves rapidly in response to the glucocorticoid receptor blockade.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/61/6099?source=see_link\">",
"       \"Patient information: Cushing's syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/19/13619?source=see_link\">",
"       \"Patient information: Cushing's syndrome (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/47/10994?source=see_link\">",
"       \"Patient information: Cushing's syndrome treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H601222861\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The hypercortisolism in Cushing&rsquo;s syndrome is primarily treated surgically, regardless of its cause. However, when surgery is delayed, contraindicated, or unsuccessful, medical therapy is often required.",
"     </li>",
"     <li>",
"      The main indications for pharmacologic control of hypercortisolism include: in preparation for surgery, persistence or recurrence of hypercortisolism after surgery, while waiting for the effect of pituitary radiation, occult ectopic ACTH syndrome, severe or malignancy-related hypercortisolism, and when surgery is contraindicated. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with hypercortisolism in whom medical therapy is indicated, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      as the first-line drug (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If ketoconazole does not control cortisol secretion, we suggest adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Adrenal enzyme inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An alternative approach that some clinicians use is to start with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      and add",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      if cortisol secretion is not controlled. (See",
"      <a class=\"local\" href=\"#H1553178\">",
"       'Suggested approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"       Mitotane",
"      </a>",
"      is an adrenocorticolytic drug that is used primarily for the treatment of adrenal carcinoma. (See",
"      <a class=\"local\" href=\"#H6330785\">",
"       'Mitotane'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"       Mitotane",
"      </a>",
"      also can be used to as adjunctive therapy during or after pituitary irradiation in patients with Cushing&rsquo;s disease. The usual duration of mitotane therapy in patients with Cushing's disease is six to nine months.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"       Mitotane",
"      </a>",
"      has significant side effects. However, important advantages over surgical adrenalectomy include a possible decreased risk of developing Nelson&rsquo;s syndrome and the possibility of not requiring mineralocorticoid replacement. (See",
"      <a class=\"local\" href=\"#H6330813\">",
"       'Side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other drugs directed at reducing ACTH levels in Cushing&rsquo;s disease include the dopamine agonist,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/21/27989?source=see_link\">",
"       pasireotide",
"      </a>",
"      , a somatostatin analog. In 2012,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      , a glucocorticoid-receptor antagonist, was approved for treatment of hyperglycemia in Cushing&rsquo;s syndrome in the United States. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Other agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/1\">",
"      Jeffcoate WJ, Rees LH, Tomlin S, et al. Metyrapone in long-term management of Cushing's disease. Br Med J 1977; 2:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/2\">",
"      Komanicky P, Spark RF, Melby JC. Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis. J Clin Endocrinol Metab 1978; 47:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/3\">",
"      Loli P, Berselli ME, Tagliaferri M. Use of ketoconazole in the treatment of Cushing's syndrome. J Clin Endocrinol Metab 1986; 63:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/4\">",
"      Schulte HM, Benker G, Reinwein D, et al. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 1990; 70:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/5\">",
"      Riedl M, Maier C, Zettinig G, et al. Long term control of hypercortisolism with fluconazole: case report and in vitro studies. Eur J Endocrinol 2006; 154:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/6\">",
"      Stalla GK, Stalla J, Huber M, et al. Ketoconazole inhibits corticotropic cell function in vitro. Endocrinology 1988; 122:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/7\">",
"      Gal M, Orly J, Barr I, et al. Low dose ketoconazole attenuates serum androgen levels in patients with polycystic ovary syndrome and inhibits ovarian steroidogenesis in vitro. Fertil Steril 1994; 61:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/8\">",
"      McCance DR, Hadden DR, Kennedy L, et al. Clinical experience with ketoconazole as a therapy for patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1987; 27:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/9\">",
"      Amado JA, Pesquera C, Gonzalez EM, et al. Successful treatment with ketoconazole of Cushing's syndrome in pregnancy. Postgrad Med J 1990; 66:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/10\">",
"      Berwaerts J, Verhelst J, Mahler C, Abs R. Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature. Gynecol Endocrinol 1999; 13:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/11\">",
"      Sch&ouml;nesh&ouml;fer M, Fenner A, Claus M. Suppressive effect of metyrapone on plasma corticotrophin immunoreactivity in normal man. Clin Endocrinol (Oxf) 1983; 18:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/12\">",
"      Santen RJ, Wells SA, Runi S, et al. Adrenal suppression with aminoglutethimide. I. Differential e-fects of aminoglutethimide on glucocorticoid metabolism as a rationale for use of hydrocortisone. J Clin Endocrinol Metab 1977; 45:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/13\">",
"      Orth DN, Liddle GW. Results of treatment in 108 patients with Cushing's syndrome. N Engl J Med 1971; 285:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/14\">",
"      Child DF, Burke CW, Burley DM, et al. Drug controlled of Cushing's syndrome. Combined aminoglutethimide and metyrapone therapy. Acta Endocrinol (Copenh) 1976; 82:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/15\">",
"      Verhelst JA, Trainer PJ, Howlett TA, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1991; 35:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/16\">",
"      Orth DN. Metyrapone is useful only as adjunctive therapy in Cushing's disease. Ann Intern Med 1978; 89:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/17\">",
"      Aron DC, Schnall AM, Sheeler LR. Cushing's syndrome and pregnancy. Am J Obstet Gynecol 1990; 162:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/18\">",
"      Buescher MA, McClamrock HD, Adashi EY. Cushing syndrome in pregnancy. Obstet Gynecol 1992; 79:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/19\">",
"      Lindsay JR, Nieman LK. The hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment. Endocr Rev 2005; 26:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/20\">",
"      Preda VA, Sen J, Karavitaki N, Grossman AB. Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review. Eur J Endocrinol 2012; 167:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/21\">",
"      Schteingart DE, Tsao HS, Taylor CI, et al. Sustained remission of Cushing's disease with mitotane and pituitary irradiation. Ann Intern Med 1980; 92:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/22\">",
"      Luton JP, Mahoudeau JA, Bouchard P, et al. Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases. N Engl J Med 1979; 300:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/23\">",
"      Baudry C, Coste J, Bou Khalil R, et al. Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center. Eur J Endocrinol 2012; 167:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/24\">",
"      Leiba S, Weinstein R, Shindel B, et al. The protracted effect of o,p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo. Ann Endocrinol (Paris) 1989; 50:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/25\">",
"      Hogan TF, Citrin DL, Johnson BM, et al. o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement. Cancer 1978; 42:2177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/26\">",
"      VILAR O, TULLNER WW. Effects of o,p' DDD on histology and 17-hydroxycorticosteroid output of the dog adrenal cortex. Endocrinology 1959; 65:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/27\">",
"      Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet 2010; 49:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/28\">",
"      Kamenick&yacute; P, Droumaguet C, Salenave S, et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab 2011; 96:2796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/29\">",
"      Robinson BG, Hales IB, Henniker AJ, et al. The effect of o,p'-DDD on adrenal steroid replacement therapy requirements. Clin Endocrinol (Oxf) 1987; 27:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/30\">",
"      Kroiss M, Quinkler M, Lutz WK, et al. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 2011; 75:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/31\">",
"      Nader N, Raverot G, Emptoz-Bonneton A, et al. Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. J Clin Endocrinol Metab 2006; 91:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/32\">",
"      Monaghan PJ, Owen LJ, Trainer PJ, et al. Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11&beta;-hydroxylase inhibitor metyrapone. Ann Clin Biochem 2011; 48:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/33\">",
"      Vilar L, Naves LA, Azevedo MF, et al. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease. Pituitary 2010; 13:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/34\">",
"      Godbout A, Manavela M, Danilowicz K, et al. Cabergoline monotherapy in the long-term treatment of Cushing's disease. Eur J Endocrinol 2010; 163:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/35\">",
"      Hofland LJ, van der Hoek J, Feelders R, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005; 152:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/36\">",
"      Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 2012; 366:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/37\">",
"      Lib&eacute; R, Groussin L, Bertherat J. Pasireotide in Cushing's disease. N Engl J Med 2012; 366:2134; author reply 2134.",
"     </a>",
"    </li>",
"    <li>",
"     European Medicines Agency. Summary of product characteristics: Signifor 0.3 mg solution for injection. file://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002052/WC500128056.pdf (Accessed on December 21, 2012).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Press Release: FDA approves Signifor, a new orphan drug for Cushing&rsquo;s disease (December 2012) file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332351.htm (Accessed on January 16, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/40\">",
"      Feelders RA, de Bruin C, Pereira AM, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med 2010; 362:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/41\">",
"      Castinetti F, Fassnacht M, Johanssen S, et al. Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol 2009; 160:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/42\">",
"      Johanssen S, Allolio B. Mifepristone (RU 486) in Cushing's syndrome. Eur J Endocrinol 2007; 157:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/43\">",
"      Fleseriu M, Biller BM, Findling JW, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012; 97:2039.",
"     </a>",
"    </li>",
"    <li>",
"     Corcept Therapeutics Incorporated Announces FDA Approval of Korlym&trade; (mifepristone) 300 mg Tablets: First and Only Approved Medication for Cushing&rsquo;s Syndrome Patients - February 17, 2012 file://www.corcept.com/news_events/pr_1329524335 (Accessed on February 29, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/0/3081/abstract/45\">",
"      Mifepristone (Korlym) for Cushing's syndrome. Med Lett Drugs Ther 2012; 54:46.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 119 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-1E1E8CC54B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_0_3081=[""].join("\n");
var outline_f3_0_3081=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H601222861\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ADRENAL ENZYME INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Oral drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16432801\">",
"      - Ketoconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16432822\">",
"      - Metyrapone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Intravenous etomidate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6330531\">",
"      ADRENOLYTIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6330785\">",
"      Mitotane",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6330792\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6330813\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H930417\">",
"      Results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1553178\">",
"      SUGGESTED APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1553430\">",
"      Replacement glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1553437\">",
"      Monitoring efficacy of treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      OTHER AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6331226\">",
"      Drugs that target pituitary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H458568781\">",
"      - Cabergoline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H458568732\">",
"      - Pasireotide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H458568952\">",
"      - Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6330490\">",
"      Glucocorticoid-receptor antagonists (mifepristone)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H601222861\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/119\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/119|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/12/43212\" title=\"figure 1\">",
"      Action of metyrapone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/7/123\" title=\"figure 2\">",
"      Adrenal steroid synthesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=related_link\">",
"      Clinical presentation and evaluation of adrenocortical tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4725?source=related_link\">",
"      Cushing's syndrome in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/132?source=related_link\">",
"      Measurement of cortisol in serum and saliva",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41319?source=related_link\">",
"      Measurement of urinary excretion of endogenous and exogenous glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1016?source=related_link\">",
"      Overview of the treatment of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/19/13619?source=related_link\">",
"      Patient information: Cushing's syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/61/6099?source=related_link\">",
"      Patient information: Cushing's syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/47/10994?source=related_link\">",
"      Patient information: Cushing's syndrome treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19496?source=related_link\">",
"      Persistent or recurrent Cushing&rsquo;s disease: Surgical adrenalectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26295?source=related_link\">",
"      Pharmacology and toxicity of adrenal enzyme inhibitors and adrenolytic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25866?source=related_link\">",
"      Therapeutic use and adverse effects of progesterone receptor antagonists and selective progesterone receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34390?source=related_link\">",
"      Treatment of adrenocortical adenomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40762?source=related_link\">",
"      Treatment of adrenocortical carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_0_3082="Meibomian gland dysfunction";
var content_f3_0_3082=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F78680%7EDERM%2F58040%7EDERM%2F66750%7EDERM%2F81954%7EDERM%2F59488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F78680%7EDERM%2F58040%7EDERM%2F66750%7EDERM%2F81954%7EDERM%2F59488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Meibomian gland dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lower eyelid with inflammation of the tarsal conjunctiva and cloudy oil and plugging at the meibomian gland orifices.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Meibomian gland dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Expression of a cloudy meibomian gland secretion, which obscures the underlying meibomian orifices. A droplet overlies the inflamed marginal conjunctiva.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gary Foulks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Meibomian gland dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plugging of the Meibomian gland orifices.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gary Foulks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Meibomian gland dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Expression of a solid white paste from blocked Meibomian glands.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gary Foulks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Meibomian gland dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cicatricial meibomian gland dysfunction. The meibomian orifices have been dragged into the conjunctiva of the posterior lid margin, which is broadened and highly inflamed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gary Foulks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_0_3082=[""].join("\n");
var outline_f3_0_3082=null;
var title_f3_0_3083="Knock-knees red flags";
var content_f3_0_3083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clues to pathologic causes of knock-knees in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Severe knock-knees (&gt;8 cm between the medial malleoli with patellas facing forward and femoral condyles together)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Progressive knock-knees deformity after age 4 to 5 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Persistent knock-knees (after age 7 years)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Unilateral or asymmetric valgus deformity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Medial thrust with ambulation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Short stature",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       History of metabolic disease, lower-extremity fracture, infection, tumor, or joint swelling/warmth",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_0_3083=[""].join("\n");
var outline_f3_0_3083=null;
var title_f3_0_3084="Age-related changes in innate immunity";
var content_f3_0_3084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F69360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F69360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Age-related changes in the innate immune system",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cell type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Decrease with age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Increase with age",
"       </td>",
"       <td class=\"subtitle1\">",
"        No change with age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematopoietic stem cells",
"       </td>",
"       <td>",
"        <p>",
"         Total number in the bone marrow",
"        </p>",
"        <p>",
"         Proliferation capacity",
"        </p>",
"        <p>",
"         Homing capacity to the bone marrow",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Macrophages",
"       </td>",
"       <td>",
"        <p>",
"         Bone marrow precursors",
"        </p>",
"        <p>",
"         Oxidative burst",
"        </p>",
"        <p>",
"         Phagocytic capacity",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Neutrophils",
"       </td>",
"       <td>",
"        <p>",
"         Oxidative burst",
"        </p>",
"        <p>",
"         Phagocytic capacity",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Bone marrow precursors",
"        </p>",
"        <p>",
"         Peripheral blood numbers",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Natural killer cells",
"       </td>",
"       <td>",
"        CD56",
"        <sup>",
"         bright",
"        </sup>",
"        natural killer cell number and percent",
"       </td>",
"       <td>",
"        Total number CD56",
"        <sup>",
"         dim",
"        </sup>",
"        natural killer cell number and percent",
"       </td>",
"       <td>",
"        Cytolytic activity",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Dendritic cells",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Number of myeloid and plasmacytoid dendritic cells",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_0_3084=[""].join("\n");
var outline_f3_0_3084=null;
var title_f3_0_3085="Mycobacteria classification";
var content_f3_0_3085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of mycobacterial species causing human disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            M. tuberculosis complex",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            M. tuberculosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            M. bovis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            M. africanum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            M. microti",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            M. canetti",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            M. leprae",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Rapidly growing nontuberculous mycobacteria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            M. fortuitum complex",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            M. fortuitum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            M. peregrinum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            M. porcinum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            M. chelonae",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            M. abscessus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            M. abscessus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            M. bolletii (previously M. massiliense)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            M. smegmatis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            M. mucogenicum",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Slowly growing nontuberculous mycobacteria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Photochromogens",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            M. kansasii",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            M. marinum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Scotochromogens",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            M. gordonae",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            M. scrofulaceum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Nonchromogens",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            M. avium complex",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            M. avium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            M. intracellulare",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            M. terrae complex",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            M. ulcerans",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            M. xenopi",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            M. simiae",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            M. malmoense",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            M. szulgai",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            M. asiaticum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            M. haemophilum",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_0_3085=[""].join("\n");
var outline_f3_0_3085=null;
var title_f3_0_3086="Contents: Eating disorders";
var content_f3_0_3086=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Eating disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Eating disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/62/38890\">",
"           Anorexia nervosa in adults and adolescents: Medical complications and their management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/16/30982\">",
"           Anorexia nervosa in adults and adolescents: The refeeding syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/56/21385\">",
"           Anorexia nervosa in adults: Cognitive-behavioral therapy (CBT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/7/3194\">",
"           Anorexia nervosa in adults: Diagnosis, associated clinical features, and assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/10/16550\">",
"           Anorexia nervosa in adults: Evaluation for medical complications and criteria for hospitalization to manage these complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/18/7463\">",
"           Anorexia nervosa in adults: Pharmacotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/28/8646\">",
"           Binge-eating disorder: Cognitive-behavioral therapy (CBT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/1/34841\">",
"           Binge-eating disorder: Overview of treatment in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/1/33816\">",
"           Bulimia nervosa and binge eating disorder in adults: Medical complications and their management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/50/33577\">",
"           Bulimia nervosa in adults: Clinical features, diagnosis, and assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/24/7560\">",
"           Bulimia nervosa in adults: Cognitive-behavioral therapy (CBT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/62/7145\">",
"           Bulimia nervosa in adults: Pharmacotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/38/7781\">",
"           Eating disorders in pregnant women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/2/23593\">",
"           Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/63/44023\">",
"           Eating disorders: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-5BAFC16592-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f3_0_3086=[""].join("\n");
var outline_f3_0_3086=null;
var title_f3_0_3087="Bilateral facet dislocations";
var content_f3_0_3087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bilateral facet dislocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 281px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lateral radiograph demonstrates anterior translation of approximately one-half of the superior vertebral body (C5) on the inferior vertebral body (C6).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles A Reitman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_0_3087=[""].join("\n");
var outline_f3_0_3087=null;
